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ABSTRACT 
BACKGROUND: Big data offers new opportunities to enhance healthcare practice.  
While researchers have shown increasing interest to use them, little is known about what 
drives research impact. We explored predictors of research impact, across three major 
sources of healthcare big data derived from the government and the private sector.  
METHODS: This study was based on a mixed methods approach. Using quantitative 
analysis, we first clustered peer-reviewed original research that used data from 
government sources derived through the Veterans Health Administration (VHA), and 
private sources of data from IBM® MarketScan® and Optum™, using social network 
analysis. We analyzed a battery of research impact measures as a function of the data 
sources. Other main predictors were topic clusters and authors’ social influence. 
Additionally, we conducted key informant interviews (KII) with a purposive sample of 
high impact researchers who had knowledge of the data. We then compiled findings of 
KIIs into two case studies to provide a rich understanding of drivers of research impact. 
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RESULTS: Analysis of 1,907 peer-reviewed publications using VHA, IBM® 
MarketScan® and Optum™ data found that the overall research enterprise was highly 
dynamic and growing over time. With less than 4 years of observation, research 
productivity, use of machine learning (ML), natural language processing (NLP), and the 
Journal Impact Factor showed substantial growth. Studies that used ML and NLP, 
however, showed limited peer-reviewed impact. After adjustments, VHA studies had 
generally higher impact (10% and 27% higher annualized Google Scholar citation rates) 
compared to MarketScan® and Optum™ (p<0.001). Analysis of co-authorship networks 
showed that no single social actor, either a community of scientists or institutions, was 
dominating. Other key opportunities to achieve high impact based on KIIs include 
methodological innovations, under-studied populations and predictive modeling based on 
rich clinical data.  
CONCLUSIONS: Big data for purposes of research analytics has grown within the three 
data sources studied between 2013 and 2016. Despite important challenges, the research 
community is reacting favorably to the opportunities offered both by big data and 
advanced analytic methods. Big data may be a logical and cost-efficient choice to 
emulate research initiatives where RCTs are not possible. 
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PREFACE 
According to a recent consensual definition, “Big Data are the information assets 
characterized by such a high volume, velocity and variety to require specific technology 
and analytical methods for its transformation into value.” 1 This description highlights 4 
inter-related characteristics of big data. First is “information” that is the fuel of big data 
and has exponentially expanded in digitized formats over the past three decades. Health 
data are no exception. The volume of structured electronic health records (EHR), for 
instance, which is generated by a single hospital, typically exceeds tens of gigabytes per 
year.2 These data are progressively warehoused at large scale for bedside decision 
support, performance improvement and research and development purposes. 3 Such data 
repositories expeditiously grow in size, variety and complexity. In light of the financial 
incentives offered for adoption of EHR in the Health Information Technology for 
Economic and Clinical Health (HITECH) Act of 2009, such data warehousing trends are 
going to accelerate.3 Adoption of electronic health records (EHRs) has doubled from 
2009 to 2011. We should acknowledge, however, that definition and dimensions of big 
data in healthcare are evolving and have not been well characterized. 2 
In addition, the explosion of environmental and genomic information has broadened 
the expectations from big data and led to increasing investments in dedicated cross-
                                                        
1 De Mauro, Andrea, Marco Greco, and Michele Grimaldi. “What Is Big Data? A Consensual 
Definition and a Review of Key Research Topics,” 97–104, 2015. https://doi.org/10.1063/1.4907823. 
2 Pah, A. R., L. J. Rasmussen-Torvik, S. Goel, P. Greenland, and A. N. Kho. “Big Data: What Is It and 
What Does It Mean for Cardiovascular Research and Prevention Policy.” Current Cardiovascular Risk 
Reports 9, no. 1 (January 2015). https://doi.org/10.1007/s12170-014-0424-3. 
3 Park, Rae Woong. “HW 04-1 Usefulness of big data in clinical research.” Journal of Hypertension 
34 Suppl 1-ISH 2016 Abstract Book (September 2016): e539. 
https://doi.org/10.1097/01.hjh.0000501482.48495.a4. 
		 x 
sectoral collaborative efforts. Partnerships between the federal government, private 
entities and academia in research are prominent examples. 4  
Together with pharmaceutical companies, and government organizations, health 
services researchers are at the forefront of the big data movement. 5 A growing number 
of health services research (HSR) projects are carried out using big data environments: 
large repositories of complex data that link identified or de-identified information curated 
from disparate sources. Most of these environments also provide powerful computational 
infrastructure for parallel processing. 2 The ultimate goal of these initiatives may be 
personalization of healthcare, performance improvement, or innovations through research 
and development. In order to achieve these ends, data also have to be linked and 
integrated in full compliance with the Health Insurance Portability and Accountability 
Act (HIPAA) of 1996. 4 
In this study, we focus on research use of big data and explore whether such use in 
recent years has led to improved scientific impact. To measure scientific impact, we 
derive methods from the science of measuring science or scientometrics and evaluate two 
groups of indices, peer-reviewed research impact (Journal Impact Factor, Web of 
Science, and Google Scholar citation measures) and non-peer-reviewed research impact 
(Altmetric attention score). 6,7,8 
                                                        
4 Wallace, Paul J., Nilay D. Shah, Taylor Dennen, Paul A. Bleicher, and William H. Crown. “Optum 
Labs: Building A Novel Node In The Learning Health Care System.” Health Affairs 33, no. 7 (July 1, 
2014): 1187–94. https://doi.org/10.1377/hlthaff.2014.0038. 
5 Murdoch, Travis B., and Allan S. Detsky. "The inevitable application of big data to health care." 
Jama 309, no. 13 (2013): 1351-1352. 
6 Ziegler, Blaine. “Methods for Bibliometric Analysis of Research: Renewable Energy Case Study,” 
2009. http://web.mit.edu.ezproxy.bu.edu/smadnick/www/wp/2009-10.pdf. 
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We examine big data environments from government sources derived through the 
Veterans Health Administration (VHA), and private sources from IBM® MarketScan® 
and Optum™. Of particular interest is whether there are specific characteristics of these 
environments that predict scientific impact of research. Our review of literature indicates 
that no study so far has systematically examined research impact of big data. Existing 
studies focus on isolated cases or present limited empirical data.  
We quantitatively analyze research that used Optum™, the Veterans Health Affairs 
(VHA) Corporate Data Warehouse (CDW), and IBM® MarketScan® data. The 3 data 
sources differ in content, analytic technologies and composition of scientific networks 
(see chapter four). We compare scientific impact of peer-reviewed publications and 
examine additional predictors of high research impact including research topic, secular 
trends, and co-authorship networks.  
A further area of examination is whether each data source is conducive to unique 
forms of research collaboration and whether structure of such collaborations is predictive 
of research impact. We measure research collaboration by the characteristics of co-
authorship networks which has been previously shown to predict research impact in non-
biomedical settings. 9,10 We compare both the social influence of scientists and also 
                                                                                                                                                                     
7 Rosas, Scott R., Jonathan M. Kagan, Jeffrey T. Schouten, Perry A. Slack, and William M. K. 
Trochim. “Evaluating Research and Impact: A Bibliometric Analysis of Research by the NIH/NIAID 
HIV/AIDS Clinical Trials Networks.” PLoS ONE 6, no. 3 (March 4, 2011). 
https://doi.org/10.1371/journal.pone.0017428. 
8 Mingers, J., & Leydesdorff, L. (2015). A review of theory and practice in scientometrics. European 
Journal of Operational Research, 246(1), 1–19. https://doi.org/10.1016/j.ejor.2015.04.002 
9 Abbasi, A., Altmann, J., & Hossain, L. (2011). Identifying the effects of co-authorship networks on 
the performance of scholars: A correlation and regression analysis of performance measures and social 
network analysis measures. Journal of Informetrics, 5(4), 594–607. 
https://doi.org/10.1016/j.joi.2011.05.007 
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research organizations to predict scientific impact and interpret the associations to 
explain how they may vary within the 3 sources of big data. 
We then expand on the findings of the quantitative study by a series of key informant 
interviews with researchers familiar with the VHA and Optum™ data sources and 
compile findings into two case studies. Despite similarities, our hypothesis is that the 
VHA and Optum™ differ in important aspects such as richness of data, and use of 
advanced analytic methods (see chapter five). These insights are then used to inform 
future topic and methodologic priorities by uncovering patterns in high impact studies 
such as the most useful clinical data, and use cases of advanced analytic methods across 
different research topics.  
  
                                                                                                                                                                     
10 Cimenler, O., Reeves, K. A., & Skvoretz, J. (2014). A regression analysis of researchers’ social 
network metrics on their citation performance in a college of engineering. Journal of Informetrics, 
8(3), 667–682. https://doi.org/10.1016/j.joi.2014.06.004 
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GLOSSARY 
Big data - “… represents the information assets characterized by such a high 
volume, velocity and variety to require specific technology and analytical methods for its 
transformation into value.”1 
Big data environments - large warehouses of complex data that link identified or 
de-identified observations across disparate heterogeneous data sources. 
Richness of data- for the purposes of this study, we define richness of a big data 
environment as its systematic use of electronic health records (EHR), or Natural 
Language Processing (NLP) of provider notes for research analytics. 
Statistical modeling- the boundary between statistical modeling and machine 
learning is not often clear. Statistical modeling often requires statisticians and clinical 
experts to work together to make important decisions as to how to develop the model. 
Such decisions include which variables to include, the relationship between the 
dependent and independent variables, variable transformations and interactions. There is 
substantial human effort involved and often little to be explicitly learned from data. 11 
Artificial intelligence (AI)- “computational technologies that, like people, can 
perform tasks such as sensing, learning, reasoning, and taking action” 12 
Machine learning- “Within the artificial intelligence’ (AI) field, many projects 
involve machine learning (ML), in which a computer can learn iteratively from data and 
                                                        
11 Beam, Andrew L., and Isaac S. Kohane. “Big Data and Machine Learning in Health Care.” JAMA 
319, no. 13 (April 3, 2018): 1317. https://doi.org/10.1001/jama.2017.18391. 
12 Saria, Suchi, Atul Butte, and Aziz Sheikh. “Better Medicine through Machine Learning: What’s 
Real, and What’s Artificial?” PLOS Medicine 15, no. 12 (December 31, 2018): e1002721. 
https://doi.org/10.1371/journal.pmed.1002721. 
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make predictions” 13 
Deep Learning- a form of AI that “can be used when, for example, linear regression 
algorithms do not suffice to model complex data. Algorithmic processing takes place in 
many nodes, and learning tunes for each node’s parameters or ‘weights’. The nodes are 
organized in layers: calculations from one layer become input to the next layer.” 13 
Natural language processing (NLP)- “the formulation and investigation of 
computationally effective mechanisms for communication through natural language."14 
Predictive modeling- “the process by which a model is created or chosen to try to 
best predict the probability of an outcome.” 15 Predictive modeling could be undertaken 
through either statistical modeling or machine learning. 
Advanced analytic methods- for the purposes of this study, we define as use of 
supervised and unsupervised machine learning methods or NLP (see Table 3). 
Healthcare analytics- the efficient use of data and related insights that are 
developed through statistical techniques and also approaches introduced primarily by  
data science such as machine learning, artificial intelligence and other emerging data-
intensive methods. 
While research analytics is typically concerned about methodologic rigor and 
scientific innovation, the goal of operations analytics is performance improvement, 
program evaluation and new product design. The boundaries between the two, however, 
                                                        
13 Marx, Vivien. “Machine Learning, Practically Speaking.” Nature Methods 16, no. 6 (June 2019): 
463–67. https://doi.org/10.1038/s41592-019-0432-9. 
14 Meystre, S. M., G. K. Savova, K. C. Kipper-Schuler, and J. F. Hurdle. “Extracting Information from 
Textual Documents in the Electronic Health Record: A Review of Recent Research.” Yearbook of 
Medical Informatics 17, no. 01 (August 2008): 128–44. https://doi.org/10.1055/s-0038-1638592. 
15 Kuhn, Max, and Kjell Johnson. Applied predictive modeling. Vol. 26. New York: Springer, 2013. 
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could be blurred as a result of collaborations between the two areas. 
Precision medicine- understanding disease at a deeper level in order to develop 
more targeted therapy 16 
Personalized medicine- the situation in which therapeutics are synthesized for 
specific individuals 16 
Scientific/research impact- “an effect on, change or benefit to the economy, 
society, culture, public policy or services, health, the environment or quality of life, 
beyond academia. … Evidence of academic impact may be derived through various 
bibliometric methods, one example of which is the H index, which has incorporated 
factors such as the number of publications and citations.” 17 
Citation rates- the cumulative number of citations to an article, from a variety of 
public or proprietary sources. 
Web of Science (WoS) citation rate- the number of times the record was cited by 
other items from within Web of Science products. 18 
Google Scholar (GS) citation rate- the number of times the record was cited by 
papers and books. GS reported citation counts are often higher than WoS estimates. 
Social network analysis (SNA)- the process of investigating social structures 
through the use of networks and graph theory 19 
                                                        
16 Ashley, Euan A. "Towards precision medicine." Nature Reviews Genetics 17, no. 9 (2016): 507. 
17 Penfield, T., M. J. Baker, R. Scoble, and M. C. Wykes. “Assessment, Evaluations, and Definitions 
of Research Impact: A Review.” Research Evaluation 23, no. 1 (January 1, 2014): 21–32. 
https://doi.org/10.1093/reseval/rvt021. 
18 Web of Science Core Collection Help: All Times Cited Counts. 
https://images.webofknowledge.com/images/help/WOS/hp_times_cited_count.html (2018) 
19 Otte, Evelien, and Ronald Rousseau. "Social network analysis: a powerful strategy, also for the 
information sciences." Journal of information Science 28, no. 6 (2002): 441-453. 
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(Social network) centrality measures- In graph theory and social network analysis, 
indicators of centrality identify the most influential actors (vertices) within a social 
network (graph). Most commonly used centrality measures are betweenness centrality, 
closeness centrality, eigenvector centrality, and degree centrality. See Table 3 and 
“Chapter Two: Section Seven: Co-authorship Networks as Measure of Research 
Collaboration” for detailed definition. 19 
Web scraping – a typically automated algorithm (through computer code) that is 
used for extracting data from websites 
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CHAPTER ONE: INTRODUCTION 
Overview 
Big data is profoundly changing healthcare by the prospect of a more comprehensive 
understanding of risk factors and diseases that may allow us to micro-target individuals 
and populations. As an example, one of the three data sources that we examine in this 
study was recently used to make discoveries about phenotypic variations of a broad range 
of complex disease conditions. 20 The findings were published in Nature Genetics in 
August 2017. Using administrative claims from 130,000 families, Wang et al. found 
previously unobserved similarities between diseases with highly different 
symptomatology (e.g. migraine and irritable bowel syndrome). 20 Wang et al. suggest that 
their work may have the potential to help scientists to cut across different clinical 
disciplines and find new applications for therapies that have been demonstrated to be 
effective for another health problem. Many new studies have built upon this 
methodology. 20 
While the number of studies like Wang are growing, biomedicine still falls behind 
other businesses and scientific disciplines in leveraging the full range of possible 
opportunities of big data.21 Intelligence, politics and finance are a few of many examples. 
Despite challenges with technology, methods, and skills, both the National Academy of 
Medicine (NAM) (formerly the Institute of Medicine) and the Food & Drug 
                                                        
20 Wang, Kanix, Hallie Gaitsch, Hoifung Poon, Nancy J Cox, and Andrey Rzhetsky. “Classification of 
Common Human Diseases Derived from Shared Genetic and Environmental Determinants.” Nature 
Genetics, August 7, 2017. doi:10.1038/ng.3931. 
21 Fihn, Stephan D., Joseph Francis, Carolyn Clancy, Christopher Nielson, Karin Nelson, John 
Rumsfeld, Theresa Cullen, Jack Bates, and Gail L. Graham. “Insights From Advanced Analytics At 
The Veterans Health Administration.” Health Affairs 33, no. 7 (July 1, 2014): 1203–11. 
doi:10.1377/hlthaff.2014.0054. 
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Administration (FDA) encourage a wise and targeted approach to the use of large and 
complex observational data as a potential cost-effective choice to address some of the 
most important challenges of the healthcare systems in the US. Poor quality, high cost, 
questionable value and health disparities are some of the examples. 22,114 
One of the crucial challenges of healthcare is that optimal medical decision making 
might be approaching the limits of typical human cognition. 22 Medical care has become 
increasingly complex due to improved life expectancy, and rapidly changing healthcare 
systems as well as the pace of advancement in healthcare technology. 21 Artificial 
intelligence (AI), machine learning (ML), and deep learning are augmenting healthcare 
practice in disciplines such as radiology and pathology, and service-oriented decision 
support is no longer the only applications of big data. 23   
In this study, we assess the value of big data for public health through impact of 
biomedical research that used healthcare big data. We were interested in data repositories 
from government and private sources, as well as research collaborations that integrate the 
continuum of research and translation of results into practice. 24 25 26 The overarching 
question of the study was what factors drive the scientific impact of research. We 
                                                        
22 Institute of Medicine (U.S.). Best Care at Lower Cost: The Path to Continuously Learning Health 
Care in America. Edited by Mark D. Smith. Washington, D.C.: National Academies Press, 2012. 
23 Obermeyer, Z., & Lee, T. H. (2017). lost in Thought—The Limits of the Human Mind and the 
Future of Medicine. New England Journal of Medicine, 377(13), 1209–1211. 
24 Wallace, Paul J., Nilay D. Shah, Taylor Dennen, Paul A. Bleicher, and William H. Crown. 
“Optum™ Labs: Building A Novel Node In The Learning Health Care System.” Health Affairs 33, 
no. 7 (July 1, 2014): 1187–94. doi:10.1377/hlthaff.2014.0038. 
25 De Mauro, Andrea, Marco Greco, and Michele Grimaldi. “What Is Big Data? A Consensual 
Definition and a Review of Key Research Topics,” 97–104, 2015. doi:10.1063/1.4907823. 
26 Madigan, David, Patrick B. Ryan, Martijn Schuemie, Paul E. Stang, J. Marc Overhage, Abraham G. 
Hartzema, Marc A. Suchard, William DuMouchel, and Jesse A. Berlin. “Evaluating the Impact of 
Database Heterogeneity on Observational Study Results.” American Journal of Epidemiology 178, no. 
4 (August 15, 2013): 645–51. doi:10.1093/aje/kwt010. 
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employed a mixed methods design to explore such factors. In the quantitative arm, we 
analyzed the impact of peer-reviewed original research publications that used VHA, 
IBM® MarketScan® and Optum™ data and evaluated a battery of measures of scientific 
impact. The second arm of the study analyzed insights that were generated through 
qualitative analysis of key informant interviews, researchers who themselves had 
published high impact studies and might have also served in various executive roles in 
the research enterprise. Although VHA and Optum™ represented healthcare systems 
with different mandates, patient populations, and service mix, they also faced many of the 
same opportunities and challenges of analysis of big data. 27 Finally, we also included, in 
the quantitative analysis, IBM® MarketScan® as a comparator that mainly provided 
“data” to researchers and lacked payer or service provision capacities.
                                                        
27 Chen, Min, Shiwen Mao, and Yunhao Liu. “Big Data: A Survey.” Mobile Networks and 
Applications 19, no. 2 (April 1, 2014): 171–209. doi:10.1007/s11036-013-0489-0. 
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CHAPTER TWO: LITERATURE REVIEW 
"The world is one big data problem."  
– Andrew McAfee, 28 
Massachusetts Institute of Technology (MIT) Sloan School of Management 
Introduction 
The number of publications featuring “big data” as a topic has been growing in the 
highly visible biomedical journals between 2010 and 2018. Prominent journals such as 
the British Medical Journal (BMJ), PLoS and the Journal of the American Medical 
Association (JAMA) have increasingly shown interest in the subject (Figure 1 a). 
Scanning broad themes in these publications indicates that their clinical focus has 
diversified over time. Initially focused on biology and genetics in 2010, the attention is 
now shifting toward clinical disciplines such as cardiovascular, gastroenterology and 
cancer. The authors underscore opportunities that “big data” is introducing in their fields 
(Figure 1 b). In these articles, machine learning (ML) and artificial intelligence (AI) are 
two concepts that co-occur consistently with big data (Figure 1 b), particularly in recent 
years. Machine learning therefore appears to be closely linked with expectations from big 
data in the research community. 
In this chapter, we first provide a definition of big data and then highlight its role, as 
viewed by the NAM and the US Food & Drug Administration (FDA), in creating 
continuously learning healthcare systems. We also summarize recommendations of the 
existing studies around “resources needed to harness big data”, “approaches to 
                                                        
28 Lopez Marino, Maria Emilia. "Big data analysis interrogating raw material variability and the 
impact on process performance." PhD diss., Massachusetts Institute of Technology, 2019. 
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mainstream big data for targeted care and research”, “big data analytics and 
methodological considerations”, and “challenges in using big data in public health”.  
We then describe a methodological basis for evaluation of the research enterprise 
and how research impact could be measured. We also define an approach to analyze 
research collaboration through study of scientific co-authorship networks. 
The final section concludes with a summary study background and significance, 
relevance to improve public health, research objectives, and research hypotheses. 
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a Number of articles including the phrase “big data” in their title 
 
b word cloud timeline 
 
Figure 1- Articles including the term “big data“ in their title in a selection of high 
impact journals since 2011 
Note: we searched publication titles for “big data” using Google Scholar in the following journals: 
American Journal of Public Health, Annals of Internal Medicine, British Medical Journal, Circulation, 
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Gastroenterology, Gut, Health Affairs, Journal of Clinical Oncology, JAMA, Lancet, Nature, New 
England Journal of Medicine and PLoS 	
Section One: What is Big Data? 
Big data has almost become a buzz word to denote integration and analysis of large 
quantities of digital information that have heterogeneous structures and complex 
interpretations. Special technologies and analytic methods are usually required to store, 
and analyze them in order to transform them into knowledge and insights. 25 
Most definitions of big data could be traced back to the Gartner characterization first 
published in 2001. 29 The Gartner model identified the following attributes, which later 
became popular as 3 Vs, as distinguishing features of big data: volume, velocity, and 
variety. The term remains a fluid concept while data scientists attempt to create a 
consensual definition. 25 For instance, De Mauro et al. define “big data” as “the 
information assets characterized by such a high volume, velocity and variety to require 
specific technology and analytical methods for its transformation into value.” Figure 2 
shows key dimensions of the concept according to Gartner with several examples specific 
to the healthcare context. More recent adaptations have also added new dimensions such 
as complexity (Figure 2 left) and veracity. While complexity refers to interpretation of 
data that could be affected by different contexts, veracity highlights the reliability of data 
after it is masked for confidentiality or other reasons.  
                                                        
29 Laney D. Application Delivery Strategie. 3D Data Management: Controlling Data Volume, 
Velocity, and Variety. 2001, https://blogs.gartner.com/doug-laney/files/2012/01/ad949-3D-Data-
Management-Controlling-Data-Volume-Velocity-and-Variety.pdf. 
		
8 
 
Figure 2- Gartner characterization of big data (left) and recent adaptations in the 
healthcare context (right) 
Source: Srini, Gomathi & Narayani, V. (2015). Applications of big data analytics and data mining in 
health care sector. International Journal of Science Technology and Management. 4. 
 
As made obvious by the label, data volume is a fundamental characteristic of “big 
data”. 1 Practice of healthcare, in particular, produces huge amounts of digitized 
information that are generated in real world settings. Laboratory, imaging, medical 
records and administrative transactions are some of the routinely used sources. 2 Too 
often, inability of an organization to manage huge amounts of data may result in 
discarding valuable information. 30 Figure 3 compares the approximate size of data 
generated from a variety of sources in a given year. Routinely reported diagnostic codes 
in a medium-sized hospital are typically captured for care management and billing 
purposes. More technology-intensive data streams such as cardiac MRI also contribute 
massively to “digital footprints” of a single person that remain highly under-used. 2 In 
summary, with mainstreaming of genetic testing and high-resolution imaging, health 
records require growing amounts of data storage as well as computational capacity to 
                                                        
30 Boles NC, Stone T, Bergeron C, Kiehl TR. Big Data access and infrastructure for modern biology: 
case studies in data repository utility. Ann NY Acad Sci. 2016; 
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efficiently move and analyze. Faster advances in medicine are dependent on improved 
and affordable physical storage technology, network connectivity and storage 
management software. 
 
Figure 3- Data Generated In A Single Year For Various Sources 
Source: Pah AR, Rasmussen-Torvik LJ, Goel S, Greenland P, Kho AN. Big Data: What Is It and What 
Does It Mean for Cardiovascular Research and Prevention Policy. Current Cardiovascular Risk Reports 
[Internet]. 2015 Jan 
 
In the computationally-intensive healthcare industry, “velocity” of data generation 
has also increased exponentially. Digital information from medical devices and log or 
streaming data from wearables are often stored now and have a great potential to be 
transformed into insights and inform wellbeing and disease status. 2 Finally, “variety” is 
what makes “big data” even more powerful in healthcare. The following five broad data 
sources could have the greatest potential to inform targeted treatments or ‘precision 
medicine’: 16  
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• Patient genomics 
• Medical imaging 
• Device, log, and sensor data 
• Electronic health records (EHRs), and 
• Unstructured text data 
In conclusion, various characteristics of “big data” make it a promising resource for 
precision medicine, research and performance improvement. Many disciplines such as 
cardiovascular health, oncology, radiology, and pathology are already leveraging “big 
data” to personalize care and diagnostics as well as producing population health insights. 
Therefore, such applications of big data do work in both directions, comparing “one to 
many” and also “many to one”. Tracking social determinants of health through 
crowdsourced environmental data is another data source that offers great potential. 
Examples include consumer behavior, household composition, activities and interests as 
well as neighborhood assets. 31 These data sources demonstrate important potential use of 
big data to advance both clinical practice and health. 16 
Section Two: Resources Needed to Harness Big Data for Biomedical Research 
To leverage big data for care improvement or research, it is imperative to build 
systematic approaches to reliably manage, integrate, analyze and interpret large and 
complex observational data. These require resources beyond routinely employed 
computational and analytic arrangements. For instance, the volume and complexity of 
                                                        
31 Meyer, Anne-Marie, Andrew F. Olshan, Laura Green, Adrian Meyer, Stephanie B. Wheeler, Ethan 
Basch, and William R. Carpenter. "Big Data for Population-Based Cancer Research The Integrated 
Cancer Information and Surveillance System." North Carolina medical journal 75, no. 4 (2014): 265-
269. 
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day-to-day healthcare data often necessitates implementation of cloud computing and 
high-speed parallel processing to more efficiently enable integration, mining and analysis 
of data for practice, performance management or research. 2 
Another critical resource is high-quality methodology, bioinformatics, and 
biostatistics expertise. 32 Despite this need, there is a lot of ambiguity about the exact 
skills required to carry out the analytic tasks. Of paramount importance are skill sets in 
the subject matter of interest, research methodology, programing, modeling and 
visualization. Often used software include R, SAS, and Matlab as well as Python, SQL, 
Java, and Ruby. Obviously, the assumption is that data base management, and cloud 
computing infra-structure exists and performs reliably. 33 Investigators, and data scientists 
should also possess the practical skills to meet the needs of working across disciplines to 
leverage complex and noisy data. Cross-disciplinary collaborations will also be key. 
Applying nuanced algorithms across petabytes of claims, EHR and a variety of other 
data sources requires powerful and flexible computational platforms. Lessons learned 
from other sectors such as intelligence indicate that computational advancements like 
cloud-computing platforms can greatly facilitate the efficiency of data analysis. If 
genomics alone is sufficiently mainstreamed, the computational capacity to accommodate 
data might exceed those currently allocated even to astronomy, YouTube and Twitter. 
                                                        
32 Khoury, Muin J., Tram Kim Lam, John P. A. Ioannidis, Patricia Hartge, Margaret R. Spitz, Julie E. 
Buring, Stephen J. Chanock, et al. “Transforming Epidemiology for 21st Century Medicine and Public 
Health.” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association 
for Cancer Research, Cosponsored by the American Society of Preventive Oncology 22, no. 4 (April 
2013): 508–16. https://doi.org/10.1158/1055-9965.EPI-13-0146. 
33 De Mauro, Andrea, Marco Greco, Michele Grimaldi, and Paavo Ritala. "Human resources for Big 
Data professions: A systematic classification of job roles and required skill sets." Information 
Processing & Management 54, no. 5 (2018): 807-817. 
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YouTube is currently using from 100 petabytes to 1 exabyte for storage but is projected 
to require between 1 and 2 exabytes per year by 2025. 34 Similar to healthcare, the 
intelligence community also routinely processes enormous amounts of data, including 
structured information, unstructured text, and multimedia, in various formats and 
taxonomies. In such contexts, less structured data-storage technologies, such as data 
lakes, are particularly appropriate and allow efficient integrating of disparate data with 
minimal data modeling. 11 
Advanced analytics and methodological considerations 
Another important group of resources are new statistical tools from the field of data 
science that are increasingly vital to both bedside decision support and healthcare 
research. 35 In addition to the computational infrastructure, analysis of large amounts of 
data could benefit from analytic methods beyond traditional statistical techniques. Use 
cases of these approaches are often classified as artificial intelligence (AI), machine 
learning (ML) and deep learning. Natural language processing (NLP), for instance, is 
itself based on ML methods because it improves its classification of unstructured text as 
it processes more free text data. 25 
AI typically refers to computer algorithms mimicking human cognition; ML, on the 
other hand, typically refers to a set of computational and statistical tools for discovering 
patterns and relationships in data. ML approaches include use of tools to make 
                                                        
34 Stephens, Zachary D., Skylar Y. Lee, Faraz Faghri, Roy H. Campbell, Chengxiang Zhai, Miles J. 
Efron, Ravishankar Iyer, Michael C. Schatz, Saurabh Sinha, and Gene E. Robinson. "Big data: 
astronomical or genomical?." PLoS biology 13, no. 7 (2015): e1002195. 
35 Obermeyer, Ziad, and Ezekiel J. Emanuel. "Predicting the future—big data, machine learning, and 
clinical medicine." The New England journal of medicine 375, no. 13 (2016): 1216. 
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predictions based on the data. Deep learning is a subtype of ML that allows flexible 
multi-layer configuration of neural networks. Deep learning has been particularly 
promising in cases such as image recognition. These early successes have led to much 
visibility among the scientific community and raised ample, and sometimes overly 
ambitious, expectations from advanced analytic methods. 36, 123 
Finally, introduction of advanced analytic methods is leading to a culture shift 
among the biomedical scientists who have been traditionally concerned about causation 
and therefore skeptical about value and generalizability of data-driven approaches. 
However, investigators are increasingly appreciative of the advantages and disadvantages 
of correlation and prediction compared to causal reasoning, and use cases in clinical 
decision-making, prognostics and performance improvement are going to increase.25 
Section Three: Role of Big Data in Continuously Learning Healthcare Systems 
The ability of big data to contribute in achieving the goal of ‘best care at lower cost’ 
was suggested in the recommendations of the Institute of Medicine (IOM) in 2012. 37 In 
its report, IOM outlined three requirements for the healthcare systems in order to fully 
transform into ‘continuously learning’ entities that were better able to respond to a 
rapidly changing healthcare landscape. First, as the report mentions, healthcare systems 
should be able to adapt to the growing complexity that was the result of faster discovery 
of diagnostic and therapeutic options for patients with a multitude of comorbid 
                                                        
36 Rodriguez, Fatima, David Scheinker, and Robert A. Harrington. "Promise and Perils of Big Data 
and Artificial Intelligence in Clinical Medicine and Biomedical Research." Circulation research 123, 
no. 12 (2018): 1282-1284. 
37 Institute of Medicine (U.S.). (2012). Best care at lower cost: the path to continuously learning health 
care in America. (M. D. Smith, Ed.). Washington, D.C.: National Academies Press. 
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conditions, and at the same time tackle fragmentation of care. Second, value for dollars 
spent on healthcare should be improved by eliminating low-value services to make gains 
in efficiency and quality. Finally, the report underscored opportunities that could be 
harnessed from advances in computing, information science, and connectivity, much of 
which were the purview of big data. Specifically, the IOM report emphasized huge 
amounts of under-used digital information, efficient yet affordable computational 
technologies and analytic tools, as well as connectivity and unprecedented inexpensive 
diffusion of information. The document concluded that these features should be the basis 
of data-driven solutions within “continuously learning healthcare systems”.37  
As summarized in Figure 4, IOM report also postulated that there are missed 
opportunities, waste and harm in each step in the basic processes of knowledge 
management in healthcare. 37 Such opportunities were reflected in “big data” but mainly 
pertain to the final block where practitioners provided care to patients in a real world 
setting. The digital foot prints of provider-patient transaction are now available enabling 
the system to embark on high value data-driven solutions and transform to a continuously 
learning organization. 
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Figure 4- Institute of Medicine's schematic of the healthcare system 
Source: Institute of Medicine (U.S.). (2012). Best care at lower cost: the path to continuously 
learning health care in America. (M. D. Smith, Ed.). Washington, D.C: National Academies Press 
 
As mentioned earlier, biomedical researchers play a critical role in healthcare 
systems but are only one of the many groups of users of big data. One could imagine how 
high -throughput sequencing of genes or multi-channel electrophysiological sensors in a 
real world setting can quickly turn into terabytes of data for a handful of individuals. 
Fortunately, the hardware and algorithmic technology is increasingly available and 
affordable to allow interrogating of data for a variety of users, including providers and 
researchers.38 Besides specialized data management and statistical methods that are 
required to analyze these large amounts of information, special methodological expertise 
is required to analyze data that are not primarily collected for research purposes. This 
                                                        
38 Boles, Nathan C., et al. “Big Data Access and Infrastructure for Modern Biology: Case Studies in 
Data Repository Utility.” Annals of the New York Academy of Sciences, 2016, p. n/a-n/a. Wiley 
Online Library, doi:10.1111/nyas.13281. 
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typically poses major challenges and is a constant source of skepticism in findings. 
Therefore, many investigators that typically use classic epidemiologic data sets find 
working with big data pipelines challenging. 21 
Section Four: Mainstreaming of Big Data for Precision Medicine and Research  
Market forces affecting mainstreaming of big data in healthcare 
The global market for healthcare big data was estimated to be between $5.5–$10 
billion dollars in 2016, and poised to grow to $27–$30 billion by 2022. 41,39 Two-thirds of 
the market is currently concentrated in the US where the growth is driven by the demand 
for precision medicine, cost savings, quality improvement and detection of fraud. 
Technological advancements in health information technology (IT) and rapid adoption of 
the electronic health record (EHR) have also been cited as contributing factors. 39 
Besides the growing number of big data sources that are publicly accessible,40,41 
other major repositories remain proprietary due to patient privacy requirements, 
technology and business justifications. 50 Democratization of big data, therefore, remains 
a myth to a large extent.  Relatively few key players exist nationally but include large 
governmental organizations such as the Department of Veterans Affairs, 21 large payers 
such as UnitedHealth Group 24 and integrated delivery systems such as Kaiser, 42 and 
                                                        
39 https://www.gminsights.com/industry-analysis/healthcare-analytics-market accessed 2017-12-08 
40 Marr, B. (n.d.). Big Data: 33 Brilliant And Free Data Sources Anyone Can Use. Retrieved May 25, 
2018, from https://www.forbes.com/sites/bernardmarr/2016/02/12/big-data-35-brilliant-and-free-data-
sources-for-2016 
41 Healthdata.gov https://www.healthdata.gov/ 125 years of US healthcare data including claim-level 
Medicare data, epidemiology and population statistics. 
42 Moore, Keith D., Katherine Eyestone, and Dean C. Coddington. "The big deal about big data." 
Healthcare Financial Management 67, no. 8 (2013): 60-68. 
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Mayo Clinic. 43 
Use of big data in healthcare faces several challenges. The divide between patients, 
payers and providers regarding ownership of medical records continues to be a barrier. 44 
Currently, providers and payers store and own patient data for their operations therefore 
availability of information is highly fragmented. In order for patients to gain control over 
their data, regulatory changes have to happen. Initial investments to curate big data are 
also high.44 Finally, interoperability, data quality, and computational capacity require 
resources. Therefore access to health care big data has remained largely limited to a few 
main national players such large governmental organizations (e.g. Department of 
Veterans Affairs), large payers (e.g UnitedHealth Group) and integrated delivery systems 
(e.g. Kaiser, and Mayo). In a nut shell, democratization of big data remains a myth. 
Role of government and private sector in investments in healthcare big data 
Governments, the private sector, interdisciplinary collaborations and citizen 
scientists are contributing to expansion of the reach of healthcare big data. The general 
idea behind this movement is that large data sets, open access, crowdsourcing and data 
sharing will lead to innovation and new applications in healthcare. 45 Genomic England, 
China’s Kadoorie Biobank and President Obama’s Precision Medicine Initiative are just a 
few examples of state-funded projects that are focused on biological, environmental and 
                                                        
43 Shah, Nilay D., and Jyotishman Pathak. "Why health care may finally be ready for big data." 
Harvard Business Review 3 (2014). 
44 Mittelstadt, Brent Daniel, and Luciano Floridi. “The Ethics of Big Data: Current and Foreseeable 
Issues in Biomedical Contexts.” Science and Engineering Ethics 22, no. 2 (April 1, 2016): 303–41. 
https://doi.org/10.1007/s11948-015-9652-2. 
45 Wang, Yichuan, LeeAnn Kung, William Yu Chung Wang, and Casey G. Cegielski. “An Integrated 
Big Data Analytics-Enabled Transformation Model: Application to Health Care.” Information & 
Management 55, no. 1 (January 2018): 64–79. https://doi.org/10.1016/j.im.2017.04.001. 
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lifestyle data in newly formed large cohorts. 46 Private players such as IBM® Watson, 
UnitedHealth’s Optum™, Oracle, Cerner Corporation, and Allscripts are some of the 
private players. They have been making investments in ‘curating’ existing data and also 
creating new infrastructure as well as collaborative networks.46, 47 Last but not least are 
the bottom up initiatives that are driven by patients and citizens with the aim of 
improving personal and population health. PatientsLikeMe 48 and the Platform for 
Engaging Everyone Responsibly (PEER) are just a few examples. These initiatives are 
focused on sharing individual patients’ experience across novel digital platforms for 
patient education and research. PatientsLikeMe now has over 600,000 members with 
more than 2,800 health conditions where newly diagnosed patients can improve their 
health knowledge through learning from others with similar conditions. 49  
Collaborations around healthcare big data are also increasing. 4 These entities bring 
together various stakeholders and data assets to conduct research and facilitate translation 
into practice.50 They typically include large cloud computing and specialized analytic 
techniques. Increased adoption of electronic health records (EHR) by health care 
providers and accountable care organizations (ACO) is another opportunity for using big 
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data to look into deep patient and provider information. Whether these approaches will 
lead to useful insights is yet to be determined. 4 
Creation of extensive repositories of “complete” health records are also complicated 
by strict data privacy regulations and lack of interoperability across fragmented EHRs. 
Despite richness of data within Veterans Health Administration (VHA), Kaiser 
Permanente, and Mayo Clinic, each one alone would not be representative of broader 
patient populations. This issue is an important caveat of the insights generated. Investors 
and other stakeholders are increasingly interested in broader data linkage. Transnational 
partnerships in Europe and Asia may be examples to monitor. 51 
OptumLabs™ that was analyzed as a case in this study is an example of such 
research and innovation collaborations 50 (see Section Three: Case Study 2 Research 
Analytics at Optum™ and OptumLabs™). 
Other public health use cases of big data 
Big data can also complement conventional public health surveillance systems to 
assess risk and prevalence of certain health conditions. 52 Some studies have shown that 
social media can provide as reliable and perhaps more timely and cost-effective local data 
(e.g. county-level) on health behaviors than the existing public health systems. 
Researchers have used attention measures such as “likes” on Facebook to stratify county-
level communities for risky behavior in order to predict mortality. 52 These studies 
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demonstrate that in addition to timeliness and cost, predictive power of such risk models 
could outperform traditional data such as the Behavioral Risk Factor Surveillance System 
(BRFSS). 52 
Section Five: Challenges in Using Big Data and Applying Advanced Analytic 
Methods in Biomedical Research 
Integration of subject matter knowledge and methodological expertise 
One of the broad barriers to adoption of advanced analytic methods and use of big 
data in biomedical research is the current thinking practices among investigators and 
methodologists. 32 Despite the opportunities, working across disciplines is difficult and 
bringing in complementary expertise, for instance, from data science into health services 
research would be no exception. 53 Health services researchers are becoming increasingly 
aware that data-driven approaches to analyze big data such as AI and ML could be as 
powerful as hypothesis-driven analysis if chosen appropriately. 54 
Another challenge is that most of the advanced analytics techniques like ML require 
validation of computational models in large quantities of data. Predictions based on such 
methods, therefore, may be difficult to replicate posing a limitation. Transparency in 
methods should be strongly encouraged when using AI and ML for prediction. 53 
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Barriers for data linkage and sharing 
Existing software and hardware solutions create an unprecedented opportunity for 
data linkages. Bridging across diverse data sources is a relatively new endeavor in 
healthcare and continues to be a major obstacle to optimal use of big data. 36 Often the 
standards that allow interoperability, data provenance, and quality assessments are not 
existent. Furthermore, lack of willingness among owners of data to more liberally share 
information limits the richness of any given big data repository. 36, 55 Despite the strong 
motivations to share data and increase richness, substantial technical, social, regulatory, 
and institutional barriers have to be overcome to make access to richer data possible. 56 
Privacy and data security challenges in working with healthcare big data 
Big data and patient privacy should not be considered as contradictory concepts. 
Measures to safeguard patient privacy have been evolving in tandem with improved 
availability of data. As shown in other sectors such as politics and finance, the potential 
benefits of big data analytics outweigh the risks. 57  On the other hand, public concern 
over privacy is legitimate. The Health Insurance Portability and Accountability Act 
(HIPAA) of 1996, for instance, has several loop holes when it intersects with the big data 
movement. For instance, “covered entities” under HIPPA currently do not extend to apps 
that typically collect a lot of personal data outside routine provider-patient encounters. 
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Devices connected through Internet of Things (IoT) pose another privacy and security 
challenge and their current state is assessed as “quite vulnerable”. 57 Threats to privacy 
consist of both misuse and also attacks and stealing information. These concerns have led 
to a great deal of skepticism and mistrust about personal consequences of centralized 
healthcare big data warehouses. 58 Enabling transparent measures for enhanced privacy 
and data security remain critical to address public concerns. Section	Six:	Evaluation	of	the	Research	Enterprise	
Increased investments in scientific innovations based on big data underscore the 
importance of systematic frameworks for evaluation of a research enterprise. A widely 
cited framework was introduced by the Transdisciplinary Tobacco Use Research Center 
(TTURC) initiative of the National Cancer Institute (NCI). 7,79,80 The NCI framework was 
based on a mixed methods approach that included both processes and outcome measures. 
80  This measurement system is based on bibliometric analysis and peer evaluation of 
research publications along with financial expenditures analysis and researcher surveys. 
80 In the following section, we provide a brief introduction of the fundamental concepts 
underlying bibliometric analysis of the research enterprise, that is sometimes referred to 
as scientometrics. 8 
Measuring the impact of research - scientometrics 
Scientometrics is the quantitative assessment of dissemination of science8 and in 
recent years, has gained popularity in the evaluation of the performance of the research 
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enterprise. Historically, scientometric measures were limited to the analysis of citations 
in the academic literature but with the expansion of digital media and social networks, 
additional measures were introduced to capture online reach and activity. These measures 
are collectively referred to as ‘Altmetrics’. 59 The overall purpose is to quantify various 
dimensions of the process of science as a communication system. 8 Therefore, they tend 
to be focused on capturing visibility of research among scientific or non-scientific 
audiences. 59  Scientometric measures could be broadly divided into two categories: 
measures of research productivity and measures of impact. The following describes 
measures of impact:  
Journal Impact Factor (JIF) – JIF is the mean citations that a paper in a journal 
receives over a fixed period of time (e.g. two-year). 59 For example, the 2014 JIF of 
journal X would be the total number of citations to papers that were published in X in 
2012 and 2013, divided by the number of papers. JIF has been suggested an indicator of 
journal quality. Some of the limitations of JIF include: 59 
• It varies considerably across different fields depending on citing habits of the 
community of the scientists (management vs. biomedicine). 
• The 2-year time window may be two short for some disciplines. This is affected 
by the lead time between submission and publication. 
• It could be distorted by journals’ deliberate choice of the types of papers they 
publish (e.g. basic review articles on average receive more citations than original 
research). 
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• JIF is not necessarily generalizable to individual papers within a journal. Studies 
show that the distribution of citations within a journal could be highly skewed. 59 
In this study, we use JIF as a measure of research impact and also the quality of the 
dissemination outlet (a peer-reviewed publication). 
Citation counts/rates – Thomson Reuters ISI Web of Science (WoS) and Google 
Scholar are two commonly used sources of citation data. 60 They mainly differ by the 
number of included journals and how far back their citation histories extend. WoS 
includes around 12,000 journals and is one of the more restrictive sources of citation data. 
Access to WoS is subscription-based. 18 Google Scholar (GS) on the other hand, is one of 
the least restrictive sources of citation data. It uses the Web, as opposed to specific 
journals, to find documents that cite papers and books (WoS does not cover book 
citations). GS reported citation counts are often higher than WoS estimates. 60 For 
biomedical peer-reviewed research, coverage of both sources is reasonably good. 59 
Google Scholar citation data is publicly available through 
https://scholar.google.com/ or could be harvested in batch by freely available APIs such 
as Publish or Perish 61 and Zotero. 62 WoS could be directly downloaded in batches using 
its Web-based API.  
Quality of data in GS could be problematic due to sensitivity of the underlying 
algorithms to spelling or date errors that could lead to double counting. 59  In this study, 
we obtained data from both GS and WoS to be able to take into account both sensitivity 
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and quality of citation data and obtain a balanced view. Sensitivity is of particular 
importance as our sample included research publications in a recent and relatively short 
period of observation. 
Altmetrics – this set of newly developed measures go beyond citations by the 
scientific community and calculate the number of times an article was viewed, 
downloaded, mentioned and recommended over the social media, news outlets and 
widely read blogs.  63 The strength of ‘altmetrics’ is that they capture dissemination 
beyond just the scientific community and by the broader public. The usual flaws of social 
media gimmicks, such as platform manipulation, could also apply. 59  Likes or tweets 
could be bought and there is also limited transparency about the theory of how they are 
generated. Also controversial papers may score higher than high quality scientific 
publications because of biased and unrestricted attention. 59 
Clustering research publications: measures of research similarity  
In order to make research impact analytically comparable across a variety of 
scientific fields, we also needed to create a number of relatively homogeneous clusters 
where publications were similar in terms of patient populations, research questions and 
methods. One approach that has been used in the literature relies upon bibliometric 
similarity. 64 65 66 Co-citation analysis and bibliographic-coupling are the two commonly 
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used methods which use citation analysis to establish similarity between research 
publications. 67 
Co-citation – Two research publications are linked (and considered similar/proximal) 
when there is a third publication “that cites” both of them. 68 Strength of proximity grows 
by the number of co-citing documents. Compared to bibliographic coupling, co-citation 
may be more reflective of the scientific influences of papers and their authors. 69 It is also 
less accurate for publications that have been published recently. 68 
 Bibliographic coupling – Chronologically, this measure is the opposite of co-
citation.  Two research articles are bibliographically coupled if there is a third publication 
“that is cited” by both publications. 70 Unlike co-citation, it measures the degree of 
overlap in the scientific references used by the two publications. Notably, the value of 
this measure is not dependent on the age of the publication. Popularity of this measure, as 
compared to co-citation, has grown in recent years. 71  
Because the age of the publications in our analysis were lower, we chose to use 
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bibliometric coupling as a more accurate measure of research similarity. 
We used ‘VOSviewer’ to analyze both measures of scientific similarity. VOSviewer 
(www.vosviewer.com) is an open-source application. It also allows for visualizing, and 
exploring bibliometric maps of collections of peer-reviewed articles. 71 
Other approaches to determine research similarity among research publications have 
also been reported. 72 Howard has developed a methodology that is based on semantic 
similarity of textual meta-data of documents (text of titles, abstract, and MeSH terms). 72 
We applied both approaches to cluster our sample into more homogenous categories. 
Section Seven: Co-authorship Networks as Measure of Research Collaboration 
Research analytics using big data is, as in other branches of science, a social 
enterprise. Studies are often the result of collaborations among scientists and insights 
about the social structure of these communities is an important step toward understanding 
various dimensions of research collaboration. 9 Research collaboration is formed by both 
personal and professional ties and allows sharing of subject matter and methodological 
expertise as well as other resources. 9 More importantly, it plays a key role in how 
innovation evolves around specific gaps in knowledge. 
Co-authorship of peer-reviewed research publications is a model of research 
collaboration and could be studied as a measure of social structure in science and shown 
to predict research impact. 9,10,73  
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Quantification of research collaboration is possible through social network analysis 
(SNA) of co-authorship communities and is increasingly applied to study biomedical 
research. 9  
SNA analyzes patterns and characteristics of relationships among individuals----here 
researchers---both visually and numerically. Social networks are built around a set of 
nodes (also called vertices), and a set of links (also called edges). 74,75 The nodes denote 
social actors such as researchers while a link represents connectedness between actors. 74  
The connection could be a co-authored research publication. Overall structure of the co-
authorship networks could be described by the following dimensions: 
1. Social network components such as isolated or dominant communities of 
researchers 73 
2. Size of communities: number of social actors or nodes included in a community 
or cluster 73 
3. Measures of social influence: 9 
a. Degree centrality: This measure represents the intensity of network 
around an author and its overall popularity. 
b. Betweenness centrality: This measure is a surrogate for the 
independence and efficiency for communicating with other actors in the 
network.  
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c. Closeness centrality: It measures the number of times a particular node 
lies ‘between’ the various other nodes in the network. The actor with a 
high value can most frequently control information flow in the network. 
d. Eigenvector centrality: A node, which is connected to many other 
nodes that are themselves well-connected, has a higher eigenvector 
centrality and a node connected to nodes with a few connections has a 
much lower score. 
In large data sets with a wide range of social ties, centrality measures could be 
normalized to values between 0 and 1 by dividing them by appropriate denominators (eg 
n-1 for degree centrality where n is the number of individuals in the network). 75 
We use SNA to describe the structure of co-authorship networks and evaluate 
associations with data source, and research impact. Co-authorship network structure is 
characterized by the extent and patterns of collaboration among researchers who have 
published one or more peer-reviewed original research studies to identify influential 
individuals, and institutions. 
 
Section Eight: Study Background and Significance 
Background  
Big data offer a new opportunity to enhance healthcare practice, and the public 
health community has shown tremendous enthusiasm in employing these resources to 
improve practice and conduct research. 76 However, little is known about what works 
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best, and how we could use big data assets to improve research impact. To guide these 
decisions, it is important to determine which characteristics of big data may be associated 
with high research impact. In this study, we examined predictors of scientific impact, as a 
measure of research translation, across three major sources of healthcare big data derived 
from the government and the private sector. We primarily focus on health services 
research (HSR) that has been at the fore front of using big data. We hypothesized that 
rich data content, use of advanced analytic methods and strong research networks in a big 
data environment are associated with high research impact. We expanded the findings 
derived from a quantitative analysis with insights gleaned from key informant interviews 
with a select group of senior-researchers and analytics experts who had extensively 
worked with big data. The qualitative study focused on best practices in the use of these 
environments. We compiled our findings into recommendations for enhanced use of big 
data in public health to optimize efficiency and impact of research.  
We used data volume, variety, and complexity as criteria to select 3 organizations to 
study. However, we acknowledge that important dimensions of big data in healthcare 
may not be limited to these factors. 77 
As mentioned before, health services researchers are at the forefront of the big data 
movement 4 and an increasing number of studies are carried out in big data environments. 
Some of these environments also provide powerful computational infrastructure for 
parallel processing for their voluminous content. 2	The ultimate goal is to turn healthcare 
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big data into actionable insights. The important question is whether such value is actually 
generated through scientific impact and translation into practice. 78 (Figure 5) 
Also of interest was whether there were specific characteristics of the data 
environment that might predict scientific impact of the research. Existing studies focus on 
isolated cases and limited empirical data. Our objective was to compare scientific impact 
of published research across three prominent healthcare “big data” environments in the 
U.S. that differed in content, analytic technologies and composition of collaborative 
networks (Table 1).  
We studied the following three big data environments: UnitedHealth Optum™, the 
Veterans Health Affairs (VHA) Corporate Data Warehouse (CDW), and IBM Watson 
MarketScan. These environments differ in key characteristics such as richness of content, 
availability of shared computing technology, and use of advanced analytic methods (table 
1). It was policy relevant to study if use of richer data with or without advanced analytic 
methods would lead to higher scientific impact (Figure 5). Another area for examination 
was whether each environment developed distinct forms of scientific networks and if 
these networks contributed to scientific impact. Research collaboration as measured by 
the characteristics of co-authorship networks has been shown to independently drive 
scientific impact in non-biomedical research 9,10. We were therefore interested to examine 
the role of collaborative networks as a predictor of scientific impact and its interplay with 
characteristics of big data.  
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Table 1 – Overview of the “big data” environments evaluated  
Environment Established Affiliation Setting Population base High level description 
Content, and Access Shared 
computing 
facility 
Number of 
included 
publications1 
VHA’s 
Corporate 
Data 
Warehouse 
(CDW) 
2006 (data 
available 
since 1991) 2 
Department 
of Veterans 
Affairs 
Federal 
organization 
Veterans and 
select nonveterans 
(e.g., VHA 
employees and 
research 
participants) 
• Administrative data, and 
linkable inpatient EMR  
• Well-developed protocols, 
mature meta data 
• Strict data security measures 
Yes 1,082 
Optum™ 
(various data 
products) 
1993,  
(data 
currently 
available 
since 1994)3, 4 
UnitedHealth 
Group 
Private data 
vendor 
UH privately 
insured and 
Medicare 
Advantage 
(Legacy); large 
Integrated 
Delivery 
Networks (IDNs), 
all-payer for 
EMR 
• Administrative claims from 
UH, linkable lab results from 
large lab vendors; linkable 
EMR (outpatient & inpatient) 
from Humedica, patient 
surveys from UM, consumer 
behavior data; mortality from 
DMF 
• Data access requires 
prequalification and access cost 
Yes 247 
MarketScan
® (various 
data 
products)  
1988 (data 
currently 
available 
since 1995) 4, 
5 
Thomson 
Reuters 
MedStat 
Private data 
vendor 
Commercially 
insured from 
multiple plans, 
Medicare and 
Medicaid patients 
and their families 
• Administrative claims from 
large employers; linkable lab 
results from large lab vendors 
• Well-developed protocols, and 
documentation 
No 578 
#- UH: UnitedHealth; EMR: electronic medical records; IDN: integrated delivery network; NLP: Natural Language Processing,  
1- Preliminary count of eligible studies between 2016 and March 15 2016;  
2- https://catalog.data.gov/dataset/corporate-data-warehouse-cdw & http://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm , 2015; 3- 
Mitchell et al. 1994; 4- Voss et al. 2015; 5- B.R.I.D.G.E. TO DATA®  2015 
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Innovation and the conceptual framework 
Our hypotheses were based upon a hybrid conceptual model that was originally 
developed by the National Cancer Institute (NCI) to assess the impact of large cross-
disciplinary research collaborations. 79,80 We integrated the Gartner characterization of 
big data with the NCI model to hypothesize causal pathways between big data 
characteristics and research impact. We postulated that the effect of big data was exerted 
through richness of data, cross-disciplinary integration and research collaborations 
(Figure 5 and Table	3). We defined richness of data, as a data environment’s systematic 
use of electronic health records (EHR), or Natural Language Processing (NLP) of 
provider notes for research purposes. Deep patient information embedded in unstructured 
or semi-structured provider notes has been suggested as a profound source of variation 
and hidden patterns that could reveal significant new insights about disease progression, 
treatment pathways, and providers’ behavior. 24 
Cross-disciplinary integration is the fundamental process of innovation through 
development of new and improved methods and scientific models (Figure 5 and Table	3). 
We defined the use of machine learning (ML) and natural language processing (NLP) as 
a measurable feature of cross-disciplinary integration. We labeled this construct “use of 
advanced analytic methods” which is a key feature of big data. 1 The innovative insights 
lead to hypothesis and interventions that could be tested and generate high impact peer-
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reviewed publications. 80 This process could consist of multiple steps, each with interim 
research outputs, such as evaluation of unmet need, quality measurements, and 
identifying pathways to optimal cost and clinical outcomes. A performance measurement 
dashboard for opioid use could be an example that identified certain gaps in performance. 
81 It then led to targeted hypothesis generation that needed to be tested according to local 
needs. 
Finally, the main outcome variable was research impact which we measured through 
a battery of scientometric indicators (Table 2). These measures were comprised of peer-
reviewed measures including citation rates and journal impact factor as well as the  non-
peer-reviewed measures of Altmetrics. 63 Scientific network metrics were also assessed to 
predict research impact based on prior studies. 6,9,10,79 No study has so far examined the 
combined effect of these factors on the research impact.  
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Figure 5- Conceptual model identifying domains affecting impact of collaborative research (Adapted from 
NCI/Trochim 2008)
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Significance 
Use of “big data” for health has gained significant momentum since 2012 both in the 
U.S. and globally. 82 This is primarily due to the following trends: a) rapid uptake of 
health information technology by the health sector, b) availability of affordable 
computing and advanced analytic methods, c) plans to scale outcome-based 
reimbursements methods to providers, and finally d) a growing need to micro-target 
preventive and curative interventions for individuals and populations. 83 With national 
healthcare expenditures rising globally (e.g. reaching 19.9% of the GDP in the US by 
2022), big data could potentially deliver great value to patients and health systems 
through service improvement and cost savings. 
One of the main promises of big data has been to enable more accurate assessment 
of health risk, for individuals and communities through the use of routinely collected 
digitized health information. Institute of Medicine (IOM, now called NAM) suggests that 
this opportunity should be harnessed through accelerated development of cross-
disciplinary innovations at the intersection of data science and healthcare. 84  
In summary, missed opportunities, waste and harm exist at alarming rates in the U.S. 
healthcare system and continuously learning healthcare systems that employ big data and 
advanced analytics may be part of the solution. 
                                                        
82 Andreu-Perez, J., Poon, C. C. Y., Merrifield, R. D., Wong, S. T. C., & Yang, G. Z. (2015). Big Data 
for Health. IEEE Journal of Biomedical and Health Informatics, 19(4), 1193–1208. 
https://doi.org/10.1109/JBHI.2015.2450362 
83 Pah, A. R., Rasmussen-Torvik, L. J., Goel, S., Greenland, P., & Kho, A. N. (2015). Big Data: What 
Is It and What Does It Mean for Cardiovascular Research and Prevention Policy. Current 
Cardiovascular Risk Reports, 9(1). https://doi.org/10.1007/s12170-014-0424-3 
84 Institute of Medicine (U.S.). (2012). Best care at lower cost: the path to continuously learning health 
care in America. (M. D. Smith, Ed.). Washington, D.C.: National Academies Press. 
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Our objective was to explore the best practices in efficient use of healthcare big data. 
We focused on research uses of big data and tried to answer the following questions: 
• Will big data help close the research-to-practice gap? 
• Will the use of advanced analytic methods, “natural language processes” and “machine 
learning”, precipitate the research impact? 
 
Section Nine: Study Objectives and Hypotheses 
Overall aim: to develop recommendations for efficient use of healthcare big 
data in research to enhance research impact. 
Objective 1 (Quantitative Study) - To examine the association between richness of 
data and use of “advanced analytic methods” with a multi-item measure of research 
impact across three data environments 
Hypotheses 
H1.1 Richer mix of data, as measured by a data environment’s systematic use of 
electronic health records (EHR), or Natural Language Processing (NLP) in research, is 
associated with high scientific impact of research. 
H1.2 Use of advanced analytic methods remains uncommon across selected data 
environments. 
H1.3 Use of advanced analytic methods is associated with high scientific impact 
across selected data environments. 
 
Objective 2 (Quantitative Study)- To examine the association between measures of 
scientific collaboration and research impact across data environments 
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 Hypotheses 
H2.1 Big data environments with intensive co-authorship networks produce higher 
scientific impact. 
H2.2 Richer mix of data sources in a big data environment is associated with 
intensive co-authorship networks. 
 
Objective 3 (Quantitative Study)- To explore why some healthcare big data 
environments may have been conducive to higher scientific impact and scientific 
networks than the others 
 
Hypotheses 
H3.1 The positive effect of richness of data on research impact across data 
environments varies by research fields, with cardiovascular disease, and cancer studies 
producing higher impact than mental health and other research fields 
H3.2 The positive effect of richness of data on research impact across data 
environments is partially mediated by the quality of the dissemination vehicle, as 
measured by journal impact factor (JIF) of the publications. 
 
Objective 4 (Key Informant Interviews) - To understand practices in conduct of 
research using healthcare big data that lead to high impact. 
(There are no pre-specified hypotheses for the qualitative study)  
Questions 
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4.1 What are key success factors of researchers in using large and complex 
observational data? 
4.2 What are the perceived roles of and opportunities for using of Natural Language 
Processing (NLP) and advanced analytic methods on research impact? 
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CHAPTER THREE: METHODOLOGY 
Chapter 3 lays out the methods used to conduct the quantitative analysis and the case 
studies. The first section outlines the process and content of the IRB approval. Section 2 
is organized by research objectives. Objectives 1 through 3 focus on the methodology for 
the quantitative analysis defining the independent and dependent variables and the 
analysis plan.  
Objective 4 describes the case study methodology to answer our research questions 
including the approach used for key informant interviews that was used to construct the 
case studies. The interview guide is included as Appendix III.  
 
Section One: Institutional Review Board (IRB) Approval 
In March 2017, the Boston University Institutional Review Board reviewed 
qualitative and quantitative methods of this study and determined that they were exempt 
human subject research (IRB Number: H-36088, APPENDIX III). Specifically, the 
interviews only examined public behavior and no protected health information (PHI) was 
collected, accessed, used or distributed during our qualitative or the quantitative analyses. 
Bedford VA IRB also reviewed the approach for key informant interviews in January 
2017 and determined that besides the home institution (Boston University), no additional 
oversight was required (APPENDIX III). 
 
Section Two: Study Design 
Overall aim: to develop recommendations for efficient use of healthcare big data in 
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research to enhance research impact. 
We used a mixed methods design comprising of both quantitative and qualitative 
arms to address the study objectives. Key informant interviews and publicly available 
literature and reports were used to develop the two case studies comparing the Veterans 
Health Administration (VHA) and Optum™ and OptumLab’s approaches to leveraging 
big data for research analytics. 
We defined healthcare big data environments as organizations that are characterized 
by the availability of large and complex observational data sources [with at least 20 
million lives], as well as research collaborations that seek to integrate the continuum of 
inquiry, research, and translation of the results into practice.85, 86, 87 	
 
Section Three: Research Plan 
Objective 1 - To examine the association between richness of data and use of 
“advanced analytic methods” with a multi-item measure of research impact across 
three data environments  
(See GLOSSARY or Table 3 for definition of terms and variables) 
Hypotheses 
H1.1 Richer mix of data, as measured by a data environment’s systematic use of 
                                                        
85 Madigan, D., Ryan, P. B., Schuemie, M., Stang, P. E., Overhage, J. M., Hartzema, A. G., … Berlin, 
J. A. (2013). Evaluating the Impact of Database Heterogeneity on Observational Study Results. 
American Journal of Epidemiology, 178(4), 645–651. https://doi.org/10.1093/aje/kwt010 
86 De Mauro, A., Greco, M., & Grimaldi, M. (2015). What is big data? A consensual definition and a 
review of key research topics (pp. 97–104). https://doi.org/10.1063/1.4907823 
87 Wallace, P. J., Shah, N. D., Dennen, T., Bleicher, P. A., & Crown, W. H. (2014). Optum™ Labs: 
Building A Novel Node In The Learning Health Care System. Health Affairs, 33(7), 1187–1194. 
https://doi.org/10.1377/hlthaff.2014.0038 
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electronic health records (EHR), or Natural Language Processing (NLP) in research, is 
associated with high scientific impact of research. 
H1.2 Use of advanced analytic methods in research remains uncommon across 
selected data environments. 
H1.3 Use of advanced analytic methods is associated with high scientific impact 
across selected data environments. 
Objective 2 - To examine the association between measures of scientific collaboration 
and research impact across data environments  
Hypotheses 
H2.1 Big data environments with intensive co-authorship networks produce higher 
scientific impact. 
H2.2 Richer mix of data sources in a big data environment is associated with 
intensive co-authorship networks.  
Objective 3 - To explore why some healthcare big data environments may have been 
conducive to higher scientific impact and scientific networks than the others 
Hypotheses 
H3.1 The positive effect of richness of data on research impact across data 
environments varies by research fields, with cardiovascular disease, and cancer producing 
higher impact than mental health and other research fields 
H3.2 The positive effect of richness of data on research impact across data 
environments is partially mediated by quality of the dissemination vehicle, as measured 
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by the journal impact factor (JIF). 
Study population and justification of the sample size - objectives 2, 3 and 4 
(quantitative study): 
Peer-reviewed original research publications between January 2013 and March 2016 
that used Veterans Health Affairs (VHA), Optum™ or IBM® MarketScan® were 
searched and integrated (APPENDIX I). For the exploratory cohort, publications were 
required to have linkable publication meta-data in both Google Scholar and PubMed. For 
the analytic cohort, studies were also required to have Web of Science and Altmetric 
data. Web of Science linkage provided data for the analysis of WoS citation rates, topic 
clusters and social network measures. Altmetric linkage supplied Twitter visibility and 
Altmetric attention score. 
Inclusion criteria 
1. Publication date had to be between Jan 2, 2013 and March 7 2016 
according to the ‘linked’ PubMed meta-data. 
2. IBM® MarketScan® and Optum™ studies had to have at least one 
mention of ‘Optum*’ or ‘MarketScan*’ after and in proximity of the following 
terms ‘data’, ‘data base’, or ‘database’ using the Google Scholar’s proximity 
operator. See APPENDIX I for further detail on search criteria and data linkage. 
3. For VHA original research, publication meta data (title, first author, and 
publication year) had to match the VHA Health Services Research & 
Development (HSR&D) list of publications obtained from: 
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http://www.hsrd.research.va.gov/publications/  (see exclusion criteria for 
exclusions) 
4. To be included in the cohort, all records were required to successfully link 
to PubMed and have a valid PubMed unique identifier (PMID) (Table 4). 
Exclusion criteria 
1. If analysis of PubMed meta data indicated that any of the terms (veteran*, 
optum*, marketscan*) were exclusively mentioned as an attribute of the authors. 
2. Publications without a valid PMID 
3. Publications classified as systematic reviews, meta-analysis, interventional 
studies (trial or quality improvement), qualitative research, comments, news and 
surveys. 
Study outcomes 
Table 2 includes specifications of outcome variables. 	  
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Table 2 - Outcome Variables 
Variable Data Source Definition Analyses 
Journal Impact 
Factor (JIF) 
 
Web of Science 
(WoS) journal 
citation report 
2013 
 
Data linkage: 
Journal Title 
“the frequency with which the 
“average article” in a journal has 
been cited in a particular year or 
period.”  
 
As published in Journal Citation 
Reports (JCR)88 
Continuous 
outcome; non-
normal distribution;  
GLM 
Continuous 
predictor (potential 
mediator) 
Times cited – 
Web of Science 
WoS 
 
Data linkage: 
PMID 
The ‘All Times Cited Counts’ 
displays the number of times the 
record was cited by other items from 
within Web of Science products.89 
Count outcome; 
may be zero inflated 
Times cited – 
Google Scholar 
Google Scholar 
 
Data linkage: “title 
text”+”publication 
year” (fuzzy link 
with PubMed 
PMID) 
The all times citations counts from 
journal articles, books and 
nontraditional sources, such as Web 
sites, dissertations, and open-access 
online journals. 90 
Count outcome 
Altmetric 
Attention Score 
api1.altmetric.com 
 
Data linkage: 
PMID 
• It is computed by altmetric.com 
and is made publicly available for 
researchers.  
• Attention Score ‘represents a 
weighted count of the amount of 
attention Altmetric.com has 
picked up for a research output’. 
It incorporates the number news 
outlets, and social media pages 
(e.g. Twitter, Google+ and 
Facebook) that mention the 
publication. 91 
Continuous 
outcome  
 
In general, these are 
‘alternative’ metrics 
of impact 
measuring the level 
of attention on the 
social media 6 
Times tweeted 
/retweeted 
api1.altmetric.com 
 
Data linkage: 
PMID 
Times tweeted, retweeted or 
mentioned 91 
Count outcome  
                                                        
88 The Clarivate Analytics Impact Factor (2019). 
https://clarivate.com/webofsciencegroup/essays/impact-factor/ 
89 Web of Science Core Collection Help (2019). 
https://images.webofknowledge.com/images/help/WOS/hp_times_cited_count.html 
90 Kulkarni, Abhaya V., Brittany Aziz, Iffat Shams, and Jason W. Busse. "Comparisons of citations in 
Web of Science, Scopus, and Google Scholar for articles published in general medical journals." Jama 
302, no. 10 (2009): 1092-1096. 
91 How is the Altmetric Attention Score calculated? (2019). 
https://help.altmetric.com/support/solutions/articles/6000060969-how-is-the-altmetric-attention-score-
calculated- 
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Independent variables 
Predictors and co-authorship metrics are defined and operationalized in Table 3. 
Table 3 - Independent Variables 
Variable Data Source Definition Analyses 
A. Independent variables 
A1. Data environment domain 
Data Source • Google 
Scholar for 
MarketScan
® and 
Optum™ 
publications 
• VHA HSRD 
list of 
publications  
• Levels: VHA, Optum™, MarketScan 
• This variable identifies three specific 
data environment used by research 
publications. 
• Classification is based on an algorithm 
that includes fuzzy text search and 
evaluates proximity of the popular 
name of the data source and words 
‘design’ and ‘methods’.  
• See appendix ‘text query syntax’. 
Categorical 
predictor 
(MarketScan as 
reference) 
A2. Individual publication domain 
Research 
Field 
PubMed meta 
data 
 
Data linkage: 
PMID 
• Clustering of Medical Subject Heading 
(MeSH) terms into the following 
categories: cardiovascular, neurological 
(including stroke and dementia), 
cancer, mental health conditions, 
endocrine conditions (e.g. diabetes and 
thyroid), other 
Binary predictors; 
a publication could 
fall into more than 
one category (e.g. 
cardiovascular 
condition, 
neurological 
outcome) 
Semantic 
similarity 
cluster – topic 
model 
PubMed 
 
Data linkage: 
PMID 
• Topic models assigned to a paper using 
the publicly available NLP software, 
Swift-Review 
• Two iterations were generated; 50 and 
100 clusters 
Binary predictors;  
Scientific 
similarity - 
topic cluster 
Web of Science 
(WOS) 
 
Data linkage: 
PMID 
• Two publications are bibliographically 
coupled if there is a third publication 
that is cited by both publications 92 
Categorical; 38 
mutually exclusive 
categories based 
on community 
membership 
Use of 
electronic 
health records 
PubMed 
abstracts 
• Levels: yes/no 
• Reported use of electronic medical 
records by individual research 
publications 
• See attachment ‘text query syntax’ for 
the fuzzy matching algorithm applied to 
Binary predictor 
                                                        
92 van Eck, Nees Jan, and Ludo Waltman. “Citation-Based Clustering of Publications Using 
CitNetExplorer and VOSviewer.” Scientometrics, vol. 111, no. 2, May 2017, pp. 1053–70. Springer 
Link, doi:10.1007/s11192-017-2300-7. 
		
47 
Variable Data Source Definition Analyses 
the title and abstract of the publication. 
Use of 
Advanced 
Analytic 
Methods  
PubMed 
abstracts 
• Levels: yes/no 
• Reported use of supervised and 
unsupervised machine learning 
methods or NLP by individual research 
publications 
• See appendix ‘text query syntax’ for the 
fuzzy matching algorithm applied to the 
title and abstract of the publication. 
Binary predictor 
Sample size - 
individual 
publication 
PubMed 
abstract 
• Numeric 
• Extracted from the abstract. See 
annexes for the algorithm. 
Continuous 
predictor; 
missing data if 
sample size 
absent in the 
abstract 
Publication 
Year 
PubMed meta 
data 
Publication year Citation counts 
depend on 
publication year. 
Funding 
source - 
federal 
PubMed meta 
data 
US government Binary predictor 
Funding 
source – non-
federal 
PubMed meta 
data 
non-US government Binary predictor 
A3. Author domain 
Lead author’s 
institutional 
affiliation 
PubMed meta 
data 
Institutional affiliation of the first author Categorical; 
missing data 
Co-authorship network metrics - We include these metrics in our analyses as 
surrogates of research collaboration. Research collaborations often form around and are 
strengthened by co-authorship social networks. They will be used both as outcome and 
independent variables.  
 
Analysis: R package iGraph 
Degree 
centrality 
 
Social Network 
Analysis (SNA) 
of PubMed meta 
data 
• The normalized degree centrality of an 
author in the network using the same 
data environment. Range:  0 - 1 
• This measure represents the intensity of 
network activity by the author and its 
popularity. 
Continuous 
outcome  
Closeness 
centrality 
SNA of 
PubMed meta 
data 
• The normalized closeness centrality of 
an author in the network using the same 
data environment. Range:  0 – 1 
• This measure is a surrogate for the 
Continuous 
outcome  
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Variable Data Source Definition Analyses 
independence and efficiency for 
communicating with other nodes in the 
network. 
Betweenness 
centrality 
SNA of 
PubMed meta 
data 
• The normalized betweenness centrality 
of an author in the network using the 
same data environment. Range:  0 – 1 
• It measures the number of times a 
particular node lies ‘between’ the 
various other nodes in the network. 
• The actor with a high value can most 
frequently control information flows in 
the network 
Continuous 
outcome  
Eigenvector 
centrality 
SNA of 
PubMed meta 
data 
• The normalized eigenvector centrality 
of an author in the network using the 
same data environment. Range:  0 –0.5 
• A node, which is connected to many 
other nodes that are themselves well-
connected, has a high eigenvector 
centrality and a node connected to 
nodes with a few connections has a 
much lower score 
• The actor with a high value is 
connected with more other centrally 
located authors. 
Continuous 
outcome  
Assembling the data set 
We first assembled a database of publications, publication meta-data, authorship 
network metrics, and research impact measures (APPENDIX I). The final data set was 
estimated to include around 2,000 publications by 7,000 co-authors. The unit of analysis 
was publication. To account for the author-level variations, we computed measures of co-
authorship and co-citation networks using Social Network Analysis (SNA) software (R 
Package iGraph). Specifically, we obtained degree, closeness, betweenness and 
eigenvector centralities that have been shown elsewhere to predict research impact. 9,10 
We assigned the greatest of the centrality measures among co-authors of a publication 
(i.e. centrality measures of the most influential author of a publication).  
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At the publication level, we had variables for richness of data sources used (use of 
electronic medical records), and also use of advanced analytic methods. Given the sample 
size, we were also able to account for secular trends by controlling for publication year. 
Using generalized linear modeling (e.g. Poisson regression), we modeled research impact 
by incrementally adjusting data source and two other sets of predictors: metrics of co-
authorship networks, publication year, funding source, and research topic (see Chapter 
two: Clustering	research	publications:	measures	of	research	similarity).   
Methodology of web scraping for scientometric variables 
This study relied on web scraping to obtain publication meta-data and research 
impact measure off the web, through application program interfaces (APIs). R was used 
as the main programming language for much of the scraping, data transformation, and 
linkages. 
We scraped the search results and Google Scholar (GS) metadata including citation 
counts by ‘Harzing's Publish or Perish’, an open source non-proprietary but stable API 
that is designed specifically to leverage GS. We crosswalk this data with PubMed using 
document title and publication year as a unique identifier (Table	2 and Table	3). The 
crosswalk was done with E-Util and ‘Entrez’, an R package that allows parametric 
leveraging of PubMed within R environment. Success rate of Google Scholar-PubMed 
crosswalk was evaluated (APPENDIX I). Text data was transported between GS, 
PubMed and Web of Science (WoS) in ‘comma separated values’ and ‘XML’ formats. 
Data was cleaned iteratively using a systematic semi-automated algorithm that 
applied exclusion criteria on document language, publication type, study design, and data 
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sources (appendix I). 
Clustering peer-reviewed publications 
Heterogeneity of original research publication makes the study of research impact 
based on bibliometric measures difficult. There are different ways to cluster publications. 
In this study, we applied three approaches to cluster research articles: 
1. Broad topics based on MeSH keywords: This method was mainly used 
as an exploratory analysis. Medical Subject Headings (MeSH) is the National 
Library of Medicine (NLM) controlled vocabulary thesaurus used for indexing 
articles in PubMed.93 All retrievable primary and secondary MeSH terms were 
scraped using the Entrez Programming Utilities (E-utilities). 94 Missingness was a 
major challenge despite several attempts for fresh downloads. MeSH terms were 
then manually clustered by the investigator into 6 buckets based on main disease 
categories under ICD-10-CM that were most common (≥5% of the sample). The 
final buckets were: Cardiology, Nervous System, Mental Disorders, Cancer, and 
Endocrine Disorders. Articles with missing MeSH data or not assigned to the 
main 5 categories were labeled as “other”. 
2. Topic modeling using a publicly available text-mining software 
SWIFT-Review: SWIFT-Review is a text mining workbench in the public 
domain that has been developed on NIH funding. The software uses a machine 
learning algorithm to cluster and prioritize manuscripts. Through an iterative 
process (number of iterations = 5, each time incrementally training the algorithm 
                                                        
93 MeSH ().https://www.ncbi.nlm.nih.gov/mesh 
94 Entrez Programming Utilities Help (2010), https://www.ncbi.nlm.nih.gov/books/NBK25501/ 
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on 10 new documents), we clustered our sample into 50 and 100 “clusters” based 
on semantic similarities in the free text of article’s title, abstract and the pre-
populated MeSH terms. The algorithm creates bag-of-words and performs latent 
Dirichlet allocation (LDA) topic modeling using term frequency-inverse 
document frequency (TF-IDF) scores. 95  
3. Bibliographic Coupling: An increasingly popular method to cluster 
research publications that is based on direct citation relations between articles. 
When studying large numbers of papers, analyzing and interpreting clusters is 
often imperfect and complicated. We used a JAVA-based tool that is freely 
available in the public domain called VOSviewer. 96 This platform clusters 
articles based on their relatedness based on bibliometric coupling. The algorithm 
used by VOSviewer performs a modularity-based community detection in large 
networks called “smart local moving algorithm”. This algorithm has been shown 
to be superior to other algorithms that are based on large-scale modularity 
optimization. 97,98 
Analysis plan 
We present univariate and unadjusted comparison of outcome variables (Table 2) by 
                                                        
95 Howard, Brian E., et al. “SWIFT-Review: A Text-Mining Workbench for Systematic Review.” 
Systematic Reviews, vol. 5, May 2016. PubMed Central, doi:10.1186/s13643-016-0263-z. 
96 Van Eck, N. J., & Waltman, L. (2014b). Visualizing bibliometric networks. In Y. Ding, R. 
Rousseau, & D. Wolfram (Eds.), Measuring scholarly impact: Methods and practice. Berlin: Springer. 
97 Waltman, Ludo, and Nees Jan van Eck. “A Smart Local Moving Algorithm for Large-Scale 
Modularity-Based Community Detection.” The European Physical Journal B, vol. 86, no. 11, Nov. 
2013, p. 471. Springer Link, doi:10.1140/epjb/e2013-40829-0. 
98 van Eck, Nees Jan, and Ludo Waltman. “Citation-Based Clustering of Publications Using 
CitNetExplorer and VOSviewer.” Scientometrics, vol. 111, no. 2, May 2017, pp. 1053–70. Springer 
Link, doi:10.1007/s11192-017-2300-7. 
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data source. We also describe characteristics of the topic clusters generated and justify a 
choice of the most relevant method. We then introduce an algorithm to meaningfully 
label the topic clusters. We also describe bi-variate analysis of the research impact 
measures by these network characteristics. 
Poisson Regression 
Almost all of our outcome variables have non-Gaussian distributions. We used the R 
packages: “glm” and “lme4” that allow Generalized Linear Modeling with useful 
distribution and link functions. The main predictors were data source and the model was 
adjusted for topic clusters, source of funding, journal impact factor, use of advanced 
analytic methods and calendar year. Given the power and sample size, we also evaluated 
the following a priori interactions for all primary and secondary outcomes: 
• Research field and data source 
• Calendar year and data source 
Objective 4 - To understand practices in conduct of research using healthcare big data 
that lead to high impact. 
Although there were no pre-specified hypotheses for the qualitative study, we 
prioritized the following questions in the interview protocol: 
1. What are best practices of researchers in using big data? 
2. What are the role of and opportunities for using of Natural Language 
Processing (NLP) and machine learning (ML) to improve research 
impact? 
The aim of the qualitative study was to expand the insights gleaned from the findings 
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of our quantitative analysis. To identify characteristics of big data environments that 
might drive high impact research, we conducted a series of key informant interviews 
(KII) with senior researchers and experts of healthcare analytics. The key informants 
were selected if they had used VHA or Optum™ data sources. Interviewees were selected 
from researchers with high impact publications (as measured by Google Scholar citation 
rates in the highest quartile of publications of their affiliated organization). The sample 
included 11 participants. The interview guide consisted of open-ended questions and the 
overall objective was to understand practices of researchers that led to improved 
translational outcomes. The interview questions (APPENDIX III) had the following flow: 
specific research projects that tangibly influenced policy, practice or scientific changes, 
research strategies that were perceived to work best in use of big data, use of advanced 
analytic methods and effective collaborative practices. We also explored if there were 
any challenges across specific research fields. All the interviews were transcribed. We 
analyzed the data thematically using the Grounded Theory approach. The overall 
sentiment and high-level themes were identified first. Next, sub-themes were identified 
and prioritized based on the frequency with which they were mentioned by the 
interviewees. We used NVivo v.12 software to develop a final map of the most common 
themes. 
All interviews were audiotaped with limited note-taking. The investigator transcribed 
the audio recordings using Express Scribe Transcription Software. The analysis focused 
on identification of major themes related to specific research strategies, organizational 
tools, and resources as well as priority fields of study that were perceived to contribute to 
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high research impact. 
Study population and justification of the sample size - objective 4 (qualitative study): 
A convenience sample of 11 senior researchers and healthcare analytics experts with 
high impact peer-reviewed publications that used Veterans Affairs and Optum™ data 
environments were selected (a total of 20 individuals were contacted of whom 11 agreed 
to participate). These individuals were identified based on the Google citation counts of 
their publications based on the data set assembled for objectives 1, 2, and 3. Interviewees 
could be current or former employees of the Veterans Health Administration, and 
Optum™.  
 Inclusion criteria 
1. Authors of peer-reviewed publications between January 2013 and March 2016 
that mentioned either the Department of Veterans Affairs or Optum™ as a source 
of data in their publication (see inclusion criteria for peer-reviewed publications 
data set) 
2. Authors whose publications was categorized as ‘high impact’ (i.e. at least one of 
their publications had 10 or more citations according to Google Scholar). 
Exclusion criteria 
Opting out of the study before, during or after the interview 
Key informant interviews 
Interviewees who met the inclusion criteria were offered participation by the 
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investigator (PI) and were asked to provide their contact information, if missing. Next, 
they were contacted by the PI. Once contact with potential participants was established, if 
a participant confirmed their interest and consent, the PI emailed a formal 'invitation 
email' and if requested a list of interview questions. 
We sent one reminder to the participants with additional reminders as needed. For 
each of the 11 suggested primary participants, there was a reserve who would be 
contacted in case, the primary invitee declined. 
An appointment with the interviewee was made through email and phone, according 
to the participant’s preference. The interviews were conducted through phone, and took 
between 30 minutes and one hour and were audio-recorded. 
Consent 
We requested IRB approval of a verbal consent since the research presented no more 
than minimal risk of harm to the participants and involved no procedures for which 
written consent would normally be required outside of the research. 
At the start of the interview, interviewer would ask if participant had any questions 
about the consent form and if he or she agreed to be interviewed and audiotaped. Prior to 
beginning the interview, a short passage (exempt information sheet/consent statement) 
was read for the interviewee (Appendix III). 
This passage included the following required information: 
1) That this was a research study 
2) The purpose and what the subjects were being asked to do and approximately, how 
long it would take 
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3) That participation was voluntary 
4) Who to contact with questions about the study 
The PI made sure the participant fully understood the verbal consent, and all 
questions were properly addressed. If the interviewee agreed with the terms of 
participation, verbal consent was confirmed. The PI also emailed the exempt information 
sheet/consent statement information to the participant. Once informed consent had been 
obtained, the interview started. 
Participants did not receive any honorarium, cash or any in-kind incentives for their 
time. As part of the invitation through email and phone, interviewees were provided, 
upon request, a list of questions on the interview guide. The key informants or his/her 
organization were not responsible for any research-related costs.  
Interview guide 
The overall objective of the key informant interview was to understand practices at 
the Veterans Health Administration and Optum™ that encourage use of big data for high 
impact research. The following themes and questions were explored, time allowing, 
during the interviews: 
1. Specific research areas that may benefit the most from big data to create 
high impact (eg influencing policy, practice or unique scientific innovation), 
2. Opportunities for improving researchers access to big data, particularly for 
the public health community 
3. Research strategies that work best in the context of large, noisy and 
complex observational data sets, 
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4. Effective (research) collaboration practices. 
5. (Potential) influence of Natural Language Processing and machine 
learning on their current or past work 
6. Having worked with the <data environment>, do they see any 
opportunities for using NLP and advanced analytic methods that may further 
enhance the impact of your research? 
The interview guide is included as APPENDIX III. 
 
Study Limitations 
The first limitation was generalizability of findings to other big data sources. 
Although we looked at only 3 data environments, one federal and two private, we believe 
the findings may be reasonably generalizable. All 3 environments are considered big data 
players in the U.S. and have been repeatedly cited as sources of big data for both 
methodology and subject matter research. 26, 99, 100 The other limitation was the use of 
citation rates as a measure of research impact which in itself is the subject of considerable 
debate. 6 To address this, we used two other measures of impact that look at different 
dimensions of research impact: journal impact factor (JIF) and AltemetricsTM in addition 
to citation rate estimates from two different sources. JIF is considered a normalized 
estimate of impact and is viewed by many researchers as the “crown indicator”. 6 A third 
                                                        
99 Voss, Erica A., et al. “Feasibility and Utility of Applications of the Common Data Model to 
Multiple, Disparate Observational Health Databases.” Journal of the American Medical Informatics 
Association, Feb. 2015, p. ocu023. jamia.oxfordjournals.org.ezproxy.bu.edu, 
doi:10.1093/jamia/ocu023. 
100 OMOP Common Data Model (2019). https://www.ohdsi.org/data-standardization/the-common-
data-model/ 
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limitation was the impact of publication bias that may differentially affect our 3 
comparator groups. Our analysis does not suggest that this was a major source of bias. 
26,85 
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CHAPTER FOUR: RESULTS OF THE QUANTITATIVE STUDY 
Section One: Sample Size and Attrition Table 
We analyzed two cohorts of peer-reviewed original research publications (Table 4). 
Cohort 1 with the larger size was used for descriptive analysis. Cohort 2 was a subset of 
cohort 1 that was used for the majority of the multivariable analyses, unless explicitly 
mentioned. Two-hundred sixty-nine publications were dropped from cohort 2 due to 
missingness of bibliometric data from the Web of Science. There were 54 publications 
that had used more than one of the 3 data sources. 
Table 4- Attrition Table 
Inclusion/exclusion steps N Notes 
Initial list of peer-reviewed 
publications 
14,963 Observation window: 1/1/2013 - 3/15/2016 
VHA 11,829  
IBM® MarketScan®  2,274 Google Scholar Search; retrieved 3/15/2016 
Optum 860 Google Scholar Search; retrieved 3/15/2016 
Successfully Linked to 
PubMed Metadata 
5,949 To link with unique identifier: PMID (for linkage 
with Web of Science and Altmetric data) 
VHA 4,613  
IBM® MarketScan®  976  
Optum 360  
Applying exclusion criteria  Exclusions: 
Systematic Reviews and Meta-analysis 
Clinical trials 
Non-RCT Interventional and Quality Improvements 
Surveys, qualitative research, case studies 
Non-research: Taskforce reports, recommendations, 
guidelines, Corrections, Editorial material, News 
VHA 1,082  
IBM® MarketScan®  578  
Optum 247  
Cohort 1 1,907 Descriptive cohort 
Cohort 2 1,638 Analytic cohort: Subset of cohort 1 excluding 
publications with missing Web of Science data that 
was required for social network analysis and related 
variables 
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Section Two: Characteristics of the Sample 
Characteristics of the analytic sample are shown in Table 5. Fifty-seven percent of 
the publications used VHA data, followed by IBM® MarketScan® with 30% and 
Optum™ 13% of the sample.  
Based on clustering of articles by Medical Subject Heading (MeSH) terms, mental 
health condition were the most common subject among the VHA studies (24%), followed 
by cardiovascular diseases (15%). Cardiovascular conditions were the most common 
subject among both Optum™ and MarketScan® studies. While all of the VHA studies 
received federal funding, only 17 and 18% of Optum™ and MarketScan® studies were 
federally funded.  
Cumulatively over the life of the study, publications were on average cited 3.2 times, 
in the Web of Science publications. Forty-seven percent of all publications had received 
no citations by March 2016 (Table 5). 
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Table 5- Characteristics of the Sample 
 Total MarketScan® (MS) 
Optum™ 
(OP) VHA 
Total N 1,907 578 247 1,082 
% 100 30 13 57 
Publication year (row %)     
2013 27% 25% 16% 31% 
2014 29% 29% 22% 31% 
2015 37% 37% 46% 34% 
2016 5% 7% 15% 2% 
Field (row %) a     
Cardiology 15% 14% 14% 15% 
Nervous System 8% 8% 6% 9% 
Mental Disorders 16% 6% 8% 24% 
Cancer 8% 8% 9% 8% 
Endocrine 7% 7% 7% 7% 
Average authors per paper - mean (std) 6.2 (2.8) 5.5 (2.4) 5.8 (3.0) 6.6 (3.0) 
% Federally funded 64 18 17 100 
WoSb Journal Impact Factor c- mean (std) 4.2 (4.7) 3.4 (3.0) 4.6 (5.8) 4.5 (5. 4) 
Times Cited (WoS) - mean (std) 3.2 (9.2) 3.1 (8.8) 1.7 (3.7) 3.6 (11.3) 
% with zero WoS citations 47 51 63 42 
a Subjects could overlap, not mutually exclusive; b WoS: Web of Science; c: 2013-2014 Impact 
Factor 
 
Section Three: Clustering of Research Publications 
We used 3 methods to cluster the cohort into more homogeneous subject groupings. 
Clustering based on bibliographic coupling yielded the most plausible classification 
based on manual validation of a 5% subset. Below we briefly describe the output of each 
clustering approach:  
Broad classification based on MeSH keywords: We started with this method as it 
required the least complex processing of the data. The MeSH terms were rank ordered 
according to their frequency and manually reviewed and assigned to the following 6 
categories matching the main disease classes of ICD-10-CM. We stopped generating new 
		
62 
categories if the MeSH terms were missing (i.e. not retrievable from PubMed) or the 
category cell size was less than 5% of the overall sample size. Fifty-four percent of 
publications could not be classified (Figure 6). As shown with the second and third layer 
in the graph, 18% of the articles were classifiable into more than one disease category, 
demonstrated by superimposing spikes with a different color. The most common 
overlapping classes were diseases of the nervous system and mental disorders (6%) 
followed by cardiovascular conditions that overlapped with endocrine disorders category 
(4%). Classification of studies based on MeSH terms appeared to be least specific. 
 
 
 
 
 
 
 
Disease categories (N=1,907): 
Cardiovascular  
Nervous system  
Cancer  
Mental Disorders  
Endocrine diseases  
Other – not classifiable  
 
Figure 6- Disease categories a assigned to studies based on manual classification of 
MeSH b Terms 
a The second and third layer in the graph, identify articles that were classifiable into more than one 
disease category, demonstrated by superimposing spikes with a different color. 
b MeSH: Medical Sub-heading 
 
54%	
13%	
15%	
8%	 7%	
4%	
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Topic modeling based on free text of the title and abstract – 
Using latent Dirichlet allocation (LDA) topic modeling, we trained a machine 
learning algorithm to cluster publications based on iterative annotation of article titles, 
abstracts and PubMed meta-data. Two sets of topic models were developed and forced to 
include 50 and 100 topic models. Articles were probabilistically assigned to each topic 
model using LDA. Labeling of the topic model was performed by the algorithm (see 
appendix II, page 148). 
Bibliographic coupling – Using the publicly available VOSViewer with default 
settings, we ran a clustering algorithm based on bibliographic proximity between 
publication pairs. The algorithm determines an optimum location (defined by X and Y 
coordinates on a two-dimensional plain) for each publication based on the number of 
references it shares with the neighboring publications in the network. 
In a sample of 1,638 publications with a linkable list of references from Web of 
Science, the algorithm identified 38 clusters (Table 6). These 38 clusters consist of 
articles that shared the highest number of references among themselves as compared to 
shared sources with other communities. The software does not assign labels to clusters. 
Labeling was carried out post-hoc by the investigator. We used word clouds of 
publication titles, weighted by number of papers, to label clusters (Figure 7). 
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Figure 7- Labeling topic clusters, frequency weighted word cloud of publication 
titles 
Figure 7 shows the frequency weighted word cloud of clusters 1 through 10. The 
clouds confirm relative within cluster homogeneity of articles based on the text of their 
titles. For instance, cluster one could be best represented by the words “cancer”, followed 
by “colon” and “breast”. We label this cluster “Cancer/ colon / breast” (Table 6). 
Wording of titles for cluster 2, however, seems to show more heterogeneity. We labeled 
this cluster “Cost 1- Insurance”. 
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Table 6- Topic clusters based on network analysis of bibliographic coupling and 
distribution by data source 
Cluster # Cluster Label MS OP VHA  
Total (N) 578 247 1,082    
(column %) 
 
0 Insufficient data to cluster 15.6 26.3 10.4 
1 Cancer 1- colon / breast 5.4 4.5 7.2 
2 Cost 1- Insurance 9.5 4.0 2.8 
3 AFib/CAD 3.6 3.6 4.6 
4 Vaccines 8.3 6.1 1.1 
5 Cost 2- Utilization 6.7 4.0 2.2 
6 MH 1-PTSD 0.2 1.6 5.7 
7 Opioid 5.0 4.5 2.2 
8 Sexual trauma 0.2 0.0 5.5 
9 Treatment Adherence: BP/CVD 1.6 3.2 3.8 
10 DM 3.3 4.5 2.6 
11 Antibiotics/Infectious complications  0.9 0.8 4.3 
12 Drug ID 5.7 4.9 0.8 
13 Surgery- Bariatric 1.2 1.2 3.1 
14 VTE 2.2 0.8 2.4 
15 Cost 3-MH 2.8 4.9 1.1 
16 HIV 0.2 0.8 3.3 
17 MH 2- Schz/Dep 1.6 0.8 2.8 
18 Dementia 0.0 0.8 3.3 
19 Cost 4-quality 3.1 1.6 1.3 
20 Cancer 2-Lung 0.2 2.0 2.8 
21 MH 3-PTSD 0.0 0.0 3.2 
22 Homelessness 0.2 0.4 3.0 
23 Eye conditions 3.1 1.6 1.2 
24 Cost 5- Utilization 2.2 1.2 1.7 
25 Hospital Readmission 0.9 1.6 2.3 
26 TBI 0.0 0.0 3.2 
27 Cost 5-MH 2.8 2.8 1.0 
28 Hepatitis C 2.9 2.8 0.7 
29 GI 1.4 0.8 1.9 
30 CAD2 1.2 1.6 1.9 
31 Fractures-Muscls. 1.6 1.6 1.6 
32 Cancer 3-Prostate 2.2 2.4 0.5 
33 MH 4-Suicide 0.2 0.0 1.8 
34 Chronic Pain 0.2 0.4 1.4 
35 Kidney1 2.8 0.0 0.1 
36 Rheumatoid A-biolog. 0.7 1.2 0.5 
37 Could not be labeled 0.5 0.4 0.2 
38 Kidney2 0.0 0.0 0.2 
AFib: Atrial fibrillation; CAD: coronary artery disease; MH: mental health; PTSD: post-traumatic stress 
disorder; BP: blood pressure; CVD: cardiovascular diseases; DM: Diabetes Mellitus; VTE: venous 
thromboembolism; Schz: Schizophrenia; Depp: depression; TBI: traumatic brain injury; biology.= biologics 
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Figure 8- Relative spread a of topic clusters by data source, n=1,638 b 
a Relative location of studies was estimated in terms of “proximity” to neighboring studies in a 2 
dimensional plain and the dimension with greatest variance displayed on the X axis. 
b each data point represents a study; Green: MarketScan, Red: Optum™, Blue: VHA 
 
Map of identified topic clusters based on bibliographic coupling is shown in Figure 8 
and 9. Relative location of studies was estimated in terms of “proximity” to neighboring 
studies in a 2 dimensional plain (distances with greatest variance displayed on the X 
axis). Upon visual inspection, greatest overlap existed between MarketScan® and 
Optum™ publications and a long tail to the right for the VHA studies (Figure 8). The 
long tail of VHA studies belong to special topics such as clusters 6, 8, 21 and 22 (Figure 
9). These clusters focus on homelessness, sexual trauma and PTSD research. One of the 
clusters that shows considerable overlap among all three data sources is cluster 7, 
opioids.  
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Figure 9- Relative area / location of various topic clusters, n=1,638 b 
a Relative location of studies was estimated in terms of “proximity” to neighboring studies in a 2 
dimensional plain and the dimension with greatest variance displayed on the X axis. 
b Each data point represents a study; Green: MarketScan, Red: Optum™, Blue: VHA 
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Mental health clusters using VHA data appear to have lower impact than “overlap” 
clusters such as opioids, AFib/CAD, or studies on vaccines and surveillance (Figure 10).  
The spread of clusters also vary by year (Figure 11). There may be fewer studies in 
mental health clusters using the VHA data in 2015 and 16.  
Publications in high impact journals appear to be more clustered around the center 
(Figure 12).  
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Figure 10- Publications-first author by data source, and publication year; node size weighted by # times ever cited 
through WoS, N=1,638   
(Each Data Point Represents a Publication; Green: MarketScan, Red: Optum™, Blue: VHA) 
WoS: Web of Science 
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Figure 11- Variation in spread of topic clusters by publication year, N=1,638  
(Each Data Point Represents a Publication; Dark Blue: 2013, Light Blue: 2014, Yellow: 2015, Red: 2016)  
		 71 
 
 
Figure 12-Clustering of subjects by journal impact factor, N=1,638  
(Each Data Point Represents a Publication; Blue; Journal Impact Factor (JIF) <5; Green, Yellow and Red JIF>5)
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Section Four: Bivariate Associations between Measures of Research Impact and 
Data Source 
 The quality of publishing journals appears to be associated with the data source. 
Unadjusted mean of Journal Impact Factor (JIF) is generally comparable among the 3 
data sources across disease categories (Figure 13). In cancer and cardiovascular research, 
VHA studies appear to be published in higher impact journals. There is wide variability 
for endocrine research using Optum™ data.
 
Figure 13- Variation in distribution of journal impact factor by data source across 
disease categories 
 
		
73 
Figure 14 shows distribution of research impact, in quintiles, across the 3 data 
sources (with dark blue and light blue representing the top and bottom quintile 
respectively). With the exception of Altmetric Attention Score, the distribution of high 
impact studies varies across data sources, with VHA including most of the high impact 
studies based on Google Scholar, while Optum™ studies were more frequently found in 
high JIF journals. 
A. Times cited - Google    
P-Value of Chi.sq  0.000 
B. Journal Impact Factor (JIF)   
P-Value of Chi.sq  0.000 
  
 
 
C. Online Attention Score (Altmetric) 
P-Value of Chi.sq  0.437 
 
 
 
 
 
Figure 14- Distribution of publications in different quintiles of impact - all research 
topics 
Legend: 
1ST quintile 2nd quintile 3rd quintile 4th quintile 5th quintile 
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Section Five: Characteristics of Co-authorship Networks Using Big Data Sources 
Distributional properties (univariate) of centrality measures of co-authorship 
networks are shown in Table 7.  The network metrics were estimated at the individual 
author level and then summarized by publication. Only the most influential author per 
publication, according to degree centrality value, was selected regardless of the order of 
authors. Due to substantial differences in sample size by data source, all metrics have 
been normalized to facilitate comparison. Twenty-one articles were dropped from the 
social network analysis because author names were either missing or included anomalous 
characters. 
Table 7 - Univariate analysis of co-authorship centrality metrics, nodes:authors, 
relation:co-authored document, # documents=1,886a 
Measures of Co-authorship 
Network Centrality b N Obs Mean Std Dev Min Max 
Degree centrality 1,886 0.014 0.014 0.000 0.082 
Closeness centrality 1,886 0.001 0.000 0.000 0.001 
Betweenness centrality 1,886 0.007 0.009 0.000 0.055 
Eigenvector centrality 1,886 0.022 0.130 0.000 1.000 
a21 articles were dropped from the social network analysis due to missing author name or 
anomalous spelling; ball 4 metrics are normalized 
 
Figure 15 a and b show co-authorship networks using VHA, IBM® MarketScan® 
and Optum™ data. Two authors are considered related if they co-authored the same 
paper.  
Figure 15a focuses on research productivity per individual researcher, that is the 
number of publications by author and shows substantial variability, mean (std): 1.7 (1.8) 
median=1, Interquartile Range=1. The authorship networks consist of both relatively 
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disconnected and also well-connected communities. 
The SNA identified 28 relatively distinct communities based on individual-level co-
authorship network analysis, each labeled by a color shown in Figure 15. These 
communities represent co-authorship collaborations among individual authors and 
typically cut across institutions. Eighty persons were co-authors in 33% of the 
publications and 71% of individuals had only co-authored one paper in the time window 
between January 2013 and March 2016. 	 	
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Figure 15 a – node size proportional to the number of documents authored 
 	 	
		
77 
Figure 15 b – node size proportional to total number of citations a received 
 
Figure 15- Co-authorship networks using VHA, IBM® MarketScan® and Optum™ 
data (2013 - 2016) 
aWeb of Science citations 
Upon visual inspection of Figure 15 a and b, there appear to be overlap between 
communities with authors with high productivity and also those with high impact. The 
unadjusted association between productivity and impact, however, was not straight 
forward. For instance, there were many one-time contributors to high impact publications 
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that appear to represent a distinct sub-sample of authors. 
The SNA identified 12 relatively distinct communities in institution-level co-
authorship network analysis. Top 20 institutions with highest research output, impact and 
network centrality are listed in Table 8. 
Table 8 - Top 20 institutions with highest research output, impact and network 
centrality 
Rank Research Output Total Citation Average Citation Network Centrality per Community 
1 Univ Washington (147) 
Univ Washington 
(1618) Mt Sinai Sch Med (83) 
Univ Washington 
(463) 
2 Univ Michigan (143) 
Univ Calif Los 
Angeles (1611) 
Univ Colorado Denver 
(76) Yale Univ (383) 
3 Stanford Univ (123) 
Baylor Coll Med 
(1468) Univ Vermont (65) Stanford Univ (341) 
4 Duke Univ (109) Harvard Univ (1455) Va Eastern Colorado Hlth Care Syst (51.8) Harvard Univ (319) 
5 Harvard Univ (102) 
Univ Michigan 
(1394) Niaaa (48. 9) Univ Pittsburgh (309) 
6 Univ Penn (100) Yale Univ (1363) Univ Texas Sw Med Ctr Dallas (43.7) Boston Univ (300) 
7 Yale Univ (96) Stanford Univ (1347) Birmingham Vet Adm Hosp (42.4) Baylor Coll Med (295) 
8 Baylor Coll Med (95) Univ Penn (1301) 
Vet Affairs Eastern 
Colorado Hlth Care 
Syst (36.2) 
Univ Michigan (285) 
9 Univ Calif Los Angeles (92) 
Univ Pittsburgh 
(1293) 
Atlanta Va Med Ctr 
(36) Univ Minnesota (195) 
10 Boston Univ (87) Michael E Debakey Va Med Ctr (1162) 
Minneapolis Vet 
Affairs Hlth Care Syst 
(35.4) 
Columbia Univ (95) 
11 Univ Pittsburgh (86) Duke Univ (1102) Va Med Ctr (30.7) 
Med Univ S Carolina 
(79) 
12 
Michael E 
Debakey Va Med 
Ctr (71) 
Univ Minnesota 
(987) 
George Washington 
Univ (27.7) 
Johns Hopkins Univ 
(74) 
13 Univ Minnesota (67) Boston Univ (917) 
Univ Texas Md 
Anderson Canc Ctr 
(27.3) 
 
14 Univ N Carolina (67) Emory Univ (830) 
Henry Ford Hlth Syst 
(25) 
 
15 Va Palo Alto Hlth Care Syst (62) Univ Colorado (813) 
Johns Hopkins Sch 
Med (24.8) 
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16 Univ Colorado (53) CDC (771) Tufts Univ (23.2) 
 
17 Univ Calif San Francisco (49) 
Univ N Carolina 
(658) Univ Maryland (22.5) 
 
18 
Brigham & 
Womens Hosp 
(48) 
Univ Texas Sw Med 
Ctr Dallas (612) 
Childrens Hosp 
Philadelphia (21.8) 
 
19 
Va Connecticut 
Healthcare Syst 
(48) 
Univ Maryland (584) Univ Rochester (21.4)  
20 Med Univ S Carolina (48) 
Univ Calif San 
Francisco (547) 
Johns Hopkins 
Bloomberg Sch Publ 
Hlth (21.3) 
 
 
We labeled communities based on institutions with highest influence (Table 9).  
Table 9 - Labeling institutional co-authorship clusters with the node with highest 
influence 
Community/Cluster 
Label 
x y Community 
# 
Total link strength Color 
Johns Hopkins Univ 0.19 -0.27 1 74  
Univ Minnesota 0.01 0.57 2 195  
Univ Michigan 0.26 0.57 3 285  
Univ Pittsburgh -0.69 -0.01 4 309  
Boston Univ -0.29 0.08 5 300  
Yale Univ -0.54 0.19 6 383  
Harvard Univ 0.33 0.04 7 319  
Univ Washington -0.21 0.28 8 463  
Baylor Coll Med -0.87 -0.41 9 295  
Columbia Univ 0.54 -0.05 10 95  
Med Univ S Carolina -0.64 -0.93 11 79  
Stanford Univ -0.32 0.06 12 341  
 
Figure 16 a and b show institutional co-authorship networks using VHA, IBM® 
MarketScan® and Optum™ data. The institutions were related if an article was co-
authored by individuals mentioning affiliations. 	 	
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Figure 16 a – node size proportional to the number of documents authored 
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Figure 16 b – node size proportional to total number of citations received 
 
Figure 16 - Institutional co-authorship networks using VHA, IBM® MarketScan® 
and Optum™ Data (2013 - 2016) 
 
Table 10 shows pair-wise (unadjusted) correlations between co-authorship network 
centrality measures and various measures of research impact. None of the measures of 
co-authorship influence appear to be associated with Altmetric attention (neither Twitter 
mentions nor overall attention score). In contrast, the 4 measures of social influence seem 
to be positively associated with scientific impact. The association between number of 
collaborators (degree centrality) and Journal Impact Factor (JIF), Web of Science 
citations and Google Scholar citations is significant. Social influence due to betweenness, 
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i.e. frequency of bridging between co-authors, is associated with JIF and to a lesser extent 
with actual citation rates. Eigenvector centrality, as a measure of quality of 
collaborations, is moderately associated with actual scientific impact but not quality of 
the publishing journal. 
Table 10- Pair-wise Correlation between Co-authorship Centrality Measures and 
Research Impact: Pearson Correlation Coefficient (p-value) 
Measures of 
Co-
authorship 
Influence 
Journal 
Impact 
Factor 
(JIF) 
Times cited 
– Web of 
Science 
Times cited 
– Google 
Scholar 
(GS) 
Annualized 
GS 
Times 
Tweeted/ 
Retweeted 
Altmetric 
Attention 
Score 
Degree 
centrality 
0.10 
(***) 
0.09 
(***) 
0.10 
(***) 
0.08 
(***) 
-0.02 
(NS) 
-0.01 
(NS) 
Closeness 
centrality 
0.02 
(NS) 
0.04 
(NS) 
0.05 
(*) 
0.04 
(NS) 
0.00 
(NS) 
0.00 
(NS) 
Betweenness 
centrality 
0.09 
(***) 
0.05 
(*) 
0.06 
(*) 
0.04 
(NS) 
-0.01 
(NS) 
0.00 
(NS) 
Eigenvector 
centrality 
0.02 
(NS) 
0.06 
(*) 
0.05 
(*) 
0.05 
(*) 
-0.01 
(NS) 
0.00 
(NS) 
NS: not significant; *: 0.05≥p>0.01; **: 0.01≥p>0.001; ***: p≤0.001 
 
 
Section Six: Multivariable and Multivariate Models 
Role of secular trends in research productivity 
Table 11 shows the secular trend of research productivity across the 3 data sources. 
Rate of change in the number of publications for 2015 compared to 2013 for Optum™ 
Studies was 2.56 times VHA (95% CI 1.74 - 3.76). Rate of change for the same time 
period for MarketScan® studies was 1.38 times VHA (95% CI 1.74 - 3.76). Since we are 
not including interventional studies, these slopes will not be reflective of the changes in 
RCT publications.	  
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Table 11 - Secular Trend Model for the Research Productivity (number of 
publications modeled as count) 
Comparisons Ratio of Change Rate a 
95% CI 
Lower 
95% CI 
Lower 
Chi-
Square Pr > ChiSq 
MS 2014/2013 vs VHA 2014/2013 1.19 0.91 1.56 1.7 NS 
OP 2014/2013 vs VHA 2014/2013 1.41 0.92 2.17 2.46 NS 
MS 2015/2013 vs VHA 2015/2013 1.38 1.07 1.78 6.01 0.0142 
OP 2015/2013 vs VHA 2015/2013 2.56 1.74 3.76 22.72 <.0001 
aModeled as count with Poisson distribution, scale parameter=1 
 
Pattern of research impact over time for individual publications 
Our models for citation rates (Google Scholar or Web of Science) are based on 
annualized rates following a Poisson distribution and log of document age in years as 
offset term.  Figure 17 shows that choice of Poisson distribution may be appropriate. 
Citation patterns of high impact publications over time could be approximated by an 
exponential distribution or equivalently a Poisson regression. As Figure 17 shows, 
citations appear to cumulate over time in a pattern similar to what bibliometric studies 
refer to as “shooting stars” as opposed to “sleeping beauties” denoting a slow increase 
then a surge with a long lag. Obtaining the same level of depth in data for the whole 
sample was out of scope for this study. Overall, it may take 2 years for these studies to 
reach maximum scientific visibility. 
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Figure 17- Citation patterns of selected high impact publications over time 
The 3 studies shown in the graph are: 
• VHA data: Vigen, Rebecca, et al. "Association of testosterone therapy with mortality, 
myocardial infarction, and stroke in men with low testosterone levels." Jama 310.17 (2013): 
1829-1836. 
• MarketScan® data: Finkle, William D., et al. "Increased risk of non-fatal myocardial 
infarction following testosterone therapy prescription in men." PloS one 9.1 (2014): e85805. 
• Optum™ data: Abraham, Neena S., et al. "Comparative risk of gastrointestinal bleeding with 
dabigatran, rivaroxaban, and warfarin: population based cohort study." bmj 350 (2015): 
h1857. 
 
Contribution of Various Covariates in Fitness of Models for Research Impact 
We evaluated Log Likelihood, Akaike Information Criterion (AIC), AIC corrected 
(AICC, and Bayesian Information Criteria (BIC) to assess model fit after adding 
covariates.  Figure 18 shows that greatest improvements in BIC (where smaller values are 
superior) occur after adding calendar year, topic cluster, and journal impact factor. There 
was also modest improvement of the model fit after adding degree centrality of the most 
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influential author. Use of advanced analytic methods and non-federal funding had little 
further influence on model fit. 
 
Figure 18- Model Fit Based on Bayesian Information Criteria (BIC) and Covariate 
Selection 
Y: calendar year; CLS: topic cluster; JIF: journal impact factor; DGC: normalized degree centrality of 
the most influential author; adv: use of machine learning or natural language processing by in the 
research; nf: use of non-federal funding 
 
Three models were therefore selected for final adjusted analyses along with the 
bivariate association (Table 10).  
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Objective 1 - To examine the association between richness of data and use of 
“advanced analytic methods” with research impact across three data environments 
H1.1 Richer mix of data, as measured by a data environment’s systematic use of 
electronic health records (EHR), or Natural Language Processing (NLP) in research, 
is associated with high scientific impact of health services research (HSR). 
Role of data source in research impact 
After adjusting for topic cluster, and calendar year, compared to MarketScan, VHA 
studies were associated with 12 to 48% higher impact across the following 3 research 
impact measures: Google Scholar (GS) citation rate per year, Web of Science (WoS) 
citation rate per year, and Altmetric attention score (Table 12). Further adjustment for 
journal impact factor and social influence of the most influential author weakened the 
association but it remained statistically significant for GS and WoS. Compared to both 
MarketScan® and VHA, Optum™ studies received significantly higher Altmetric 
attention score, with Optum™ v MarketScan® rate ratio 2.52 (95% CI 2.42 - 2.62) and 
VHA v Optum™ rate ratio 0.43 (95% CI 0.41 - 0.44). 	  
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Table 12 - Adjusted Citation Rate Ratio Comparing VHA studies to MarketScan, 
adjusted incrementally for data source, topic clusters, journal quality, researcher 
influence and other covariates 
Research Impact measure Unadjusted  Adjusted for 
similarity 
network 
location  
Adjusted for 
similarity 
network location 
and Journal 
Impact Factor 
Adjusted for 
similarity 
network location, 
Journal Impact 
Factor and social 
influence 
VHA vs MarketScan Rate Ratio (95% CI) 
GS citation rate per year  1.34 (1.29 - 1.39) 
1.28 
(1.23 - 1.34) 
1.16 
(1.11 - 1.21) 
1.10 
(1.04 - 1.15) 
Web of Science citation 
rate per year 
1.05  
(0.99 - 1.11) 
0.99  
(0.92 - 1.05) 
0.89  
(0.83 - 0.95) 
0.83  
(0.77 - 0.89) 
Altmetric attention score 0.85 (0.83 - 0.88) 
1.48 
(1.42 - 1.53) 
1.12 
(1.08 - 1.16) 
1.08 
(1.04 - 1.12) 
Optum™ vs MarketScan     
GS citation rate per year  0.74  (0.69 - 0.79) 
0.89  
(0.83 - 0.95) 
0.85  
(0.78 - 0.92) 
0.86  
(0.79 - 0.93) 
Web of Science citation 
rate per year 
0.64  
(0.57 - 0.71) 
0.88  
(0.79 - 0.98) 
0.92  
(0.82 - 1.04) 
0.93  
(0.82 - 1.05) 
Altmetric attention score 2.47  (2.39 - 2.56) 
2.44  
(2.35 - 2.53) 
2.46  
(2.37 - 2.56) 
2.52  
(2.42 - 2.62) 
VHA vs Optum™      
GS citation rate per year  1.81  (1.70 - 1.93) 
1.44  
(1.35 - 1.54) 
1.36  
(1.26 - 1.47) 
1.27  
(1.17 - 1.38) 
Web of Science citation 
rate per year 
1.64  
(1.49 - 1.82) 
1.12  
(1.01 - 1.25) 
0.96  
(0.86 - 1.08) 
0.89  
(0.79 - 1.01) 
Altmetric attention score 0.34  (0.33 - 0.36) 
0.61  
(0.58 - 0.63) 
0.45  
(0.44 - 0.47) 
0.43  
(0.41 - 0.44) 
 
H1.2 Use of advanced analytic methods in research remains uncommon across selected 
data environments 
Overall, 4.4% of the studies reported use of NLP or ML. The rate almost 
monotonically increased from 2.8% in 2013 to 6.7% in the first 3 months of 2016. 
Compared to 2013, likelihood of studies using advanced analytic methods increased >2.5 
fold in 2016 for all data sources (95%CI 1.09 - 6.60) (Figure 19).The increase was, 
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however, almost solely driven by the VHA studies although interaction with data source 
wasn’t significant due to small cell size for Optum and MarketScan studies p>0.05. 
 
 
Figure 19- Secular trend in likelihood of studies using advanced analytic methods 
(ML or NLP) 
Odds of a publication using advanced analytic methods was modeled as a function of: calendar year, 
and data source 
 
H1.3 Use of advanced analytic methods is associated with higher scientific impact 
across selected data environments. 
We found that use of advanced analytic methods in a study was associated with 
lower rates of both peer-reviewed and non-peer-reviewed citations (Table 13). 
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Table 13 - Role of using advanced analytic methods in research impact 
Outcome 
Predictor 
use of advanced 
analytic methods 
Adjusted 
Rate Ratio 95% CI 
Pr >  
ChiSq 
GS citation rate per year Yes v no 0.84 0.77 0.92 0.0002 
Altmetric attention score Yes v no 0.56 0.52 0.61 <.0001 
aadjusted for data source, calendar year, Topic Clusters, authors’ social influence, use of advanced 
analytic methods and non-federal funding  
 
Objective 2 - To examine the association between measures of scientific collaboration 
and research impact across data environments 
H2.1 big data environments with intensive co-authorship networks produce higher 
scientific impact. 
The findings of bivariate association of co-authorship networks (Table 14) were 
confirmed in the multivariable analysis. Stronger social influence as measured by the 
most influential author’s normalized degree centrality was associated with higher peer-
reviewed and non-peer-reviewed research impact. 
 
Table 14 - Role of authors' social influence in research impact 
Outcome Parameter Βeta Estimate 
Lower 
Wald CL 
Upper 
Wald CL P value 
GS citation rate per year Normalized degree centrality 4.1564 2.8174 5.4954 0.0000 
WoS citation rate per year Normalized degree centrality 5.1787 3.1086 7.2488 0.0000 
Altmetric attention score Normalized degree centrality 2.1199 0.8997 3.3402 0.0007 
aadjusted for data source, calendar year, Topic Clusters,  use of advanced analytic methods and non-
federal funding ; Poisson regression 
GS: Google Scholar; WoS: Web of Science 
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H2.2 Richer mix of data sources in a big data environment is associated with intensive 
co-authorship networks. 
Compared to IBM® MarketScan, authors of VHA studies had higher social influence 
as measured by normalized degree centrality. Social influence of Optum™ authors was 
not significantly different than IBM® MarketScan. 
 
Table 15 - Association between data source and normalized degree centrality 
Parameter Levels Βeta Estimate Lower Wald CL Upper Wald CL P value 
Data source MarketScan 0 (REF)    
 Optum -0.0651 -0.2070 0.0768 0.3686 
 VHA 0.7463 0.6404 0.8523 <.0001 
aadjusted for data source, calendar year, Topic Clusters,  use of advanced analytic methods and non-
federal funding ; Gamma regression 
 
Objective 3 - To explore why some healthcare big data environments may have been 
conducive to higher scientific impact and scientific networks than the others 
H3.1 The positive effect of richness of data on research impact across data 
environments varies by research fields, with cardiovascular, and cancer producing 
higher impact than mental health and other research fields 
The interaction between data source and research field was significant for both 
cardiovascular, and cancer studies, p value<0.0001 for both models. VHA studies in the 
cardiovascular field had significantly higher Google Scholar citations than Optum™ and 
MarketScan, Βeta Estimate 0.753 v 0.415 v 0.00. For cancer, the heterogeneity was even 
more pronounced. While cancer studies using VHA data were associated with higher 
Google Scholar citation rates than MarketScan® (Βeta Estimate 0.260), cancer research 
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using Optum™ had significantly lower citation rates than MarketScan® (Βeta Estimate -
0.256). The model was adjusted for data source and calendar year. 
H3.2 The positive effect of richness of data on research impact across data 
environments is partially mediated by quality of the dissemination vehicle, journal 
impact factor (JIF). 
Role of journal impact factor in research impact 
After adjustments for data source, topic cluster, and authors’ social influence, 
publications within higher impact journals were associated with statistically significant 
higher research impact and public attention (Table 16). Altmetric attention score, as a 
measure of public attention, was almost monotonically associated with journal impact 
factor and publications in the highest quintile attracted almost 14 times more attention 
than those in the first quintile. 
Table 16 - Adjusted citation rate ratio comparing publications in various quintiles 
of journal impact factor 
Quintile of Journal 
impact factor 
(range) 
GS citation rate 
per year  
Web of Science 
citation rate per year 
Altmetric attention 
score 
 Adjusted rate ratio (95% CI) a 
1st quintile (0 - 
2.00) 
1.00 (REF) 1.00 (REF) 1.00 (REF) 
2 (2.00 – 2.65) 1.29 (1.20 - 1.38) 1.55 (1.37 - 1.74) 1.40 (1.28 - 1.55) 
3 (2.65 – 3.28) 1.67 (1.56 - 1.79) 2.36 (2.11 - 2.65) 2.43 (2.22 - 2.66) 
4 (3.28 – 4.72) 1.70 (1.59 - 1.82) 1.98 (1.76 - 2.22) 3.51 (3.23 - 3.83) 
5 (>4.72) 4.17 (3.92 - 4.43) 5.91 (5.33 - 6.56) 13.77 (12.71 - 14.93) 
aadjusted for data source, calendar year, Topic Clusters, authors’ social influence, use of advanced 
analytic methods and non-federal funding 
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CHAPTER FIVE: FINDINGS OF THE KEY INFORMANT INTERVIEWS 
Section One: Characteristics of the Key Informants 
The key informants consisted of health services researchers, research leaders and 
analytics experts at Veterans Health Administration (VHA) and UnitedHealth’s 
OptumLabs. As explained in the methods, the two organizations were selected because of 
similarities and differences in their approaches to use of big data for research, and 
operations analytics. Key informants consisted of a convenient sample of researchers who 
had received at least 10 Google Scholar citations over the observation window. 
Researchers with leadership roles were selected based on input from members of the 
dissertation committee which was driven by seniority and knowledge of the strategic 
directions within the two organizations. The IRB ruling allowed verbal consent upon the 
start of the interviews. A set of 11 open ended questions were used to guide the interview 
(APPENDIX	III). To preserve confidentiality, recorded interviews were coded. 
In the first round, a total of 10 individuals were invited to participate from whom 5 
agreed to interview. In the second round, 10 additional individuals were contacted which 
made a total of 11 interviews possible (Table 17).  
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Table 17 – Key informants characteristics 
Participant 
codes Organization Title Gender 
Years of 
experience with 
data source 
AV Veterans Health Administration (VHA) 
Senior leader (retired) 
health services research 
& development 
M >20 years 
BV VHA Physician policy researcher M 10 – 20 years 
CV VHA Senior leader, analytics and business intelligence M >20 years 
DV VHA Senior leader, analytics and business intelligence M >20 years 
EV VHA Physician policy researcher M 10 – 20 years 
FV VHA Physician policy researcher M 10 – 20 years 
AO OptumLabs Collaboration (Boston University) Principal investigator F <5 years 
BO OptumLabs Collaboration Chief officer M >20 years 
CO OptumLabs Collaboration Former chief officer M >20 years 
DO OptumLabs Collaboration (Mayo Clinic) Principal investigator M <5 years 
EO OptumLabs Collaboration (Mayo Clinic) 
Physician policy 
researcher F <5 years 
 
 Thematic analysis was performed in order to identify major themes in the expressed 
opinions by the interviewees. Annotating, tagging and grouping were performed 
manually. Main themes and sub-themes were identified first based on the sentiment of the 
views (emphasis and repetition by interviewee) and then depending on the frequency of 
mentions across interviewees. Themes were first recorded verbatim and then normalized 
across individuals for improved labeling and messaging. Whenever used or quoted in the 
text, two-letter codes are mentioned in square brackets to reference a specific 
interviewee. Wherever interviewees referred to a specific publication or research study, 
those documents were also reviewed to add clarifying information.  
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Section Two: Case Study 1 – Research Analytics at the Veterans Health 
Administration 
Objective 4- To understand practices in conduct of research using VHA data that may 
lead to high impact  
Context 
In both case studies, we broadly define the term healthcare “analytics” as the 
efficient use of data and related insights that are developed through statistical techniques 
and also approaches introduced by the data science such as machine learning, artificial 
intelligence and other emerging data-intensive methods. Often based on real world data, 
as opposed to experimental settings, “analytics” is usually used to reveal and study 
historical data patterns, assess correlations and causality, predict future outcomes, and 
ultimately provide insights to drive evidence-based decision-making. The ultimate 
objective is to improve health, at individual and population levels, and also enhance 
healthcare practice and operational performance of healthcare systems. 101 Research and 
operations analytics are two sub-themes that are introduced to distinguish between the 
primary purpose of each endeavor. While research analytics is typically concerned about 
methodologic rigor and scientific innovation, the goal of operations analytics is 
performance improvement, and program evaluation. The boundaries between the two, 
however, could be blurred as a result of collaborations between the two areas. 101 
                                                        
101 Shaikh, Abdul R., et al. “Collaborative Biomedicine in the Age of Big Data: The Case of Cancer.” 
Journal of Medical Internet Research, vol. 16, no. 4, 2014, p. e101. NCBI PubMed, 
doi:10.2196/jmir.2496. 
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Macro-level trends exist that affect healthcare analytics. They include increasing 
government incentives to electronic health records (EHR) adoption, growing urgency to 
curb costs, availability of big data assets, increasing investments, growing emphasis in 
improving patient outcomes, and also affordable technological advancements. As a result 
of these forces, healthcare analytics market has been expanding quickly.102 
Background – First established in 1930, the Department of Veterans Affair (VA) 
has long been in a unique place to engage in research and operations analytics using its 
large and complex data resources. With an annual budget of approximately $220 billion 
and approximately 235 thousand employees, VA is the second largest of the fifteen 
cabinet departments in the US Government and provides healthcare, financial support, 
pension, disability and other benefits to military veterans and their families. As the 
largest integrated delivery system (IDS) in the US with over 150 hospitals and 1,000 
clinics, Veterans Health Administration (VHA) is responsible to serve approximately 5 
million patients annually.103 VHA has pioneered development of modern electronic 
health records (EHR) since 1982. This extensive experience has led to creation of a rich 
data environment with longitudinal depth based on digitized and automatically collected 
                                                        
102 Healthcare Analytics Market by Type (Predictive, Prescriptive, Cognitive) Application (Clinical, 
RCM, Claim, Fraud, Waste, Supply Chain, PHM) Component (Service, Software) Delivery (On-
demand, Cloud) End User (Payer, Hospital) - Global Forecast to 2024 (summary) (2019). 
MarketsAND Markets. https://www.marketsandmarkets.com/Market-Reports/healthcare-data-
analytics-market-905.html 
103 Kupersmith, Joel, et al. “Advancing Evidence-Based Care For Diabetes: Lessons From The 
Veterans Health Administration: A Highly Regarded EHR System Is but One Contributor to the 
Quality Transformation of the VHA since the Mid-1990s.” Health Affairs, vol. 26, no. Suppl1, 2007, 
pp. w156–w168. 
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data streams that are used for clinical services, research, and operation analytics. 
104,105,106,107  
VHA’s integrated EHR system is a critical component of its big data asset. The 
Veterans Health Information Systems & Technology Architecture or VistA and the 
Computerized Patient Record System (CPRS) serve as the foundation of VHA’s data 
repository. This repository is currently set up as the Corporate Data Warehouse (CDW). 
VistA and CPRS, similar to their successful private sector counterpart Epic,108 were 
originally developed in an antiquated but powerful data base administration platform 
called MUMPS (Massachusetts General Hospital Utility Multi-Programming System). 
First rolled out in 1997, the VHA’s EHR system was primarily developed to support 
clinical care and decision support. 103 
Research analytics use cases of big data at the VHA 
VHA has a prolific intramural research system with an annual budget of roughly $1 
billion spanning the spectrum of basic health services to translational research [CV, DV, 
104]. Between 2013 and the first quarter of 2016, researchers using VHA data published 
an average of 27.6 peer-reviewed articles per months (Figure 20). Inspired by the vision 
                                                        
104https://www.va.gov/budget/products.asp. Last updated: May 3, 2019 
105 Atkins, D., Kilbourne, A. M., & Shulkin, D. (2017). Moving From Discovery to System-Wide 
Change: The Role of Research in a Learning Health Care System: Experience from Three Decades of 
Health Systems Research in the Veterans Health Administration. Annual Review of Public Health, 
38(1), 467–487. https://doi.org/10.1146/annurev-publhealth-031816-044255 
106 Brown, S. H., Lincoln, M. J., Groen, P. J., & Kolodner, R. M. (2003). VistA—US department of 
veterans affairs national-scale HIS. International journal of medical informatics, 69(2-3), 135-156. 
107 Fihn, S. D., Francis, J., Clancy, C., Nielson, C., Nelson, K., Rumsfeld, J., ... & Graham, G. L. 
(2014). Insights from advanced analytics at the Veterans Health Administration. Health affairs, 33(7), 
1203-1211. 
108 The Epic Corporation. 2019. www.epic.com. Accessed October 2019. 
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of a learning health care system as outlined by the Institute of Medicine (IOM), VHA has 
intensified its efforts to leverage big data to evaluate and implement innovations and best 
practices. 105 The integrated structure of the VHA healthcare system generally enables 
researchers to study a range of topics, either uniquely affecting veterans or of broader 
importance. [EV] Yet, the multitude of hospitals operating in every state allows a 
comprehensive view of substantial variation in care processes that sometimes even makes 
its way into the headlines. 105 
 
Figure 20 – Peer-reviewed publications per month by data source between 2013 and 
2016  
Calendar year 2016 only includes first 3 months  
Citation rates were observed between April – June 2016 
The abrupt drop in 2016  may be due to cyclical (quarterly) changes in the publication rate in the VHA 
(2016 data only included the first quarter). 
Data source: dissertation’s analytic data set 
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In the following sections, we asked key informants in VHA to identify characteristics 
of their research that uniquely influenced research impact and contributed to fulfillment 
of a ‘learning healthcare system’. Some of these characteristics are further evaluated in 
the context of specific missions, patient population, and service mix of the VHA. 
Data content  
The convergence of an integrated national EHR, a population-based healthcare 
delivery system and a network of researchers across the nation has enabled VHA to 
pioneer prolific research and performance improvement initiatives using big data. [AV, 
CV, DV]  
Corporate Data Warehouse (CDW) was created in 2006 to consolidate patient-level 
information that were extracted from CPRS and VistA across the VHA’s national 
healthcare system. 21  As of 2014, more than 16 billion clinical records had been 
captured. 21 Table 18 provides a high-level quantification of the underlying data streams 
that populate the content of CDW. For instance, this data shows that on a daily basis, 
CDW could capture more than a million provider notes, 1.2 million electronic orders by 
providers, 2.8 million images (including radiology, electrocardiograms, and 
photographs), and over one million vital signs. CDW also includes the time and date of 
more than 600,000 inpatient medication administrations. 21 Some of these features, such 
as the most granular timing of procedures, are unique to big data based on EHRs 
[EV,FV]. 	  
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Table 18 - Overview of the population served, health facilities and clinical 
encounters in the VHA 
System characteristic Number 
Patients and provision of health services  
Enrolled veterans 8.93 million 
Unique patients treated 6.49 million 
Outpatient visits  86.4 million 
Outpatient surgeries  292,600 
Inpatient admissions  694,700 
Skilled nursing home daily census  34,746 
Source: Fihn 2014 21 
 
Figure 21- VHA Corporate Data Warehouse visual architecture 
Source: Bala, Hillol, et al. 2009 109 
Notes: VistA: Veterans Information System Technology and Architecture; HDR: Health Data 
Repository; NPCD: National Patient Database; DSS: Decision Support System; VHA: Veterans 
Health Administration; ADR: Administrative Data Repository; CMS: Center for Medicare and 
Medicaid Services; VA: Veterans Administrations; DoD: Department of Defense 
                                                        
109 Bala, Hillol, et al. "Disaster response in health care: A design extension for enterprise data 
warehouse." Commun. ACM 52.1 (2009): 136-140. 
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The other unique feature of CDW is that it brings together internal and external data 
sources [CV,DV]. As Figure 21 shows, in-house clinical, administrative, and pharmacy 
benefit management data are routinely merged, at the individual level, with external 
information sourced from the Centers for Medicare and Medicaid Services (CMS) claims 
and the National Death Index (NDI). Such data complexity and heterogeneity is 
unprecedented with only a few counterparts in the national stage such as Kaiser 
Permanente’s integrated EHR and the UnitedHealth Group’s data warehouses (UHG) 
[CV, DV, BO,110]. 
The following factors also differentiate VHA data from comparable sources of big 
data: 
Increasing Diversity and Complexity of Data - VHA’s data sources are growing 
even further in heterogeneity and complexity [CV,DV]. Million Veteran Program (MVP) 
is one example [CV,DV]. MVP is based on an ongoing prospective cohort that integrates 
genetic data, medical records, biomarkers, self-reported health status as well as selected 
life style and occupational exposures. “With more than 725,000 enrollees (as of January 
2019), representing all service eras, the MVP is the largest genetic research cohort of its 
kind.”111 Research findings based on MVP data may lead to innovations in preventing 
and treating illnesses in Veterans and others. 
                                                        
110 Wheatley, Benjamin. "Transforming care delivery through health information technology." The 
Permanente Journal 17.1 (2013): 81. 
111 Harrington, Kelly M., et al. “Gender Differences in Demographic and Health Characteristics of the 
Million Veteran Program Cohort.” Women’s Health Issues, vol. 29, June 2019, pp. S56–66. 
ScienceDirect, doi:10.1016/j.whi.2019.04.012. 
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Demographics and Health Risk Profile of Veterans- As a representation of the US 
military workforce, there are important demographic discrepancies between the veterans 
and the US population. For instance men greatly outnumber women in the VHA data 
[CV, DV, EV]. This factor impacts both the types of research and also generalizability of 
findings based on VHA studies. Programs like MVP are unique in improving gender 
representation in the male-dominated VHA cohort [DV]. In addition, veterans served by 
the VHA are generally sicker than the general population with increased propensity for 
mental health disorders, homelessness, substance use and chronic medical morbidities 
such as obesity, diabetes, and hypertension [DV,EV,FV]. 
Question 4.1: What are key success factors of researchers in using VHA data? 
Opportunity to study organizational setting  
Some of the most high impact VHA research has examined the effect of site 
characteristics on care practices, treatment patterns or care coordination [AV, EV]. 112,113 
These studies investigated, for instance, how optimal follow-up infrastructure and 
modifiable site-level factors influenced adherence to newly introduced guidelines and 
treatments. This focus area is particularly important while system-wide initiatives for 
“whole person care” and population health are underway within the VHA [AV]. One 
example that was highly cited by other investigators was an investigation of the role of 
primary care providers in proper follow-up of patients on life-long anticoagulants and 
                                                        
112 Shore, Supriya, et al. "Site-level variation in and practices associated with dabigatran adherence." 
Jama 313.14 (2015): 1443-1450. 
113 Katon, Jodie, et al. "VA location and structural factors associated with on-site availability of 
reproductive health services." Journal of general internal medicine 28.2 (2013): 591-597. 
		
102 
medication adherence [EV]. In addition to the possibility of conducting in-depth chart 
reviews to determine patient selection and care coordination, an unprecedented number of 
detailed and automatically generated provider and site characteristics are also available as 
part of the CDW including provider demographics, specialty, location, site type as well as 
detailed information on contributions by non-clinician providers (e.g. pharmacist led 
monitoring and education) [AV]. These data enable conduct of mixed methods studies 
that could supplement statistical analysis with qualitative insights [AV,112]. 
One potential limitation of organizational variables in CDW is that it may be 
inconsistently collected across sites. This may be a source of bias and adversely affect 
generalizability of findings. Under-represented sites typically serve fewer patients or lack 
the capacity for certain types of providers and services [AV]. 
Well powered study of unique disease conditions 
Veterans are at increased risk of developing certain conditions that could be of great 
public health importance [CV,EV,FV]. Human immunodeficiency virus (HIV) and 
hepatitis C are examples. As the rates of these infections grew and the survivorship 
improved, in-depth clinical data that sourced from EHR became available to researchers 
in unprecedented amounts [EV, FV]. Table 19 summarizes some of the high impact peer-
reviewed studies that have used VHA data in recent years.  	  
		
103 
Table 19 - High impact original research on unique clinical conditions using VHA 
data 
Year First 
Author 
Affiliation Sample 
size 
Journal Key findings Times 
Cited 
(GS) a 
Altmetric 
Attention 
Score114 
b 
2013 Freiberg  University 
of 
Pittsburgh 
82,459 JAMA IM Researchers investigated 
whether HIV was associated 
with increased risk of acute 
myocardial infarction 
among veterans and found a 
50% increase in risk of AMI 
that could not be explained 
by measured confounding.  
309 36 
2013 Womack Yale. VA 
Connecticut 
40,115 Clinical 
Infectious 
Diseases 
Investigators found that 
frailty, as measured by the 
Veterans Aging Cohort 
Study (VACS) Index, was 
predictor of fractures among 
HIV-infected male Veterans. 
38 3 
2014 Goetz UCLA 1,153 AIDS 
Research 
Researchers validated a 
deterministic algorithm to 
identify new diagnosis of 
HIV in large administrative 
datasets. 
5 43 
2015 Sico Yale. VA 
Connecticut 
76,835 Neurology Investigators showed that 
HIV was associated with 
increased risk of ischemic 
stroke 
22 14 
2014 El-Serag Baylor 
College of 
Medicine 
11,721 Gastro-
enterology 
A predictive model using 
lab tests, and demographics 
was validated that allowed 
early identification of 
hepatocellular carcinoma 
among patients with 
hepatitis C and cirrhosis 
36 11 
2013 White Michael E. 
DeBakey 
VA Medical 
Center 
289 Alimentary 
pharma-
cology 
The researchers show 
heterogeneity of the 
association between high 
serum vitamin D and 
hepatitis C-related liver 
disease 
9 - 
a. Times cited according to Google Scholar as of March 2016. b. api.altmetric.com/as of September 
2016.  
                                                        
114 The Altmetric Attention Score for a research output is the weighted sum of counts of times the 
publication is mentioned in the news outlets, Blogs, and social media (see sources and weights 
https://help.altmetric.com/support/solutions/articles/6000060969-how-is-the-altmetric-attention-score-
calculated-). Visibility in the news and blogs receives the highest weight.  
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As shown in Table 19, these studies often had sample sizes greater than 10,000 and 
were highly visible despite predominance of men. Use of laboratory findings 
(biomarkers) in conjunction with administratively collected diagnoses and utilization 
were other features [EV,FV].  
Availability of biomarkers in large numbers in patients with uncommon conditions 
has made the VHA data unique for evaluation of algorithms and predictive models [EV]. 
Development and validation of these models have enhanced accuracy and personalization 
of health risk and may be appealing to providers and payers outside the VA [EV]. The 
longitudinal nature of CDW is another unique feature that allows research designs based 
on repeated longitudinal measurements [EV]. 
Opportunity to study mental health conditions and combat related injuries 
Some of the highly impactful studies using VHA data have been in the field of 
mental health and combat related injuries [BV, CV, DV, FV].  
Interestingly, some of these studies have assessed biomarkers in mental health [FV]. 
The work of Satish on C-reactive protein (CRP) predicting emergence of post-traumatic 
stress disorder (PTSD) is an example. The study suggested that inflammation perpetuated 
PTSD symptoms.115 The implications for providers were substantial and drew attention to 
the importance of monitoring physical comorbidities with an inflammatory nature in 
PTSD patients. Bringing together longitudinal data on biomarker and diagnosis is a 
unique feature of CDW. 
                                                        
115 Eraly, Satish A., Caroline M. Nievergelt, Adam X. Maihofer, Donald A. Barkauskas, Nilima 
Biswas, Agorastos Agorastos, Daniel T. O’Connor, and Dewleen G. Baker. "Assessment of plasma C-
reactive protein as a biomarker of posttraumatic stress disorder risk." JAMA psychiatry 71, no. 4 
(2014): 423-431. 
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Care patterns for pain management, opioid use and opioid use disorder have been 
another area of mental health with many high impact studies using VHA data [FV]. 
Edlund characterized the dosing and duration of chronic opioid therapy for chronic non-
cancer pain and found that major depression and posttraumatic stress disorder were 
predictive of receiving high-volume daily dose of opioids. Such association did not exist 
for nonopioid substance use disorders. 116 
Care coordination in mental health has been another area of research using VHA data 
[FV].  Publishing their findings in 2015, Park et al. showed that dual prescription of 
opioids, from VHA and non-VHA sources, had a higher risk of fatal overdose when co-
prescribed with benzodiazepines (a class of anti-anxiety medications commonly 
prescribed to veterans). 117 This evidence was then used by the National Institute for 
Occupational Safety and Health (NIOSH) to develop programs to address use of opioids 
among workers. 118 The same evidence has been cited by the CDC guideline for 
prescribing opioids for chronic pain.118,119 
VHA data has also been extensively used to study combat-related injuries such as 
traumatic brain injury (TBI) and military sexual trauma. 120,121 In their study of over 
                                                        
116 Edlund, Mark J., Mark A. Austen, Mark D. Sullivan, Bradley C. Martin, James S. Williams, John 
C. Fortney, and Teresa J. Hudson. "Patterns of opioid use for chronic noncancer pain in the Veterans 
Health Administration from 2009 to 2011." PAIN® 155, no. 11 (2014): 2337-2343. 
117 Park, Tae Woo, Richard Saitz, Dara Ganoczy, Mark A. Ilgen, and Amy SB Bohnert. 
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20,000 veterans, Shannon showed that those, both men and women, who were subject to 
sexual assault or harassment, while serving in the military, were at increased risk of 
suicide. 120 In another large cohort of veterans, Caplan found that prior traumatic brain 
injury (TBI) substantially increased the risk of epilepsy among service members with 
potentially life long health and economic consequences on individuals and their families. 
121 These highly cited studies suggest the value of VHA data in conduct of sufficiently 
powered studies in the US that allow assessment of long-term effects of combat related 
injuries over the life course. 
With its healthcare system distributed nationally, VHA has also enabled study of 
considerable treatment variability in mental health [AV,FV]. This feature of the data goes 
beyond the field of psychiatry and applies to many other medical specialties [FV]. Over 
65% of all US-trained physicians and 70% of US psychologists go through the VHA 
system at some point during their training. Therefore in many cases, study of treatment 
variations in VHA could be reasonably generalizable to provider behaviors nationwide. 
122 
Understudied and rare populations 
VHA data has been used to examine clinical and cost outcomes of understudied or 
hidden populations [CV, EV, FV]. While also used to study individuals with common 
                                                                                                                                                                     
veterans: Correlates of sexual assault and sexual harassment." American journal of preventive 
medicine 50, no. 1 (2016): 77-86. 
121 Caplan, Bruce, Jennifer Bogner, Lisa Brenner, Mary Jo V. Pugh, Jean A. Orman, Carlos A. 
Jaramillo, Martin C. Salinsky et al. "The prevalence of epilepsy and association with traumatic brain 
injury in veterans of the Afghanistan and Iraq wars." Journal of head trauma rehabilitation 30, no. 1 
(2015): 29-37. 
122 U.S. Department of Veterans Affairs (VA). Office of Academic Affiliations (2019), “Mission of 
the Office of Academic Affiliations,” https://www.va.gov/oaa/oaa_mission.asp. 
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chronic conditions (e.g. diabetes, Chronic Obstructive Pulmonary Disease (COPD), and 
cardiovascular diseases) high impact researchers have also used VHA data for difficult-
to-identify, rare, and understudied populations where validated cohort identification 
algorithms did not exist [EV, FV]. As an example, VHA researchers used nationally 
representative data of veterans to develop approaches to identify transgender individuals, 
an understudied population, where little is known about quality of care [EV]. Such 
examples demonstrate other aspects of VHA data and the opportunity to fill gaps in 
knowledge about populations whose health is poorly understood and for whom research 
can be conducted efficiently and at relatively low cost using retrospective data [CV, EV, 
FV]. 
Question 4.2: What are the perceived roles of and opportunities for using of Natural 
Language Processing (NLP) and advanced analytic methods on research impact? 
Use of advanced analytic methods in the VHA data 
Both Natural Language Processing (NLP) and Machine Learning (ML) algorithms 
have been extensively applied for research and operations analytics in the VHA data 
[CV,DV]. The research impact has been substantial in a few areas but remains limited in 
others. Despite the uncertainties, in-house expertise and best practices in NLP, machine 
learning and artificial intelligence continue to cumulate in the VHA and success stories 
are emerging [BV, CV, DV]: 
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Applications of Natural Language Processing (NLP) in the VHA data 
• VHA is uniquely positioned to harness the power of NLP. Key drivers include 
a multitude of potential applications of NLP that are generated by the large group 
of VHA’s research community, the mutually beneficial relationship between the 
organization and academic collaborators, and research-operations partnerships 
within VHA [DV]. 
• Use of NLP in VHA may be more advanced than private sector examples. 
VHA has a long history of applying natural language processing in the EHR to 
mine information, validate routinely collected codes and for predictive modeling 
[DV,EV]. Such efforts have been initiated earlier than 2010 [EV]. Substantial in-
house expertise, including clinicians’ input to annotate notes, has been developing 
[DV,EV]. These may differ from private sector uses of NLP, that have primarily 
focused on mining free text for fairly standard clinical assessments such as left 
ventricular ejection fraction (LVEF) and Mini-Mental State Examination 
(MMSE). Attempts at the VHA to use NLP to enhance sensitivity and specificity 
of diagnosis codes in conditions like stroke present a more complex application of 
NLP to data mining [EV]. 
• Development of NLP algorithms could be costly. Some applications of NLP 
require extensive expert (usually clinicians) annotation of free text to train and 
validate algorithms. In addition to pre-processing of data, annotations of free text 
by clinicians are labor intensive and costly [EV]. Once annotated, classified 
documents should have the potential to be re-used to save cost. The current 
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system at the VHA may not be ready to reliably preserve and re-use such research 
investments [EV]. 
• NLP applications have not always been equally successful within VHA 
[DV,EV]. Natural language used in provider notes is extremely heterogeneous. 
Even clinical terminology remains non-standard across geographies, educational 
programs and hospitals. Despite such variability, the integrated nature of the EHR 
at the VHA has presented a unique opportunity for large-scale application of NLP 
despite heterogeneity in clinical processes and communications using non-
standard terminology. Heterogeneity in natural language remains a challenge and 
is further complicated by the type of note, provider, discipline, and style of 
documentation.  
• Measurement and reporting of infectious complications has been enhanced 
by NLP [DV]. A successful use case for NLP in VHA is the semi-automated 
gathering and reporting of microbiology data from EHR in partnership with the 
CDC. The initiative is part of the CDC’s national infection control efforts. 
Microbiology data are typically generated in free-text format. Using NLP, data on 
organism type and antibiotic susceptibility are extracted from the text fields. The 
pre-processed data is then cleaned and validated by a team of infection control 
nurse practitioners much more efficiently than de novo manual extraction. These 
microbiology extracts are now routinely collected and reported from all the VHA 
hospitals nationally, and make a unique contribution to the CDC’s infection 
control efforts [DV].  
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• Surveillance of post-operative complications- Another positive experience with 
NLP at the VHA is safety surveillance and monitoring of post-operative 
complications [AV,DV]. Surgical complications are commonly preventable and 
have a detrimental effect on clinical and cost outcomes. VHA studies have 
developed multiple algorithms to identify complications that were based on both 
structured EHR data and NLP –derived variables as part of the Veterans Affairs 
Surgical Quality Improvement Program (VASQIP) initiative [AV].  
• Validation of medical codes. Most of the routinely monitored performance 
measures rely upon high quality coding of diagnoses and procedures. Using NLP, 
VHA is undertaking a nationwide effort to assess and validate the reported ICD 
diagnostic codes for high priority medical conditions such as cerebrovascular 
accidents and stroke [DV,EV}. Despite challenges that were mentioned earlier, 
early results are promising [DV]. 	  
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Table 20 - High impact original research applying Natural Language Processing 
(NLP) in VHA data 
Year First 
Author 
Affiliation Sample 
size 
Journal Key findings Times 
Cited 
(GS) a 
Altmetric 
Attention 
Score114,b 
2013 FitzHenry Tennessee 
Valley 
Health 
System 
VA 
33,565 Medical care Researchers showed 
that algorithms using a 
combination of 
structured data and 
natural language 
processing (NLP) of 
text notes had excellent 
sensitivity and 
specificity to identify 9 
post-operative 
complications. 
24 0.5 
2013 Imler Indiana 
University 
6379 Clinical 
gastroenterology 
and hepatology 
With 98% accuracy, 
NLP was able to 
identify the highest 
level of pathology from 
non-surveillance 
colonoscopies. 
23 - 
2014 Meystre University 
of Utah 
800 J biomedical 
informatics 
The investigators show 
that Text de-
identification minimally 
reduces the 
informativeness of 
clinical notes. 
17 - 
2014 Hope University 
of Utah 
25 BMC research 
notes 
The study showed that 
documentation of 
delirium is highly 
inconsistent even with a 
confirmed diagnosis 
11 - 
a. Times cited according to Google Scholar as of March 2016. b. api.altmetric.com/as of September 
2016.  
 
Machine Learning (ML)  
Machine learning (ML) is a field of artificial intelligence (AI) and is often 
interchangeably used with it in the medical literature. 101  ML relies upon a collection of 
quantitative techniques that integrate principles from computing, optimization, and 
statistics. The core of all ML algorithms is to automatically and recursively learn to 
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perform these tasks by processing data. 123 ML is commonly classified into supervised 
and unsupervised methods. The supervised learning methods train a classifier algorithm 
based on previously “labeled data” (training data set), whereas the unsupervised methods 
analyze patterns in variables to discover hidden similarities in data that is not labeled. For 
supervised methods, the trained algorithm is then applied to previously unseen data (test 
data set) to infer the correct classification. Unsupervised ML, on the other hand, has two 
broad purposes: data dimensionality reduction, and clustering. 124 
 
• ML has assisted VHA physicians to more accurately estimate risk and 
prognosis using veterans’ data [CV,DV]. VHA uses ML for predictive models 
to identify veterans who are at high risk of suicide and would be otherwise missed 
based on clinical judgement alone {DV]. Using suicide data from the National 
Death Index, demographic and clinical features extracted from the VHA EHR, a 
number of ML algorithms have been applied to estimate suicide risk. The most 
recent application includes 61 predictors and used elastic net regression 
penalizing for overfitting. 125 Sensitivity of these models have been shown to 
improve by expanding  the predictor set to include sociodemographic variables 
such as geographical data, social media, search queries on the internet and smart 
                                                        
123 Saria, Suchi, Atul Butte, and Aziz Sheikh. "Better medicine through machine learning: What’s real, 
and what’s artificial?." (2018): e1002721. 
124 Goodfellow, Ian, Yoshua Bengio, and Aaron Courville. Deep learning. MIT press, 2016. 
125 Kessler, Ronald C., et al. "Developing a practical suicide risk prediction model for targeting high
risk patients in the Veterans Health Administration." International journal of methods in psychiatric 
research 26.3 (2017): e1575. 
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phone data [DV]. Predictive modeling has also been used to identify veterans at 
risk of homelessness and opioid use disorder [DV]. 
• Estimating risk of hospitalization and death for the veterans in primary care. 
Studies have suggested that busy clinicians may be poor prognosticators, for 
instance, failing to recognize patients at high risk for hospital readmission [CV]. 
VHA is now routinely estimating Care Assessment Need (CAN) scores using the 
following six data domains within CDW: demographics, diagnoses  (inpatient and 
out-patient), vital signs, medications, biomarkers, and utilization histories. Online 
reporting systems, accessible through VHA’s EHR or web-based applications, 
show physicians or nurse practitioners a list of patients ranked by CAN scores 
alongside their active diagnoses, recent visits to primary care or the emergency 
department to create personalized care management plans or make referrals. CAN 
scores are also summarized geospatially into management reports for resource 
management [DV]. 107 
• Alarm fatigue could be a potential limitation of ML and predictive models 
[DV]. Although scores like CAN are accessed thousands of times per month by 
VHA clinicians, the extent to which they actually contribute to improved 
outcomes is unknown. As more predictive models are added to the EHR for 
decision support, the risk of information overload and “alarm fatigue” for 
providers also increases [CV, DV]. 
 
In summary, both supervised and unsupervised ML classifiers have been shown to 
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provide valuable tools in VHA to assist a wide range of classification scenarios in clinical 
decision support, prediction and reporting [CV,DV]. 
Data access 
Access to VHA data is carefully regulated but external partnerships (e.g. academia) 
have also been prospering [AV,DV,EV]. While in-house expertise in methodology, 
biostatistics and data science may be abundant and accessible, there are suggestions that 
the VHA might not be sufficiently investing in innovative methodologies needed to 
tackle challenges of big data such as in causal inference, noise, and data quality [EV]. In 
summary, research remains primarily intramural at the VHA, but collaboration with 
academic institutions in design and conduct of studies may not be adversely affected.   
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Section Three: Case Study 2 Research Analytics at Optum™ and OptumLabs™ 
Objective 4- To understand practices in conduct of research using Optum™ data that 
may lead to high research impact 
Context 
Background – Established in 1993 and geographically located in Minnesota, 
Optum™ is the health services and innovation company of the UnitedHealth Group. 126 
With more than 124,000 employees worldwide and an annual revenue of $83.6 billion (as 
of 2016), it provides a variety of services to healthcare providers, employers, health 
plans, life sciences companies, researchers and governmental agencies. Many of 
Optum™ products and solutions are built around data and analytics. These services 
include pharmacy benefit management, population health management, health care 
delivery, and health care operations. 126 
With hundreds of peer-reviewed publications based on retrospective administrative 
claims, Optum™ has also been a proactive player in the conduct of research based on real 
world evidence (RWE, see “Promises and Challenges of Big Data and Real World 
Evidence (RWE) in Causal Inference” page 126).127 The company’s core data assets 
consist of 180 million lives in claims and 85 million lives of clinical data. Some of its 
main data products that may be of relevance to this analysis include: 128 
                                                        
126 About Optum (2019). www.optum.com/about.html   
127 Retrospective database analysis (2014). 
https://www.Optum™.com/content/dam/optum/resources/productSheets/Retrospective-Database-
Analysis.pdf 
128 Data and the new era of visibility. https://www.Optum™.com/campaign/ls/data-new-era-of-
visibility/download.html 
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• Retrospective Databases (such as Clinformatics™ Data Mart)129 – Clinformatics™ 
targets health economics and outcome research. It includes UnitedHealthcare 
commercially insured data with an average of 13 million lives annually. Updated 
quarterly, Clinformatics™ includes de-identified patient-level facility, office and 
pharmacy claims, enrollment records and, for a subset of individuals, laboratory 
results. 
• Electronic Health Records (EHR) Clinical Data (or Optum™  One formerly branded 
as Humedica) (see below) 
• Integrated Claims and EHR (such as OptumLabs™ Data Warehouse) 127 (see page 
118) 
Optum™ also provides a variety of other analytics solutions such as Optum360™ 
and Optum™ One that are primarily targeting non-research clients. Optum™ 360, for 
instance, includes analytics solutions designed for healthcare providers for effective 
revenue cycle management, budgeting, and forecasting.130 Detection of fraud, waste, and 
abuse (FWA) is another category of products offered by Optum’s financial analytics.131 
Optum™ data products leverage a shared core of data assets integrating claims, 
enrollment records, provider information, and EHR. Optum™ One (formerly branded as 
Humedica) includes approximately 85 million treated patients with EHR data. As 
healthcare providers assume more risk, products like Optum™ One are designed to 
manage patient populations in the march towards value-based payments. In addition to 
                                                        
129 ClinformaticsTM Data Mart (2014). Optum™.com/life-sciences-solutions 
130 Health care revenue cycle management resources (2019). 
https://www.optum360.com/resources/revenue-cycle-management.html 
131 Fraud, Waste and Abuse Services (2019). https://www.Optum™.com/solutions/care-
operations/claims-administration/payment-integrity/fraud-waste-abuse-cpl.html 
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diagnoses, medical procedures, medication prescriptions and lab results, Optum™ One 
includes data from a large volume of provider notes extracted through NLP. 132 Designed 
to generate insights at the point of care, the modular structure of Optum™ One provides a 
longitudinal view of patient populations with regards to treatment patterns, care delivery 
setting, clinical alarms generated by predictive models, gaps in care, and quality measure 
tracking. 133 Financial analysis of risk, and spending to manage bottom line is another 
critical functionality of Optum™ One. Finally, this product includes tools to identify and 
manage gaps in care, care transition and care coordination for groups of patients. 132  
Inception of OptumLabs 
OptumLabs was founded in 2013 as several already existing initiatives within the 
UnitedHealth Group (UHG) converged and formed a partnership with Mayo Clinic, a 
major external partner [CO,24]. OptumLabs is one of the many national investments in 
multi-institution collaborations for innovation, exemplifying payers continued 
dominance, compared  to providers, in harnessing big data [BO, CO, DO].  
Lewin Group, also a UHG company and a major research contractor of the federal 
government, had a major role in the inception of the idea of OptumLabs [CO]. A group of 
policy researchers within Lewin pursued the goal of forming a broad private-academia 
partnership to better leverage linked data for performance measurement, comparative 
effectiveness research (CER) and advanced analytics. As a major UHG partner and also 
                                                        
132 Optum™ One (2015).  
https://www.Optum™.com/content/dam/optum/resources/brochures/6747_Optum_One_Brochure_ove
rview.pdf 
133 Evaluate individual and population risk. Impact Pro (2019). 
https://www.optum.com/solutions/data-analytics/data-analytics-health-plans/impact-pro-cpl.html 
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client of Optum™ services, Mayo Clinic was a natural collaborator [CO]. The Rochester-
based integrated delivery system (IDS) and academic power house had also been 
investing heavily in big data initiatives. The convergence of these two giants, an 
insurance company and a healthcare system, led to establishment of OptumLabs in 2013. 
Although OptumLabs and its portfolio have been evolving, the original partnership with 
Mayo Clinic has remained robust and highly productive [CO,DO]. 
Question 4.1: What are key success factors of researchers in using OptumLabs data? 
Data content  
OptumLabs leverages Optum™ shared core data assets. Historically, two separate 
data streams were brought together to make up this core: Ingenix and Humedica 
[BO,CO]. With a legacy going back many years, Ingenix was established in 1997 as one 
of the business segments of UHG consolidating health insurance claims. At the time, 
1,500 payer organizations fed data into the Ingenix software for management of their 
operations. This information system consisted of more than 100,000 providers and 
approximately 100 of the Fortune 500 employers. 134 Ingenix’s upgraded data repository, 
Galaxy, underwent several database enhancements over time and built extensive 
experience in managing interoperability and data quality assurance. Ingenix later evolved 
into OptumInsight™  that currently provides data and analytics and other healthcare IT 
services, software and information products, advisory services, and business process 
                                                        
134 Kahn, Beverly K., Raïssa Katz-Haas, and Diane M. Strong. "How to get an Information Quality 
Program Started: The Ingenix SM Approach." (2000). 
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outsourcing to a wide array of organizations in the healthcare industry [CO, 135]. 
The second data stream was EHR data that was operated by Humedica [CO]. 
Humedica was a Boston-based market lead in EHR-based analytics primarily serving 
healthcare providers. The company was acquired by Optum™ in January 2013. 136 A 
subset of the clinical data elements in Humedica were extracted from provider notes 
through NLP, and normalized and then linked to claims at the individual level. 50 
Humedica was rebranded as Optum™ One after acquisition. It currently contains records 
of over fifty million patients. Humedica/Optum™ One includes patients served by all 
types of payers primarily through large integrated health delivery networks such as Mayo 
Clinic [BO, 137]. In addition to diagnoses and medical procedures captured in electronic 
health records, Optum™ One includes pharmacy prescriptions, medication history, 
provider text notes, pathology reports, surgery reports, and imaging reports. 50 Unlike 
adjudicated claims, EHRs include services that are rendered but may not be billed 
separately.. In summary, integration of Humedica and Ingenix was intended to address a 
long-standing gap in administrative databases, enriching claims with clinical information 
[BO, CO]. 
OptumLabs data asset is called OptumLabs Data Warehouse (OLDW) and currently 
contains de-identified data of more than 150 million people in compliance with the 
                                                        
135 Tillman, Katherine. "Building the Infrastructure of the Affordable Care Act: Hillary Clinton, 
UnitedHealth Group/Optum™, and the Center for American Progress." J Am Phys Surg 20 (2015): 
110-115. 
136 David Shaywitz (2013) “We Have A Winner! Quick Take On The Humedica Acquisition By 
United Health” https://www.forbes.com/sites/davidshaywitz/2013/01/25/we-have-a-winner-quick-
take-on-the-humedica-acquisition-by-united-health/#35daec6553dd 
137 Collins, Allan J., et al. "Association of serum potassium with all-cause mortality in patients with 
and without heart failure, chronic kidney disease, and/or diabetes." American journal of nephrology 
46.3 (2017): 213-221. 
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Health Insurance Portability and Accountability Act (HIPAA).50 As Figure 22 outlines, 
OLDW is comprised of claims and electronic health records (EHR) with links to useful 
additional data sets such as Health Risk Assessment (HRA), laboratory results, medical 
benefit design information, a family identifier, socioeconomic status variables, and 
mortality. 138 OLDW contains longitudinal information on commercially insured and 
Medicare Advantage members of a diverse mixture of ages, racial background and 
geographical regions across the US. It does include a pediatric population and those over 
the age of 65. 50  The claims in OLDW consist of adjudicated medical, laboratory and 
pharmacy claims. The EHR data in OLDW represent a subset of all EHR data that has 
been normalized and standardized and is research ready. 50  
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Figure 22- High level definition of data assets in OptumLabs Data Warehouse 
Source: Jasuja et al. 2019 138 
 
Claims in OLDW represent a national sample of the commercially insured and 
Medicare Advantage members from all 50 states [BO,DO]. Therefore, analysis using 
these data may not generalize to other populations such as Medicaid or the uninsured who 
are predominantly low income, women of reproductive age, children and patients with 
serious mental health conditions [BO]. The commercially insured segment of OLDW 
may also have a disproportionately lower burden of chronic comorbidities such as 
metabolic risk factors compared to Medicaid enrollees. 26, 139 
OLDW also has the advantage of including a limited set of socio-economic (SES) 
variables in addition to age, sex and zip code [BO,CO]. The race/ethnicity variable, for 
                                                        
139 Gillespie, Catherine W., and Pamela E. Morin. "Osteoporosisrelated health services utilization 
following first hip fracture among a cohort of privatelyinsured women in the United States, 2008–
2014: an observational study." Journal of Bone and Mineral Research 32.5 (2017): 1052-1061. 
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instance, is acquired from a third-party vendor using an algorithm based on both self-
reported race and wherever possible, imputations based on census tract and member 
name. 139, 140 Other SES variables are education, net worth of assets and income 
categories. 140 
Academic/corporate partnership model to drive research impact 
OptumLabs brings together diverse collaborators and rich data to drive research 
impact in topics spanning patient and provider behaviors [BO,CO,DO]. Some 
partnerships have been more effective than others. The collaboration with Mayo Clinic 
has been extremely successful because of its unique link between research and bedside 
implementation [BO,DO]. As a large integrated delivery network with an internationally 
recognized academic community, Mayo Clinic has been leveraging OptumLabs data 
assets in parallel with its own integrated EHR. The intersection of clinical expertise, 
access to rich data, and an in-house expertise in analytics has been conducive to a number 
of high impact studies ranging from diabetes, and cardiovascular diseases, to opioid 
crisis, and allergy [DO]. 
                                                        
140 Bernstein, Judith, Emily Quinn, Omid Ameli, Myrita Craig, Timothy Heeren, Ronald Iverson, 
Brian Jack, Aviva Lee-Parritz, and Lois McCloskey. "Onset of T2DM after gestational diabetes: What 
the prevention paradox tells us about risk." Preventive medicine 113 (2018): 1-6. 
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Question 4.2:  What are the role of and opportunities for using of Natural Language 
Processing (NLP) and machine learning (ML) to improve research impact? 
Use of advanced analytic methods in OptumLabs data 
OptumLabs may be a model to evaluate the actual impact of advanced analytic 
methods such as ML and NLP on patient outcomes {BO,DO]. Conventional statistical 
approaches as well as ML and AI have been advocated for and invested in to address 
crucial methodological challenges, such as  the role of expanding data sources, 
approaches to data linkage, missing data, and the use of ML as a complement to the 
conventional hypothesis-driven data analysis [BO]. Below are highlights of best 
practices: 
Investment in innovative methodologies to address bias and missingness in data   
OptumLabs has invested in innovative methodologies to address common challenges of 
observational studies that use real world data (RWD) [BO]. Given the complexity of 
clinical decision-making and cost considerations, many implementation questions could 
not be answered with randomized controlled trials (RCT). A methodology collaborative 
consisting of OptumLabs, Tuft and Brown Universities are applying study designs and 
analytic approaches to emulate RCT designs [BO,141]. 
Use of NLP-derived EHR variables as an efficient business model to minimize 
risk of patient re-identification– NLP is used upstream in OLDW to curate and 
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normalize diagnostic measures such as left ventricular ejection fraction, signs and 
symptoms, and past medical history from EHR. Provider notes pose a greater risk of 
patient and provider re-identification as they include richer information and language 
patterns. The business model of Humedica addressed data privacy risks. It extracted and 
organized EHR-derived data upstream, through NLP or otherwise, for providers to 
measure and improve operational performance. It then warehoused the de-identified 
longitudinal patient data, cleaned it, and made it available for business analytics. It is 
suggested that this business model may be the only viable solution for EHR-based 
analytics if access to data is to be expanded to a wide group of users of data [CO].  
ML-assisted early detection of priority diseases – ML has been successfully used 
in OLDW to predict Alzheimer's disease (AD) years in advance [BO].  Using a training 
data set of 215 thousand individuals, ML using a Lasso algorithm selected a 
parsimonious model with a subset of variables to predict fast progression toward AD.142 
The model developed by Nori et al. was designed to inform identification of patients at 
high risk of AD for more frequent assessments and medication therapy. 142 In general, 
predictions to facilitate personalized preventative interventions are a growing area for 
ML with the potential to substantially improve clinical and cost outcomes. 
ML-assisted study of individualized disease management – OLDW has been also 
used to enhance personalized disease management by applying ML techniques [BO,DO]. 
A team of researchers from Mayo Clinic studied patient characteristics that predicted 
                                                        
142 Nori VS, Hane CA, Martin DC, Kravetz AD, Sanghavi DM (2019) Identifying incident dementia 
by applying machine learning to a very large administrative claims dataset. PLOS ONE 14(7): 
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glycemic trajectories of diabetic patients with great accuracy over time. With a large 
sample of patients with type 2 diabetes (T2D) and availability of hemoglobin A1C results 
from linked lab data, ML methods were applied to discover distinct glycemic control 
trajectories among T2D patients. The novel approach, which came to fruition after 
several previous studies, enabled a deep dive into linked claims and EHR data, and was 
rapidly adopted within the Mayo Clinic. The predictive model greatly enhanced diabetes 
care for individuals and populations with T2D [DO]. 143 
Opportunity to Employ Deep Learning to improve diagnosis – The intersection 
of big data and powerful computation through the use of graphics processing units 
(GPUs) has opened the possibilities to application of deep learning methods. Deep 
learning is particularly powerful in multi-level modeling to enhance predictive power of 
models [BO]. Ideally, NLP would extract content from provider notes in the EHR and 
feed them into deep learning models to assist with prevention, risk assessment and 
treatment pathway optimization.  
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Section Four: Crosscutting Themes 
Promises and challenges of big data as source of real world evidence (rwe) in causal 
inference 
While randomized clinical trials remain the gold standard in the hierarchy of truth, it 
has been shown repeatedly that real world data (RWD) could  also be used to estimate 
effect size at much lower costs [DV,CO,DO]. To that end, study designs and analytic 
approaches should be meticulously adapted. The term real world evidence (RWE) was 
initially introduced by the 21st Century Cures Act, that was enacted in 2016. The Cures 
Act required the FDA to establish a program to evaluate RWE to: a) help to support the 
approval of new indications for a drug that had already been approved, and b) help to 
support or satisfy post-approval study requirements. The FDA guidance defines RWE as 
“the clinical evidence regarding the usage and potential benefits or risks of a medical 
product derived from analysis of real world data (RWD)”. 144 RWD are defined as “the 
data relating to patient health status and/or the delivery of health care [that are] routinely 
collected from a variety of sources” 144 such as electronic health records (EHRs), claims 
and billing activities, product and disease registries, patient-generated data including in 
home-use settings, and data gathered from other sources that can inform on health status, 
such as mobile devices. RWE is typically prone to bias because prognostic factors of 
treatment are typically unequally distributed between patients with and without an active 
treatment. Approaches like propensity score matching, instrumental variable analysis and 
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more sophisticated modeling techniques with time-varying variables should be 
encouraged to evaluate and minimize bias in studies based on big data [EV,BO,DO]. It 
should be noted that although these approaches may reduce the risk of bias, none could 
replace the balancing effect of randomization [BO]. 
Large samples are also susceptible to false statistical inference due to multiple 
comparisons and p-hacking [DV]. 
Funding agencies and research using big data 
Due to the limitations mentioned in the previous section, investigator-initiated 
research using big data may be at a disadvantage in grant applications, particularly those 
to federal agencies [AO,CO]. There was mixed sentiment about whether this situation 
may ease under provisions of the Cures Act [AO,CO]. 
Payers continue to be ahead of providers in applications of big data and advanced 
analytics 
Generally, healthcare is lagging behind other sectors such as intelligence, politics 
and finance in use of big data and advanced analytics [CV,DV,EV,FV,BO,CO]. When 
there are investments, payers are typically ahead of providers [DV,CO]. The intelligence 
community could also be viewed as a model where a balanced approach to using big data 
has been adopted [DV, 11]. 
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Big data conducive to research impact across full continuum of care 
Both case studies show feasibility of high impact studies addressing the full 
continuum of care. The following mapping of areas may be of interest to health services 
research:  
• Disease prevention, screening and early detection [EV,FV,BO,DO] 
• Assessing the clinical effectiveness of real world treatment pathways – both 
conventional statistical methods and ML may be used to cluster patients for discovery of 
disease subtypes. These clusters (also referred to as phenotypes) could then be evaluated 
using comparative effectiveness research designs to inform care pathway optimization 
decisions [EV,BO,DO]. Outcomes could include both clinical and cost end points. 
• Variation in coordination, transition, and quality of care [AV,DO] 
• Health economics and policy evaluation [CO,DO] 
• Safety and adverse events following emerging treatments or off label use of existing 
therapies [CV,DV,BO] 
• Survivorship following life extending treatments [CO] 
Opportunity to conduct well powered analysis to evaluate heterogeneity of effect 
Large samples mined from big data allow for sophisticated analysis in highly 
stratified manners [EV,FV,CO,DO]. This is one of the critical advantages of big data. 
Rose et al. have been able to use a data set of close to a million veterans with various 
clinical indications for anticoagulant therapies to study adherence and guideline 
concordance to prevent stroke and other thromboembolic events. Because of their sizable 
sample, they were able to apply multivariate analytic approaches in a wide range of 
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patient strata. 145,146,147 Using OptumLabs Data Warehouse, Abraham et al. and 
Noseworthy et al. also analyzed effectiveness and safety profiles of patients on novel oral 
anticoagulants (NOACs) and cardiac ablation techniques in subsamples of  patients [EO]. 
148 
Development, updating and validation of performance indicators 
A common theme that was repeatedly mentioned with regards to both VHA and 
Optum™ data, was development of performance indicators [AV,DV,EV,FV,CO,DO]. 
Performance measurement remains a critical gap in healthcare systems [AV,DV]. The 
opioid crisis was a recent example where its immense complexity exposed important gaps 
in healthcare systems ability to respond in a data-driven manner [CO]. A team at 
OptumLabs developed a comprehensive measurement framework consisting of 29 
claims-based measures targeting the opioid crisis. 149 The performance measures 
benefitted from the input of a panel of national clinical and public health experts, many 
affiliated with academic partners. Initial round of measurement uncovered unprecedented 
variation in prescription opioid use, guideline-compliance, pain management and 
evidence-based treatment of opioid use disorder (OUD). Introduction of the measure set 
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had a substantial translational impact across the UnitedHealth Group. In addition to 
initiation of targeted studies to answer focused questions, initiatives for safer prescribing 
via pharmacy benefit management, access to medication assisted treatment (MAT) via 
expanded provider networks, and clinical and consumer education programs were rolled 
out in various consumer segments and geographic regions. 149 
Opportunity for public health to gain more from big data 
Key informants generally expressed optimism about opportunities to generate public 
health value from big data [CV,DV,EV.AO,BO,CO,EO]. Linking claims and data on 
community health assets, such as Area Health Resource File (AHRF), is a unique 
opportunity to develop and study community health measures. Analytic techniques and 
various data visualizations could be used to identify correlations between health 
outcomes and community attributes. Social determinants of health are also an under-
studied domain in big data compared to outcome assessments as a function of patient, 
and provider factors [BO]. 
Big data analytics has also been used to estimate unmet needs in public health. Use 
of supervised machine learning to identify patients with opioid use disorder is an 
example. Hasan et al. used predictive models in administrative claims to probabilistically 
identify patients that were likely to have opioid use disorder and would otherwise be 
unaccounted for in public health surveillance. 150 Prevalence estimates based on these 
models have been generally superior to estimates purely based on diagnostic codes in 
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administrative data. Jasuja et al. used OptumLabs Data Warehouse to design detailed 
algorithms to identify transgender populations based on healthcare utilization patterns. 138 
Transgender individuals have been extremely hard to study because of the difficulty in 
identifying them in automatic data sources. As a result gaps in care have been poorly 
characterized. 138 
Estimating unmet needs for services in vulnerable populations is an area that may 
benefit greatly from big data and advanced analytics [EV, FV, EV]. 
Common challenges 
Key informants identified a number of important limitations in use of big data 
broadly divided into two categories of data quality and the potential for spurious 
statistical inference.  
Many use cases of VHA or Optum™ data require using at least one other data source 
National Death Index (NDI) data to study mortality outcomes and third-party 
sociodemographic data are examples of external data sources that are often required in 
addition to claims and EHR. 
Noise versus Signal in Big Data [DV, BO] 
The analytic mind is even more susceptible to error when dealing with uncertainty 
and complexity of big data. Both VHA and Optum™ data are real world evidence that 
are generated for specific non-research purposes. Both sources primarily represent 
measurements made at the point of care and are likely to over-represent the sick. 
Furthermore, claims are produced for billing and may be systematically upcoded to 
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maximize payments to providers. Therefore, merely more information of the same type 
may be misleading.  The investigator should also constantly critique mental models, 
mind-sets, potential biases and analytical assumptions while analyzing the data [DV]. 
ML is susceptible to irrational extrapolation [DV, BO] 
ML algorithms are typically tuned to replicate situations and classifications in the 
past. If those decisions and trends were biased around issues such as patients’ 
socioeconomic status or sex, the prediction models could actually harm future patients.151 
Such risk should be avoided by careful validation. To apply machine learning methods, 
researchers usually do not need to have years of computational expertise, but they do 
need a cautious and inquisitive mind-set. 
The issue could be further compounded by analytic choices that are data dependent 
and non-reproducible. Transparency and generalizability of ML approaches remains a 
persistent challenge [DV]. 
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CHAPTER SIX: DISCUSSION AND CONCLUSIONS 
Section One: Review of Background and Study Objectives 
In this mixed methods analysis of the research using a variety of healthcare big data 
sources from the government and the private sector, we found that the overall research 
enterprise was highly dynamic and growing over time. With less than 4 years of 
observation, we also showed that the research productivity, use of machine learning and 
NLP, and the quality of dissemination of studies improved. Lastly, analysis of the co-
authorship networks showed that no single actor, either a community of scientists or 
institutions, was dominant which was surprising.  
Despite growing attention and interest, we also found that critical challenges remain 
in the use of big data for research. We showed that a considerable portion of research 
publications were low value or poorly disseminated. The key informants suggested that 
the payers continue to be ahead of healthcare providers and other stakeholders in 
leveraging big data to contain costs and improve bottom line. Also, despite investments 
in methodological innovations, there was much to be learned and be cautious about in 
using real world evidence (RWE) for causal inference and tackling bias and confounding. 
Most key informants also expressed caution about risks of unwarranted extrapolations, p-
hacking and data driven post hoc analytic choices. Within large sample sizes, studies 
using big data were considered particularly prone to report statistically significant 
associations that might be either of low clinical relevance or difficult to reproduce. 
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Quantitative analysis of predictors of research impact 
The number of studies using the 3 big data sources increased over time, and the 
growth was even more pronounced for Optum™ and IBM MarketScan than the VHA. 
Number of studies having no scientific impact (ie having zero citations till March 2016) 
also increased for all 3 data sources.  
We showed that overall and after adjustments for topic similarity, and quality of the 
journal, scientific impact of studies using VHA data was higher compared to the other 
two environments. Although we were not able to evaluate more detailed and proximal 
predictors of research impact in the VHA, our parallel analysis of co-authorship networks 
was hypothesis generating. In Table 10, we showed that characteristics of co-authorship 
collaborations accounted for part of the variability. VHA collaboration with centers of 
excellence and influential academic institutions over the years were shown to be strong 
and stable compared to Optum™ and IBM MarketScan.  
Number of research studies using machine learning and NLP remained less than 5% 
of total studies and the average impact was lower than the studies using conventional 
statistical modeling. KIIs suggested that clinicians might be skeptical about the long-term 
relevance of the increasing predictive models that function in the background of EHR 
systems causing “alarm fatigue”.  
Finally, we showed that authors’ social influence was associated with higher 
research impact.  
It is not surprising that research using big data was affected by the natural social 
networks built by and around scientists. Most impactful studies tended to cluster around 
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institutions, influential researchers and geographies. Academic institutions with most 
impactful research were University of Washington, University of California Los Angeles, 
and Baylor College of Medicine which worked with all 3 data sources but predominantly 
VHA (Figure 16). Unlike Duffett’s recent study of co-authorship networks associated 
with pediatric randomized clinical trials, 152 we found that the pattern of influence in big 
data research was more distributed and not dominated by one or few large communities 
(Figure 15 and Figure 23). In their study, Duffett describes a highly fragmented research 
enterprise that appeared to be dominated by a single large community. 
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Figure 23-Coauthorship network diagram in pediatric critical care randomized 
controlled trials (RCTs).  
Each circle represents a researcher who has published an RCT in pediatric critical care. The area of 
each circle is proportional to the number of RCTs that each researcher has published. A line 
connecting two researchers indicates that they have coauthored at least one published RCT. The width 
of each line is proportional to the number of RCTs that each pair of researchers has coauthored 
together.  
 
Source: Duffett, Mark, et al. “Research Collaboration in Pediatric Critical Care Randomized 
Controlled Trials: A Social Network Analysis of Coauthorship.” Pediatric Critical Care Medicine, 
Oct. 2019, p. 1. DOI.org (Crossref), doi:10.1097/PCC.0000000000002120. 
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Juxtaposing the two cases of research analytics using big data 
Two environments, two approaches to use of advanced analytics: While 
OptumLabs has been primarily functioning as a collaborative innovation network, VHA 
is actively applying machine learning and NLP for performance analytics. OptumLabs 
has made major investments in innovative methodological approaches to tackle 
limitations of RWE such as emulating RCTs, imputation techniques for missingness, as 
well as design and analytic strategies to mitigate bias. VHA, on the other hand, has been 
taking on challenges such as validation of diagnostic codes and improving accuracy of 
bed-side prognostic assessments by clinicians. Finally, the VHA has the unique 
advantage of an embedded, large-scale research program that can directly innovate or 
collaborate with the operations and healthcare delivery arms. 
Common drivers of impact were also observable across both systems. Both 
continuously leverage big data to study under-studied populations. Furthermore, both 
data sources actively pursue development of conventional and ML that build upon 
richness of clinical information in EHRs, including biomarkers, and data extraction using 
NLP. 
Some of the common barriers include the following:  
• Big data and RWE should always be critically evaluated to ensure it’s fit for 
purpose. For a given clinical or policy question, use of big data should be based on 
an accurate assessment of data quality, representativeness, clinical relevance, and 
rigor of the analytic approaches. No matter how big, sample size can never make up 
for flaws in data quality and relevance. 
		
138 
• As value-based payment systems are rolled out, healthcare systems broadly lack up 
to date performance measures. There is a constant need to review and improve the 
existing measures, and develop and validate new measures that could be 
operationalized in automated data sets. On the other hand, the number of existing 
measures has grown dramatically leading to a perception of measurement overload. 
Review of feasibility, relevance and alignment of the existing performance metrics 
with the evolving priorities of the healthcare system would be critical.  
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Section Two: A Generic Framework For Research Using Big Data: a Closer Look at 
the Opioid Studies Using Big Data as They Relate to an Ongoing Public Health 
Crisis 
The portfolio of opioid studies in VHA, Optum and MarketScan data may offer 
insights into development of a generic framework for research. This cluster has 
specificity of subject matter, and a broad array of research questions examined during the 
study period. Closer examination of the topic clusters in Figure 24 indicates that the 
opioid cluster was more centrally located than many source specific studies. This issue 
suggests broader generalizability across various data sources. The following sub-
clustering suggests a pattern that may inform specific recommendations about a generic 
approach to research using big data: 
1. Measures for opioid use, misuse, opioid use disorder (Logan (2013), Birt (2014) , 
Painter (2013)) 153,154,155 
2. Opioid prescribing/treatment patterns, predictors (Edlund (2014), Park (2015), Hirsh 
(2014)) 156,157,158 
3. Clinical outcomes /effectiveness of treatment patterns (Larochelle (2015), Sessler 
(2014)) 159, 160 
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4. Cost outcomes (Rice (2014)) 161 
 
 
Figure 24- sub-clustering of studies in the opioid cluster (size proportional to the 
number of Google Scholar citations) 
Blue: VHA studies; Red: IBM® MarketScan; Green: Optum 
GS: Google Scholar citations 
 
Quality measures for opioid use, misuse, and opioid use disorder appear to be an 
integral starting point to identify performance gaps and unmet need, geographically or 
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clinically. They could also point into less obviously known gaps in quality (e.g. co-
prescribing of opioids with benzodiazepines). The peripheral location of these studies in 
the network visualization may also be suggestive of this role (Figure 24). 
Variations in treatment patterns and their predictors appear to be a logical next step. 
Most of these studies relied upon conventional statistical modeling approaches but there 
were opportunities for using clustering techniques based on machine learning. 
The last two sub-clusters appear to include comparative effectiveness studies. With 
greater frequency and peer-reviewed visibility, these are studies looking at clinical 
outcomes such as overdose, deaths and relapse of opioid use disorder (OUD). Although 
equally important, economic studies seem to have received lower scientific recognition. 
In summary, studies in the opioid cluster are suggestive of a pattern in the conduct of 
research with potentially high impact. Starting with existing or newly developed 
performance measures to identify gaps and opportunities for improvement and then 
evolving to more focused studies trying to define real-world treatment pathways and what 
determines treatment choices based on patient and provider factors. Finally, there are 
comparative effectiveness studies assessing clinical and cost outcomes. 
 
Section Three: Recommendations and Next Steps 
1. Increasingly, advancements in health aren’t brought about by miracles or major 
breakthroughs. With carefully crafted study designs, big data have the potential to 
become particularly relevant to identify faint signals, e.g. small odds ratios that can 
inform incremental refinements in treatment pathways, benefit design choices and 
practice guidelines. Proponents of big data in research might have to shift their 
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narrative to explain the context and justify so called “small effectology” 162 research. 
We suggest the following roadmap of incremental research inquiry where each step 
is informed by the findings as well as the experience in exploration of data in 
previous steps (Figure 25). The relationship between the steps should not be viewed 
as linear and sequential. 
 
Figure 25- A roadmap for research using healthcare big data 
RW: real world 
 
2. Big data and real world evidence (RWE) continue to be under-utilized for research 
analytics. Big data sources each with their unique characteristics and limitations 
need to be transparently explained to funding agencies, academia and providers for 
better use. Carefully designed studies that are implemented with rigor could be both 
scientifically impactful and cost saving. 
3. Investments in methodological innovation should expand using expanding funding 
available through federal and private sources.  
4. Payers and providers should streamline use of healthcare big data to rapidly 
develop, validate and update performance indicators. Researchers should collaborate 
with operations analytics teams to implement rapid cycle measure development, 
validation and testing. Outdated metrics and misaligned indicators should be 
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discarded or replaced. A suggested organizational setup for continuously learning 
healthcare system is depicted in Figure 26. 
 
Figure 26- Organizational setup for a continuously learning healthcare system, 
conducive to research impact 
 
5. Opportunities to leverage big data and advanced analytics for public health programs 
should be advocated.. VHA, state agencies and private sector’s use of big data to 
respond to the opioid epidemic provide lessons to learn from. The large data 
repositories that were established in Massachusetts and Tennessee generated high 
quality evidence with broad scientific impact. For instance, machine learning was 
applied to estimate unmet needs for underserved stigmatized populations with opioid 
use disorder (OUD). These success stories should be broadly disseminated. Also not 
surprisingly, our findings suggest that advanced analytic methods were only used by 
a small proportion of studies. This observation suggests that to answer most research 
questions, big data could still be harnessed with conventional statistical modeling 
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techniques.  Table 21 outlines recommendations as to when statistical modeling or 
machine learning might be a superior analytic choice. 163 Overall, machine learning 
methods should be used for situations where causal inference is not the main 
objective. 164 
Table 21 - Advantages and disadvantages of statistical modeling versus machine 
learning approaches 163, 164 
Statistical modeling works well 
when: 
Scenarios where machine learning may be a 
superior choice: 
• Training data is imperfect 
• Goal is to isolate effects of a 
few specific predictors 
• Additivity is the dominant 
way that predictors affect the 
outcome, or interactions can 
be pre-specified 
• The sample size isn’t huge 
• Intuitive interpretability 
of the model is important 
• Prediction is the goal and scientists are not 
concerned that the model may be a “black 
box” 
• The learning algorithm can be trained on a 
large number of high-quality responses 
• One is not interested in the impact of 
specific predictors or estimating 
uncertainty in related forecasts  
• Non-additivity is expected and interactions 
cannot be pre-specified variables  
• The sample size is huge 
 
6. Linking publicly available or crowdsourced measures of social determinants of 
health are increasingly possible but use cases remain limited. Funding agencies and 
proprietary producers of big data should encourage use of such possibilities by 
investigators. 
7. Application of conventional analytic approaches to tackle common issues of big data 
could be strengthened. Pre-service training curricula for health services research 
degrees should focus on applied advanced knowledge of programming languages 
such as structured query language (SQL), and R should be included in the curricula. 
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8. Finally, it may be of interest to broaden the time span of the current study to re-
examine our findings in lieu of the enactment of the Cures Act and the potential 
impact on use of big data and RWD/RWE and advanced analytics. 
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Section Four: Review of Study Limitations 
Our analysis has several potential limitations. First, key informant views on the full 
spectrum of challenges in working with big data may have been under-represented. 
Probing questions might have been ignored because of the organizational affiliations. We 
tried to fill in this gap through a limited review of literature. Second, the time span of 
quantitative analysis was short and more use cases of big data in healthcare are rapidly 
emerging. To address this issue, we decided to expand the scope of the original study to 
include key informant interviews. The qualitative arm of the study has been a critical 
source of insights to explain findings of the quantitative analysis. Third, methodologies 
used to analyze research impact or co-authorship networks were new and in part rooted in 
the evolving world of text analytics and imperfect data linkages. This poses risk of 
misclassification of exposure and outcome resulting from issues such as variability in 
spelling of authors’ names, and institutional affiliations. Our assessment is that such 
misclassifications would be non-differential and not be a major threat to internal validity 
of the comparisons. Our sample size, on the other hand, was fairly large and might 
mitigate the effect of additional random noise. Finally, the social network algorithm that 
was used for visualization of co-authorship networks was subject to the same limitation 
mentioned above to cluster individual authors and institutional affiliations. Given the 
large number of authors and institutions, roughly 7000 and 1700 respectively, our 
assessment is that the impact of potential misclassification would be limited. 
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Section Five: Conclusion 
In conclusion, use of healthcare big data for research analytics appears to have 
increased within the 3 data sources that we quantitatively studied between 2013 and 
2016. Despite the challenges, the research community appears to be reacting favorably to 
the opportunities presented both by the data and advanced analytic methods. Studies that 
used machine learning or natural language processing, however, showed limited visibility 
beyond corresponding research circles. Other key opportunities to achieve high research 
impact using big data were: methodological innovations to address confounding, under-
studied populations and predictive models based on rich clinical data and biomarkers. 
Bias and confounding remained a major limitation in research using big data. In 
situations where the body of clinical evidence is limited and difficult to expand and 
tolerance for uncertainty is relatively high, big data may be the only logical choice. In 
these circumstances, appropriate study designs and mitigating analytic approaches such 
as propensity matching, instrumental variables and other methodological innovations are 
becoming routine to tackle confounding. Findings of this study will be helpful to gauge 
resources, skills, and subject matter focus for those who seek greater involvement in 
healthcare big data across the spectrum of research inquiry. 
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APPENDIX I 
Search strategy 
We mined multiple publicly available disparate sources on the web to build our research 
database. We used open source non-proprietary Application Programming Interfaces 
(APIs) and analytic software to query, organize and pre-process the data. The databases, 
scientific search engines, APIs, and the retrieval process are outlined below: 
 
1. Extracting article titles - initial search: 
• Data source is highly under-reported in the PubMed meta-data. Google 
Scholar, on the other hand, allows for simultaneous search of full text for at 
least a proportion of articles, and is estimated to include 90% of the 
biomedical literature to date (Falagas et al. 2008). 
• Google Scholar was therefore used for the initial search for the IBM® 
MarketScan® and Optum™ research articles because of the following 
reasons: 
o It allows searching of the full text of the articles. 
o Data sources are not consistently indexed in the PubMed. An 
initial search of PubMed using the term “MarketScan” in 2015 yields 
204 titles. Same search in Google Scholar yields 808 documents.  
o GS allowed for more flexible querying of free text by using text 
proximity operator “AROUND” which we incorporated in our search 
algorithm.  
• We used ‘Harzing's Publish or Perish’ version 4.25.1.5861 © 1990-2016 
as the API to scrape Google Scholar for document titles and citation rates. 
This software is an interactive and user-friendly application that allows 
extraction of partial metadata and citation counts from Google Scholar (Mikki 
2009). 
• Between January 2013 and March 9, 2016 when we conducted the last 
run, we identified 3,421 publications citing either ‘MarketScan’ or ‘Optum’ in 
proximity to terms ‘data’, ‘data base’, or ‘database’ 
• We use the VA’s Health Services Research & Development publication 
repository at http://www.hsrd.research.va.gov/publications/search_pubs.cfm 
to obtain the list of research publications that were based on VHA data. 
o The repository is publicly available and allows downloading a list 
of titles, authors, publication dates, and document type from the web. 
o Between January 2013 and March 9 2016, there were a total of 
11,829 publications, conference abstracts, and posters indexed in the 
publication repository. 
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2. Scraping PubMed to obtain NLM metadata for the three groups of publications: 
• We use NLM’s ‘E-utils’ API facility and ‘Entrez’ R package to download 
matching metadata (including abstracts, list of authors, and full list of Mesh 
terms) in XML format. 
• We use multiple R packages to mine, parse and structure the PubMed 
metadata. 
• Availability of metadata for MarketScan® and VA publications are as 
follows (as of March 12, 2016): 
o MarketScan: 976 (43%) 
o Optum: 360 (42%) 
o VHA: 4,615 (39%) – The retrieval rate seems to be lower as the 
VHA list includes 1,776 documents that do not seem to be scholarly 
documents. 
3. Data cleaning, editing and pre-processing: 
• We eliminate all non-English articles (XML field <Language>: ENG, case 
insensitive) 
• We eliminate all metadata that are classified as reviews, comments or 
news (XML field <PublicationType>: Journal Article, case insensitive) 
• Elimination of non-matching metadata 
o We use ‘Damerau-Levenshtein distance’ measure on article title 
and first author’s last name to filter potential errors in retrieval of 
metadata. 
o We set a cut-off to ‘Damerau-Levenshtein distance’ values that are 
greater than 10% of the length of the document title and the first author’s 
last name. 
• We used the Swift-Review software to identify and filter out randomized 
controlled trials. This application uses a machine learning text classification 
algorithm that could be trained iteratively based on the language used in the title, 
abstract and MeSH terms to isolate articles that appeared to report an RCT design. 
Articles were scored probabilistically and the subset with more than 50% 
probability of being an RCT were manually reviewed and cleaned. 
4. Missingness: 750 of the publications in the final sample (out of a total of 2,155, or 
34%) miss PubMed’s Medical Subject Headings (MeSH). We use the National Library of 
Medicine (NLM) natural language processing (NLP) tool, Medical Text Indexer (MTI) to 
automatically generate MeSH terms for the records with missingness.  
• Medical Text Indexer (MTI) is NLM’s publicly available Natural 
Language Processing (NLP) tool. 
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APPENDIX II 
Supplemental table – Identified clusters through topic modeling of abstracts and MeSH 
terms; number of clusters= 50 
Topic 0: veterans, health, care, affairs, mental, administration, vha, services, medical, utilization 
Topic 10: children, vaccine, influenza, vaccination, pediatric, varicella, rotavirus, barrett's, asd, hospitalizations 
Topic 11: costs, patients, utilization, care, health, cost, healthcare, total, medical, resource 
Topic 12: opioid, pain, prescription, opioids, medications, chronic, prescriptions, drug, prescribed, overdose 
Topic 13: coronary, patients, pci, acute, events, myocardial, acs, artery, disease, infarction 
Topic 14: women, sexual, veterans, men, military, health, assault, service, veteran, violence 
Topic 15: data, quality, study, research, health, measures, studies, potential, clinical, system 
Topic 16: complications, complication, postoperative, urinary, rates, surgery, patients, reoperation, spinal, procedure 
Topic 17: hiv, hiv-infected, infection, uninfected, veterans, individuals, antiretroviral, index, vacs, score 
Topic 18: differences, disparities, racial, statin, white, african, race, sex, black, american 
Topic 19: hospital, hospitals, patients, day, hospitalization, discharge, inpatient, admission, readmission, mortality 
Topic 1: patients, treatment, therapy, study, months, days, index, period, initiation, patterns 
Topic 20: alcohol, drinking, life, quality, employment, scores, depression, consumption, patients, satisfaction 
Topic 21: antibiotic, variation, prescribing, imaging, guidelines, geographic, rates, utilization, antibiotics, national 
Topic 22: women, pregnancy, contraceptive, delivery, reproductive, birth, pregnancies, unintended, pregnant, 
sterilization 
Topic 23: cancer, patients, treatment, chemotherapy, breast, prostate, survival, stage, men, adjuvant 
Topic 24: veterans, suicidal, suicide, freedom, ideation, deployment, operation, military, oef/oif, service 
Topic 25: physician, services, payments, physicians, prices, private, payment, price, outpatient, paid 
Topic 26: weight, patients, transplantation, bmi, levels, mass, body, obesity, loss, transplant 
Topic 27: surgery, patients, surgical, postoperative, underwent, procedures, bariatric, undergoing, imaging, total 
Topic 28: colonoscopy, screening, transfusion, blood, bowel, preparation, guidelines, crc, criteria, patients 
Topic 29: chronic, disease, patients, conditions, copd, pulmonary, anxiety, obstructive, depression, comorbidities 
Topic 2: cannabis, anxiety, treatment, participants, randomized, trial, group, therapy, placebo, study 
Topic 30: depression, disorder, disorders, mental, mdd, bipolar, antidepressant, psychiatric, medication, depressive 
Topic 31: ptsd, symptoms, stress, veterans, disorder, posttraumatic, depression, social, symptom, support 
Topic 32: treatment, substance, drug, sud, abuse, alcohol, mental, medical, disorders, seeking 
Topic 33: drug, observational, databases, drugs, risk, healthcare, safety, controls, data, method 
Topic 34: failure, heart, cardiac, mrsa, left, patients, device, ventricular, positive, fraction 
Topic 35: visits, emergency, department, visit, health, literacy, ambulatory, room, transfer, departments 
Topic 36: adherence, medication, oral, therapy, patients, medications, mpr, prescription, pdc, adherent 
Topic 37: diabetes, patients, type, control, insulin, hypertension, mellitus, blood, pressure, glycemic 
Topic 38: cost-effectiveness, treatment, cost, costs, qaly, model, analysis, cost-effective, sensitivity, qalys 
Topic 39: aki, claims, sinus, database, injection, databases, macular, laser, amd, ranibizumab 
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Topic 3: patients, hepatitis, hcv, disease, hcc, chronic, liver, kidney, ckd, cirrhosis 
Topic 40: mortality, risk, patients, death, cohort, hazard, ratio, study, compared, cardiovascular 
Topic 41: stroke, patients, warfarin, atrial, fibrillation, ischemic, bleeding, risk, vte, dabigatran 
Topic 42: care, patients, patient, primary, intervention, management, medical, providers, reported, program 
Topic 43: older, adults, cognitive, physical, dementia, participants, impairment, dysfunction, functional, function 
Topic 44: homeless, smoking, veterans, homelessness, housing, smokers, cessation, program, quit, compared 
Topic 45: asthma, omalizumab, laryngeal, exacerbations, diverticulitis, medications, acute, ppi, allergic, voice 
Topic 46: years, states, united, prevalence, increased, age, rates, incidence, trends, population 
Topic 47: injury, tbi, brain, traumatic, mild, loss, disability, trauma, visual, injuries 
Topic 48: testing, screening, test, clinical, information, text, recommendations, tests, notes, diagnostic 
Topic 49: pain, sleep, quality, men, osa, older, insomnia, apnea, daytime, poor 
Topic 4: codes, icd, data, classification, identified, administrative, diagnosis, code, diseases, identify 
Topic 5: lung, cancer, surgical, surveillance, screening, palliative, resection, tomography, patients, scans 
Topic 6: risk, study, factors, age, regression, higher, association, odds, increased, models 
Topic 7: fracture, women, fractures, osteoporosis, men, hip, bone, events, year, osteoporotic 
Topic 8: arthritis, biologic, patients, rheumatoid, switching, switched, relapse, disease, therapy, biologics 
Topic 9: health, medicare, care, insurance, medicaid, spending, cost, expenditures, impact, plans 
  
Supplemental table – Identified Clusters through Topic Modeling of Abstracts and MeSH 
Terms; number of clusters= 100 
Topic 0: hiv, hiv-infected, uninfected, veterans, individuals, index, infection, antiretroviral, vacs, viral 
Topic 10: older, adults, cognitive, dementia, years, participants, dysfunction, function, health, impairment 
Topic 13: surgery, complications, patients, surgical, postoperative, rates, procedures, complication, underwent, 
undergoing 
Topic 14: support, social, relationship, role, relationships, family, personality, research, activation, emotional 
Topic 16: veterans, homeless, homelessness, housing, program, criminal, supported, incarcerated, veteran, risk 
Topic 17: ifn, reoperation, anemia, adjustable, strabismus, esa, rash, marginal, sham, mrgfus 
Topic 19: prices, physician, services, paid, price, anesthesia, market, private, payments, hospital 
Topic 25: mental, health, disorder, disorders, psychiatric, substance, treatment, depression, diagnoses, illness 
Topic 26: severe, anaphylaxis, trajectory, trajectories, transfer, community, plwh, moderate, transferred, pcu 
Topic 28: care, management, evidence, treatment, research, improve, review, important, evidence-based, factors 
Topic 2: children, variation, geographic, pediatric, rates, states, regional, utilization, united, child 
Topic 31: nephrectomy, stenosis, partial, carotid, renal, patients, rmb, cca, caps, ratio 
Topic 32: caregivers, literacy, caregiver, ocular, burden, film, uveitis, vision, low, tablet 
Topic 34: patients, claims, months, years, study, period, index, database, retrospective, days 
Topic 36: hospital, hospitals, patients, hospitalization, admission, discharge, day, readmission, inpatient, hospitalized 
Topic 39: risk, model, models, predictive, prediction, validation, predicted, adjustment, liver, predict 
Topic 3: surgery, patients, bariatric, inflammatory, bowel, disease, open, diverticulitis, ibd, centers 
Topic 40: depression, treatment, care, health, mental, participants, social, beliefs, primary, reported 
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Topic 41: patients, disease, hypertension, kidney, pressure, blood, ckd, cardiovascular, control, cvd 
Topic 45: vte, patients, barrett's, gerd, esophagus, controls, endoscopy, venous, thromboembolism, initial 
Topic 46: risk, incidence, increased, cohort, interval, rate, confidence, association, study, compared 
Topic 47: transplantation, survival, patients, cell, allogeneic, acute, leukemia, hct, hematopoietic, persistence 
Topic 48: patients, treatment, therapy, initiation, clinical, received, diagnosed, patterns, initiated, days 
Topic 49: charges, reimbursement, fusion, rhbmp, group, nonunion, single-level, bone, total, cases 
Topic 4: years, states, united, age, increased, rates, prevalence, year, trends, rate 
Topic 51: life, quality, physical, scores, health, health-related, patients, hrqol, employment, qol 
Topic 52: medication, medications, prescribing, prescription, antibiotic, prescriptions, prescribed, inappropriate, 
psychotropic, antidepressant 
Topic 53: events, cardiovascular, coronary, statin, risk, myocardial, infarction, patients, disease, event 
Topic 54: influenza, testosterone, men, season, seasons, prescription, antiviral, vaccine, trt, high-dose 
Topic 56: chemotherapy, adjuvant, cancer, prophylaxis, patients, regimen, colon, received, receipt, iii 
Topic 59: diabetes, type, patients, insulin, glycemic, hba, control, mellitus, diabetes-related, baseline 
Topic 61: duloxetine, potential, pregabalin, ddi, clients, prevalence, interactions, score, tcm, drug-drug 
Topic 64: quality, measures, care, performance, measure, composite, indicators, metrics, improvement, individual 
Topic 65: opioid, opioids, prescription, abuse, overdose, dose, prescribed, drug, prescriptions, pain 
Topic 66: users, generic, clinic, off-label, claims, copayment, branded, nonusers, compounded, overuse 
Topic 68: asthma, omalizumab, treatment, allergic, asthma-related, uncontrolled, decreased, telehealth, hdics, hics 
Topic 73: antipsychotic, schizophrenia, antipsychotics, disorder, oral, bipolar, lai, adolescents, pylori, long-acting 
Topic 77: mortality, patients, heart, death, failure, risk, hazard, outcomes, all-cause, survival 
Topic 79: syndrome, acs, acute, clopidogrel, prasugrel, left, coronary, awakening, spontaneous, shock 
Topic 7: utilization, care, visits, health, emergency, patients, outpatient, department, visit, inpatient 
Topic 81: veterans, care, health, affairs, administration, vha, medical, system, department, received 
Topic 82: copd, pulmonary, disease, chronic, obstructive, hospitalization, exacerbations, maw, labd, copd-related 
Topic 83: mrsa, pneumonia, antimicrobial, antibiotic, de-escalation, score, spectrum, aureus, methicillin-resistant, 
positive 
Topic 86: warfarin, patients, atrial, fibrillation, stroke, bleeding, dabigatran, anticoagulation, ablation, oral 
Topic 88: disparities, differences, racial, white, african, race, black, racial/ethnic, american, whites 
Topic 8: bowel, switching, preparation, relapse, sclerosis, implantable, therapy, device, multiple, implantation 
Topic 90: stroke, ischemic, acute, time, afib, times, monitoring, minutes, ecg, dtn 
Topic 91: codes, icd, diagnosis, classification, code, diseases, international, revision, diagnoses, epilepsy 
Topic 92: smoking, smokers, cessation, quit, current, tobacco, cigarette, prior, rape, craving 
Topic 93: criteria, sensitivity, positive, algorithm, specificity, identifying, accuracy, cases, diagnostic, case 
Topic 95: health, spending, insurance, care, cost, expenditures, plans, coverage, impact, private 
Topic 98: costs, cost, patients, total, healthcare, care, medical, higher, resource, inpatient 
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APPENDIX III 
Key Informant Consent Form 
“This is a research study being conducted as part of the doctoral dissertation ‘Assessing 
the Value of Big Data for Public Health: Which Characteristics of Big Data 
Environments Predict High Research Impact?’ The purpose of this interview is to explore 
factors in healthcare big data environments and related research practices that may drive 
high impact. You will be asked a series of open ended questions that help describe your 
experience in working with [NAME OF THE DATA ENVIRONMENT]. This interview 
should take approximately 30-60 minutes to complete and will be audio-recorded. Your 
participation is voluntary. Identities will be kept confidential and anonymity will be 
preserved consistent with the terms of our Institutional Review Board requirements. 
Specifically, the content of discussions will be anonymized. Should you have any 
questions about this study, you may contact me at 617-512-4216 or Dr. Lewis Kazis, 
Professor of Health Policy and Management at Boston University School of Public 
Health, who is my academic advisor. He can be reached by phone at 617-414-1418.” 
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Interview Guide 
Key informant Interview Guide 
Procedures for obtaining informed consent 
 
TELEPHONE INTERVIEWS:  
At start of interview, interviewer will ask if participant has any questions about the 
consent form and if he or she agrees to be interviewed and audiotaped. Prior to beginning 
the interview, the following passage will be read for the interviewee:  
 
“This is a research study being conducted as part of the doctoral dissertation ‘Assessing 
the Value of Big Data for Public Health: Which Characteristics of Big Data 
Environments Predict High Research Impact?’ The purpose of this interview is to explore 
factors in healthcare big data environments and related research practices that may drive 
high impact. You will be asked a series of open-ended questions that help describe your 
experience in working with the [NAME OF THE DATA ENVIRONMENT]. The 
interview should take approximately 30 minutes to complete and will be audio-recorded. 
Your participation is voluntary. Identities will be kept confidential and anonymity will be 
preserved consistent with the terms of Boston University’s Institutional Review Board 
requirements. Specifically, the content of discussions will be anonymized. Should you 
have any questions about this study, you may contact me at 617-512-4216 or Dr. Lewis 
Kazis, Professor of Health Policy and Management at Boston University School of Public 
Health, who is my academic advisor. He can be reached by phone at 617-414-1418.“ 
 
Duration: 30 minutes  
 
		
155 
Introduction:  
 
Thanks, again, for agreeing to participate in this interview. Before we start, I wanted to 
mention our goals for these interviews.  
 
I am conducting a mixed methods dissertation to identify drivers of research impact in 
healthcare big data. The overall aim of my work is to measure impact and identify 
predictors of high impact research in data environments that include large and complex 
data sources. 
 
In this interview, I would like to talk about your experience in working with [NAME OF 
THE DATA ENVIRONMENT]. 
 
Do you have any questions about the consent statement that I email to you on 
[DATE/EARLIER]? I want to reiterate that your identity, specific research projects that 
you might mention and all other specific names will be masked in the study reports 
including the dissertation and any publications. 
 
This study protocol has been approved by Boston University School of Public Health 
IRB, and I have also obtained IRB waivers from Bedford and Boston VA Medical 
Centers. 
 
ORIENTATION/ICE BREAKER QUESTION 
1. I am aware of your extensive experience in leading research on large 
and complex observational data, but in order to put it into your own words, 
could you please tell me briefly about your current/previous role at [NAME 
OF THE DATA ENVIRONMENT] and for how long? 
 (This is asked to establish experience,  seniority etc.) 
 
2. In your opinion, are there any recent research projects using [NAME 
OF THE DATA ENVIRONMENT] that you have been involved in and made 
unique contributions to policy, or practice in the [VA/UnitedHealth] 
healthcare system?  
2.1. Potential probes:  
• By unique contributions, I mean any significant change to 
organizational or healthcare system policies,  or any changes in the 
practicing behaviors of groups of healthcare providers, that you attribute 
to the findings of a specific research and would not have emerged that 
research wouldn’t have been carried out. 
• Could you please name the principal investigator, if it was other 
than you, and briefly describe the research questions? 
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•  Were you directly involved in conduction of this research? 
 
3. In what ways in your opinion, has [THE RESEARCH IDENTIFIED 
ABOVE] been different from other work that used [NAME OF THE DATA 
ENVIRONMENT]? 
Potential probes:  
3.1. Was the difference because of:  
• Specific aspects [richness] of the content of [NAME OF THE 
DATA ENVIRONMENT], integration of external data sources, data 
extracted through NLP etc 
• Specific methodologic approaches, including those which dealt 
with challenges of using large observational data 
• Use of Big Data Analytics such as classification algorithms, cluster 
analysis, machine learning (supervised and unsupervised), natural 
language processing, regression methods such as Ridge and LASSO, 
network analysis, pattern recognition, predictive modelling, sentiment 
analysis 
• Quality of data within [NAME OF THE DATA ENVIRONMENT] 
• Ease and cost of accessing data in [NAME OF THE DATA 
ENVIRONMENT] 
• Computational capacity provided by [NAME OF THE DATA 
ENVIRONMENT] 
• Other factors such as researcher seniority, connectedness etc 
• Research question: policy relevance, feasibility, etc 
• Research collaboration 
• Cross-disciplinary nature of the research strategy 
• Specific area of study 
• Other tools and resources that were made available by [NAME OF 
THE DATA ENVIRONMENT] 
 
4. Were there any unique scientific outcomes – such as patents, or other 
innovations -- that emerged as a result of [THE RESEARCH IDENTIFIED 
ABOVE] -- that would not have emerged otherwise?  
 
5. In addition to policy and scientific impacts, have there been any 
unique public health impact that emerged due to the findings of  [THE 
RESEARCH IDENTIFIED ABOVE]  that you think would not have 
occurred otherwise?   
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6. Were there any other outcomes for [NAME OF THE DATA 
ENVIRONMENT]?  Such as changes in institutional culture, administrative 
routines, or institutional policies? 
7. A preliminary analysis of research impact metrics indicates that peer 
reviewed research publications using [NAME OF THE DATA 
ENVIRONMENT] have had a [higher/lower] impact compared to [NAME 
OF THE OTHER TWO DATA ENVIRONMENT] in [NAME THE 
SPECIFIC RESEARCH FIELDS]. What do you think explains this 
observation? 
Potential probes:  
• Research impact was measured by a variety of available measures: 
journal impact factor, citation rates, and metrics measuring referrals by 
selected social media 
 
 
COLLABORATIVE RESEARCH 
Now, I’m going to ask some questions about any collaborative research that you 
know of and is based on [NAME OF THE DATA ENVIRONMENT].  By 
collaborative research, we mean research initiatives that transcend organizations 
and or disciplines. 
 
8. Based on your experiences, in what ways has [NAME OF THE DATA 
ENVIRONMENT], as a whole, helped to support collaborative research?  
For example, things like institutional policies and interventions, scientific 
leadership, specific infrastructure, etc?  
 
a. What specific strategies have [NAME OF THE DATA 
ENVIRONMENT] used to facilitate cross-disciplinary collaborative 
research?  
 
b. Could you reflect, in particular, on the [NAME OF THE 
DATA ENVIRONMENT] structure – such as the coordination center, 
working groups, scientific meetings?    To what extent have these 
structures helped to support cross-disciplinary collaboration? 
 
9. Based on your experiences with [NAME OF THE DATA 
ENVIRONMENT], what challenges have emerged related to engaging in 
collaborative research? 
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a. Were any of the challenges addressed?  And if so, how? 
 
OTHER IMPACT 
10. Were there any outcomes for you, academically or professionally, 
such as how you approach your research, or the influence on your career 
trajectory? 
 
a. What aspects of [NAME OF THE DATA ENVIRONMENT] 
contributed to these outcomes? 
 
WRAP-UP QUESTION 
11. That completes my questions for you.  Is there any other feedback 
you’d like to share, before we end the interview? 
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